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Approximately 7000 women are diagnosed with epithelial ovarian cancer every year in
the UK. The majority of these women will die from their disease. Understanding the
molecular biology ofepithelial ovarian cancer will lead ultimately to the identification
of targets for therapeutic intervention and diagnosis.
Tumour suppressor genes play a crucial role in carcinogenesis yet few of these genes
have been identified in sporadic ovarian cancer.
Previously published studies suggest that a tumour suppressor gene in epithelial ovarian
cancer is located at chromosome 1 lq24-5. To identity the tumour suppressor gene from
this region 1 have performed the largest LOH study in this region to date using 16
polymorphic microsatellite markers and DNA pairs from 1 12 patients with epithelial
ovarian cancer. The results from this study have led to the identification of several
critical regions of LOH. One of these regions unambiguously identifies OBCAM as a
strong candidate tumour suppressor gene.
OBCAM is an extracellular GPI-linked cell adhesion molecule that is shown in this
work to be almost ubiquitously inactivated in epithelial ovarian cancer by a combination
of LOH and methylation. Furthermore 1 have demonstrated that it is a functional tumour
suppressor both invitro and invivo.
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1.1 EPITHELIAL OVARIAN CANCER
1.1.1 Epidemiology
Ovarian cancer is the 4th most common cancer among women in the United Kingdom
after breast, lung and colon cancer respectively. In 1997, there were 6820 new cases of
ovarian cancer in the UK accounting for 5% of the cancer burden in women. The
lifetime risk of developing ovarian cancer is approximately 1 in 48 and it is
predominantly a disease of postmenopausal women. The incidence of ovarian cancer
varies among different geographic regions and ethnic groups with a high incidence in
northern Europe and the United States and a low incidence in Japan.
1.1.2 Aetiology
The majority of ovarian cancers are sporadic suggesting that almost all cases can be
attributed to spontaneous or environmentally induced carcinogenesis. Whilst there are
several models of ovarian carcinogenesis the aetiology of ovarian cancer is poorly
understood. In his theory of incessant ovulation Fathalla proposed that chronic repeated
ovulation without pregnancy contributes to neoplasia of the surface epithelium (Fathalla
1971b). Many observations support this theory. A further hypothesis suggests that
ovarian neoplasia is a result of excessive hormonal stimulation. The ovary is responsive
to steroid and gonadotrophin hormones and perturbations of these hormone levels may
lead to excessive ovarian epithelial proliferation and malignant transformation. Exposure
of the ovaries to pelvic contaminants and carcinogens may play a role in carcinogenesis
and lifestyle factors such as dietary and alcohol intake and cigarette use have been
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investigated. The most influential risk factors for ovarian cancer are age and a family
history ofthe disease.
1.1.2.1 Incessant Ovulation
The necessary proliferation of the ovarian surface epithelium after ovulation suggests
that the process of ovulation may play a role in the aetiology of ovarian cancer. Poultry
hens that have been kept hyperovulatory for long periods have a tendency to develop
ovarian or tubal adenocarcinomas (Wilson 1958).
Factors such as pregnancy that suppress ovulation are associated with a reduction in risk
of ovarian cancer. Many epidemiological studies have found parity to be protective
against ovarian cancer (Risch, Marrett, and Howe 1994) (Modan et al. 2001). Multiparas
have a risk reduction of between 40 and 60% as compared to nulliparas. It has been
estimated that each successive delivery confers a 16 to 22% risk reduction (Risch 1997).
Use of the oral contraceptive pill is associated with reduced risk of ovarian cancer. In a
25 year follow up cohort of 46000 British women, amongst current and recent users
(within 10 years) the relative risk of death from ovarian cancer was 0.2 (Beral et al.
1999). By increasing the number of ovulatory cycles in a woman's lifetime it has been
suggested that early menarche and late menopause may be associated with an increased
risk of ovarian cancer. Breast-feeding can suppress ovulation and as such may be
expected to offer some protection from ovarian cancer (Siskind et al. 1997).
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1.1.2.2 Hormonal factors
Excessive gonadotrophin stimulation is postulated to be a risk factor for ovarian cancer.
This hypothesis was first formulated after observations that ovarian tumours occurred in
rodents following bilateral oophorectomy and ovary transplantation under the splenic
capsule (Biskind 1944). The same author subsequently demonstrated that intact ovarian
function in these rodents suppressed tumour formation apparently by reducing the
gonadotrophin hypersecretion (Biskind 1948). However, in a prospective study,
Helzlsouer et al (Helzlsouer et al. 1995) found that case subjects with ovarian cancer had
significantly lower levels of FSH than control subjects. There was no difference in
serum LH levels. Overall the evidence suggests that whilst gonadotrophins are involved
in feedback regulation of ovarian steroid hormone production they in themselves may
not be responsible for alterations in ovarian cancer risk.
1.1.2.3 Estrogens
During menstrual cycles, the ovarian surface epithelium proliferates at times when
estrogenic influences are high. At these times, mitotic activity is high and thus the
epithelium is vulnerable to acquiring mutations. As well as its role in inhibiting
ovulation, the protective effect provided by the contraceptive pill may in part be due to
reduction in endogenous estradiol production through suppression of the midcycle LH
peak.
Evidence suggesting that estrogen is not a risk factor derives from the knowledge that
pregnancy is protective and yet is associated with dramatically elevated serum estrogen
9
levels. Contradictory evidence has been accumulated on the effect of postmenopausal
estrogen replacement therapy and ovarian cancer risk.(Kaufman et al. 1989; Risch 1996)
(Purdie et al. 1995b). The most recent study published concludes that ever users of
estrogen only hormone replacement therapy and users of hormone replacement
involving administration of sequentially added progestins may be at increased risk of
epithelial ovarian cancer (Riman et al. 2002). Users of continuously administered
progestin hormone replacement therapy were not found to be at increased risk.
Normal ovarian surface epithelial cells and ovarian tumours have been shown to express
estrogen receptors although only a small number of tumours respond to anti-estrogen
therapy (Brandenberger, Tee, and Jaffe 1998). A study of 35 normal ovaries using
monoclonal antibodies was barely able to detect estrogen receptors in surface epithelial
cells or in inclusion cysts (Zeimet et al. 1994). The same study showed progesterone
receptors in 85% of sections of surface epithelium and 100% epithelial inclusion cysts.
1.1.2.4 Progestogens
The normal ovarian surface epithelium is capable of both estradiol and progesterone
production. In a study by Ivarsson et al, progesterone appeared to act as a negative
regulator of ovarian surface epithelial growth while estradiol had no effect (Ivarsson et
al. 2001).
The elevated levels during pregnancy suggest a possible protective role ofprogesterone
in the aetiology of ovarian cancer. The progestogens in oral contraceptive pills may
contribute to the reduced risk of ovarian cancer in users by a mechanism other than
suppression of ovulation. Progestogen only pills do not totally suppress ovulation and
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ovulatory cycles do occur. In a case control study ofwomen who had used progestogen
only contraceptive there was a significant reduction in ovarian cancer risk compared to
never users. Use of depot medroxyprogesterone acetate (DMPA), a progestogen that
suppresses endogenous progesterone synthesis and ovulation does not appear to affect
the risk ofepithelial ovarian cancer (Kaunitz 1996).
Physical activity (without amenorrhoea or other menstrual disturbances) is associated
with decreased progesterone levels (Ellison and Lager 1986). In a study of31000 Iowa
women who were followed for greater than 7 years there was an increased risk of
ovarian cancer with increasing levels of physical activity (Mink et al. 1996).
1.1.2.5 Androgens
The presence of androgen receptors in the ovarian surface epithelium has been directly
demonstrated (al-Timimi, Buckley, and Fox 1985) and the ovarian surface epithelium
has been demonstrated to be an androgen responsive tissue (Edmondson, Monaghan, and
Davies 2002).The function ofandrogens within ovarian epithelial cells is unclear. In the
ovaries the secretion rate ofandrogens is greater than that of oestrogens. Androgens are
present in follicular fluid and are the principal sex steroid of fluid in growing follicles
(McNatty et al. 1979). There is evidence to support the relationship between androgens
and the risk of ovarian cancer. Helzlsouer et al showed that as well as normal LH and
slightly lower FSH levels than controls, patients with epithelial ovarian cancer had
significantly elevated levels of androgens (Helzlsouer et al. 1995). A further piece of
evidence concerns the association observed between history of polycystic ovary
syndrome and risk of epithelial ovarian cancer. In general these patients have elevated
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serum androgen levels and in the Cancer and steroid hormone case-control study, case
subjects were more likely to have been diagnosed with polycystic ovary syndrome than
controls (Schildkraut et al. 1996).
1.1.2.6 Environmental and dietary factors
Perineal talc exposure has long been debated as a risk factor for the development of
epithelial ovarian cancer. There have been many epidemiologic studies providing
conflicting results (Cramer et al. 1999) (Purdie et al. 1995a; Wong et al. 1999). Tubal
sterilisation and hysterectomy have both been demonstrated to provide a reduction in
risk of ovarian cancer (Green et al. 1997). An explanation for this finding is that
contaminants from the vagina such as talc gain access to the peritoneal cavity through
patent fallopian tubes and may enhance or promote malignant transformation of the
ovarian surface epithelium either directly or as a consequence of inflammation. Surgical
tubal occlusion may reduce risk by preventing the access of such agents.
Evidence of dietary risk factors for ovarian cancer is inconsistent. Several studies have
found an increased risk ofovarian cancer with saturated fat intake (Risch et al. 1994) but
others have not found the same relationship (Kushi et al. 1999). Moderately elevated
risks have been found with lactose and cholesterol intake and total vegetable intake was
modestly associated with reduced risk of ovarian cancer (Risch et al. 1994) (Verhoeven
et al. 1996). Analysis of risk associated with coffee, alcohol and tobacco intake has also
been investigated but findings have generally been inconclusive (Kato, Tominaga, and
Terao 1989) (La Vecchia et al. 1992) (Marchbanks et al. 2000; Polychronopoulou et al.
1993) (Kuper et al. 2000).
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1.2 EPITHELIAL OVARIAN CANCER: BIOLOGY AND PATHOPHYSIOLOGY
1.2.1 Embryological development of the ovary and female reproductive system
Knowledge of the embryological development of the female reproductive system
provides a basis for understanding the range of tumour types that can develop from the
ovary.
During the third week after fertilisation, gastrulation occurs. Gastrulation is the process
that establishes the three germ layers in the embryo (i.e. the ectoderm, mesoderm and
endoderm). The mesoderm develops to be comprised of paraxial mesoderm,
intermediate mesoderm and lateral plate mesoderm. The ovary and indeed the rest of the
urogenital system develop from the intermediate mesoderm (Sadler 1990).
The sex of the embryo is genetically determined at the time of fertilisation, however the
gonads do not acquire male or female morphological characteristics until the seventh
week ofdevelopment. The gonads initially appear as a pair of longitudinal ridges called
the genital ridges. These ridges are formed by proliferation of the coelomic epithelium
and a condensation of the underlying mesenchyme, both of which are derived from the
mesoderm layer. The germ cells appear in the wall of the yolk sac and migrate to the
region of the genital ridge by approximately four weeks. Concurrently, the coelomic
epithelium overlying the ridge begins to proliferate and forms primitive sex cords, which
penetrate into the underlying mesenchyme. At this stage ofdevelopment it is impossible
to differentiate between a male and female gonad and it is therefore known as the
indifferent gonad. In the absence of a Y chromosome, the gonad develops into an ovary.
The primitive sex cords degenerate and are replaced by a second generation of cords
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called cortical cords. The cortical cords then degenerate into cell clusters surrounding
the germ cells. These surrounding cells develop into follicular cells and the germ cells
develop into oogonia.
The reproductive system develops in close association with the urinary system, both
being derived from the mesoderm. Initially in the embryo there are two pairs of genital
ducts namely the mesonephric (or Wolffian ducts) and the paramesonephric (or
Mullerian ducts). In the female the mesonephric ducts degenerate whilst the
paramesonephric ducts continue to develop. The paramesonephric ducts arise as a
longitudinal invagination of the coelomic epithelium on the anterolateral aspect of the
genital ridge. Cranially the ducts open into the coelomic cavity and ultimately develop
into the Fallopian tubes. Caudally the two paramesonephric ducts lie adjacent to each
other and eventually fuse to form the uterine canal which develops into the body of the
uterus, cervix and upper one third of the vagina. The lower portion of the vagina is
formed from the urogenital sinus.
1.2.2 Neoplasms of the ovary
The vast majority (85%) of ovarian tumours arise from the surface epithelium of the
ovary (Auersperg et al. 2001). The remainder arise from germ or stromal cells and will
not be discussed further.
In the embryo the coelomic epithelium gives rise to both the ovarian surface epithelium
and the Mullerian duct system. It can therefore be appreciated that when the ovarian
surface epithelium becomes malignant it can express a variety of Mullerian type
differentiations i.e. serous (akin to fallopian tube epithelium), endometrioid (akin to the
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uterine endometrium) and mucinous (akin to the cervical epithelium). Tumours of the
ovary can be benign, borderline or malignant.
1.2.2.1 Benign tumours
Benign tumours grow by expansion often compressing adjacent tissues and developing a
rim ofcondensed connective tissue at their periphery. Unlike malignant tumours, benign
tumours are not invasive or infiltrating and they have an excellent prognosis.
Histologically, cells within most benign tumours closely mimic corresponding normal
cells. Benign tumours do not have the capacity for metastasis.
The most common benign tumour derived from the ovarian surface epithelium is the
serous cystadenoma. These tumours present as large spherical masses and are bilateral in
20% of cases. Macroscopically these tumours are usually unilocular cysts that have a
smooth inner lining. Microscopically the appearance resembles that of the fallopian tube.
Benign mucinous tumours tend to be larger than their serous counterparts. They are
often multiloculated and filled with thick mucinous material. Approximately 5% ofthese
tumours are bilateral. Benign endometrioid tumours are rare. Transitional cell or
Brenners tumours are thought to arise through metaplasia of the ovarian surface
epithelium to form urothelial nests. They are normally unilateral.
1.2.2.2 Borderline tumours
Borderline tumours or tumours of borderline / low malignant potential account for
approximately 4 - 14% of all ovarian malignancies (De-Vita, Hellman, and Rosenberg
1997). The presence of epithelial budding, multilayering of the epithelium, increased
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mitotic activity and nuclear atypia distinguish these tumours from benign mucinous and
serous tumours. However, like their benign counterparts they do not breach the
basement membrane and there is no stromal invasion. Borderline tumours can however
locoregionally disseminate. These tumours have a relatively benign prognosis. The
tumours can be large and mucinous tumours can be associated with pseudomyxoma
peritonei. In this condition, the presence of large quantities of mucinous material in the
abdominal cavity is often fatal. As well as mucinous and serous tumours, Brenner and
endometrioid borderline tumours have been reported but are rare.
Borderline tumours should be staged in the same manner as malignant tumours. Surgery
is the main treatment for this disease. There is little evidence to suggest that treatment
beyond that of initial surgery has any beneficial role. This is thought to be the same for
both stage II and III disease as well as stage I disease.
1.2.2.3 Malignant tumours
Malignant tumours tend to grow faster than benign tumours. Histologically they display
patterns ranging from well differentiated to poorly differentiated or anaplastic.
Anaplastic cells are characterised by nuclear and cellular pleomorphism. Malignant
tumours demonstrate an elevated nuclear/cytoplasmic ratio and abundant mitoses.
Malignant tumours are invasive and infiltrating and can destroy normal surrounding
tissues. Invasion is identified histologically as breach of the basement membrane.
Finally, malignant tumours are distinguished by their ability to metastasise to sites
discontinuous with that of the primary tumour.
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Serous tumours are the most common malignant tumour arising from the ovarian
surface epithelium. Two thirds are bilateral. Macroscopically, serous
cystadenocarcinomas often have small mural papillary projections. Histologically they
are composed of a multilayered epithelium with many papillary projections forming
solid epithelial masses.
Malignant mucinous tumours form multilocular cysts and are bilateral in approximately
one fifth of cases. Seeding of the peritoneal cavity with multiple implants can result in
pseudomyxoma peritonei.
Endometrioid tumours are distinguished by their resemblance to glands of the
endometrium. One third of cases have coexisting endometriosis.
Clear cell carcinoma of the ovary frequently presents with early stage disease as a large
pelvic mass. There is an association with endometriosis, vascular thrombotic events and
hypercalcaemia. Clear cell tumours tend to respond poorly to platinum based
chemotherapy and their overall prognosis is poor.
1.3 EPITHELIAL OVARIAN CANCER: CLINICAL MANAGEMENT AND
PREVENTION
1.3.1 Prognostic factors
Many different clinical, biological, pathological and surgical factors have been evaluated
as predictors of outcome in ovarian cancer. The importance of some of these prognostic
factors is undisputed but for others the evidence is not so clear.
Tumour stage at the time of diagnosis is undoubtedly one of the most significant
prognostic factors. The SEER study in 1999 reported five year survival rates for ovarian
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cancer as follows; Stage 1 93%, Stage II 70%, Stage III 37% and Stage IV 25% (Trimble
1999).
Optimal debulking of ovarian cancer at the time of primary surgery is an important
determinant of survival. Suboptimal debulking, leaving residual disease at the end of the
surgical procedure is associated with adverse survival.
Of all the histological types of ovarian cancer, clear cell carcinomas have shorter
survivals stage for stage than serous carcinomas but histological type per se is not a
prognostic factor. In contrast, grade of tumour has been accepted as a prognostic factor
(Vergote et al. 2001).
DNA ploidy has emerged as an independent prognostic factor in most but not all studies
(But and Gorisek 2000; Kimmig et al. 2002; Nagai et al. 2001; Ozalp et al. 2001). Other
pathological features such as measurements of cellular proliferative activity have not
been found to be ofprognostic value.
Measurement of serum levels of the cancer-associated antigen CA125 forms an integral
part of the management of ovarian cancer. CA125 levels at the time of diagnosis are of
limited prognostic significance but in patients with stage III and IV disease, an elevated
level of CA125 after cytoreductive surgery and three cycles of chemotherapy has been
shown to be an adverse and independent prognostic variable (van Dalen et al. 2000).
Evaluation of molecular biological markers as prognostic factors in ovarian cancer has
produced conflicting results. The most frequently detected molecular abnormality in
ovarian cancers is mutation of p53 but its prognostic significance remains unclear.
Overexpression of ErbB2 is observed in a proportion of ovarian cancers and evidence
suggests that this correlates with adverse survival (Meden and Kuhn 1997).
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Finally, performance status and age are strong predictors of disease outcome as shown
by a meta analysis of trials involving over 2000 patients (Thigpen et al. 1993).
1.3.2 Staging and primary surgical treatment
In the absence of extra-abdominal metastatic disease, definitive staging of ovarian
cancer requires laparotomy. Staging of ovarian cancer is carried out surgically and is
important in determining prognosis and subsequent management. Laparotomy should be
performed through a midline vertical incision. Surgical staging should include a
thorough methodical assessment of the abdominal cavity. The exact extent of disease
must be noted. Even if the disease appears to be limited to the ovaries or pelvis, it is
essential to examine the diaphragm, liver, spleen, both paracolic gutters, the peritoneum,
para-aortic and pelvic lymph nodes and omentum. If ascites is present a sample should
be sent for cytological examination, otherwise peritoneal washings should be obtained.
Table 1.1 shows the FIGO staging classification for ovarian cancer.
Surgery aims to reduce tumour cell volume as much as possible. The ideal outcome is
that no macroscopic tumour is visible at the end ofthe procedure. Residual disease at the
end of the procedure must be documented. If there is no residual macroscopic tumour at
the end of the surgical procedure, the patient is said to be completely debulked. A
procedure leaving residual tumour deposits < 2cm is classed as optimal debulking whilst
a patient with residual disease >2cm would be described as suboptimally debulked.
Prognosis in patients with ovarian cancer depends on the stage of tumour and efficacy of
the debulking procedure. In a postmenopausal woman, it is standard procedure to carry
out a hysterectomy, bilateral salpingo-oophorectomy and omentectomy. Management of
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a premenopausal woman wishing to retain her fertility has to be highly individualised
and based on intra operative findings.





Growth limited to the ovaries
Growth limited to one ovary, no ascites, no tumour on the external
surface, capsule intact
Growth limited to both ovaries, no ascites, no tumour on the external
surfaces, capsules intact
Tumour stage la or lb but with tumour on the surface of one or both
ovaries,with capsule ruptured,with ascites present containing malignant





Growth involving one or both ovaries with pelvic extension
Extension or metastases to the uterus or tubes
Growth involving one or both ovaries with pelvic extension
Tumour either stage Ila or lib but with tumour on the surface of one or
both ovaries, with capsule ruptured, with ascites present containing





Tumour involving one or both ovaries with peritoneal implants
outside the pelvis or positive retroperitoneal or inguinal nodes,
superficial liver metastases equal stage III, tumour limited to the
true pelvis but with histologically verified malignant extension to
small bowel or omentum
Tumour grossly limited to the true pelvis but with histologically
confirmed microscopic seeding of abdominal peritoneal surfaces
Tumour of one or both ovaries with histologically confirmed implants
of abdominal peritoneal surfaces, none exceeding 2cm in diameter,
nodes negative
Abdominal implants greater than 2cm in diameter, or positive
retroperitoneal or inguinal nodes
IV Growth involving one or both ovaries with distant metastases, if
pleural effusion is present, there must be positive cytologic test results




It is generally accepted that surgery alone is adequate for stage la and lb if the tumour is
well differentiated (Vergote et al. 2001). All other patients require some form of
chemotherapy. Ovarian cancer in general is a chemosensitive disease. The gold standard
first line chemotherapy is a combination of a platinum compound and a taxane. For
patients with refractory or relapsed disease the choice of subsequent treatment must be
tailored to the individual. In this group of patients, all treatment is palliative and
therefore quality of life and toxicity of treatment are especially important considerations.
1.3.3.1 Platinum compounds
Cis-Diamminedichloroplatinum (II) or cisplatin is a highly effective antitumour agent
used in the treatment ofovarian cancer. Cisplatin reacts with purines to form a variety of
DNA adducts. The mechanism by which the cisplatin-DNA adducts induce cell death is
not fully understood. The formation ofboth intrastrand and interstrand crosslinks induce
structural distortions in DNA. These are thought to inhibit DNA replication and
transcription and ultimately induce apoptosis. Cisplatin can cause severe nephrotoxicity
and neurotoxicity. Carboplatin, an analogue of cisplatin produces less neurotoxicity but
has myelosuppression as its dose limiting toxicity. Nevertheless, its equivalence of
efficacy and lower toxicity have resulted in carboplatin largely replacing cisplatin in the
clinic.
1.3.3.2 Taxanes
Paclitaxel was identified as the active anti tumour agent in the extract of bark from the
pacific yew tree in 1971. A synthetic analogue, based on an extract ofthe European Yew
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tree (Taxus baccata), docetaxel is now also available. The taxanes act by binding to
microtubules that are integral components of the mitotic spindle. Binding of taxanes to
the microtubules stabilizes them and prevents their depolymerisation. This inhibits cell
proliferation by causing a metaphase arrest in dividing cells.
1.3.4 Drug Resistance
Drug resistance is a major obstacle limiting our ability to cure patients with ovarian
cancer. Multiple mechanisms lead to drug resistance and resistance to any one drug is
likely to be multifactorial. Resistance to chemotherapeutic drugs can be an intrinsic
property of the tumour or can be acquired following treatment.
Reduced intracellular drug accumulation is an important mechanism by which cells
become drug resistant. A family of transmembrane proteins has been identified that use
an energy dependent process to transport drugs out of the cell. The first such protein
identified was P-glycoprotein (Ueda et al. 1986). P-glycoprotein is the product of the
MDR1 gene and is an ATP dependent, transmembrane transporter. This protein
functions as a drug efflux pump. Cells that overexpress P-glycoprotein accumulate less
drug resulting in insufficient intracellular drug levels to mediate cytotoxicity. Many
tumours display a multidrug resistant phenotype and in many instances this has been
shown to correlate with P-glycoprotein overexpression. Multi drug resistance associated
protein, (MRP), is another of the family whose expression confers a similar but not
identical drug resistant phenotype (Cole et al. 1994).
Enhanced inactivation of drug is another mechanism that can render a cell drug
resistant. Elevated levels of intracellular glutathione and metallothioneins are associated
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with drug resistance. Conjugation of these compounds with drugs produces a more water
soluble less toxic product that is readily excretable.
Drugs such as platinum compounds and alkylating agents exert their cytotoxic effects
by forming lesions in DNA. Following DNA damage, cells must repair or tolerate DNA
damage to survive. The ability of tumour cells to repair DNA may be a mechanism of
drug resistance. Enhanced DNA repair has been observed in cisplatin resistant ovarian
cancer cell lines (Masuda et al. 1990). Other studies have identified a link between
mismatch repair deficiency and cytotoxic drug resistance (Strathdee et al. 1999).
Alterations in expression of oncogenes (myc,ras.jun,fos,v-abl,Her/neu) can influence
cellular sensitivity to cytotoxic drugs although the mechanisms of this resistance are
uncertain. Since the expression of these oncogenes can lead to pleiotropic changes in
cells, the mechanism of resistance may be multifactorial. Alteration of the tumour
suppressor gene p53 may also influence chemosensitivity.
1.3.5 Natural history of ovarian cancer
The defining feature of a malignant as opposed to a benign tumour is the capacity for
invasion. In the context of carcinomas, invasion involves breach of the basement
membrane with infiltration of the underlying stroma. Following neoplastic
transformation, the initial step in tumourigenesis is local multiplication of malignant
cells. In order for a tumour cell to invade, it must first be able to detach itself from the
primary tumour. This occurs by a reduction in tumour cell adhesiveness which is
commonly associated with a reduction in expression ofE- Cadherin (ECDH). ECDH is a
calcium dependent cell to cell adhesion molecule whose expression has been shown to
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be frequently downregulated in epithelial cancers (Risingeretal 1994). ECDH promotes
cell to cell adhesion by connecting to the cytoskeleton via beta and alpha catenins.
Degradation of the basement membrane and extracellular matrix by tumour cells is a
prerequisite for invasion. Metalloproteinases are proteolytic enzymes produced by both
connective tissue and tumour cells that can degrade the components of the extracellular
matrix and basement membrane allowing tumour cell invasion. Following detachment
and invasion, tumour cells must be able to reattach in their new location where they can
then proliferate and or invade.
For tumours to survive, angiogenesis must take place. Growth factors secreted by both
tumour and host cells stimulate angiogenesis.
Unlike many other cancers, epithelial ovarian cancers rarely form metastatic deposits
outwith the abdominal cavity. Instead there is often extensive locoregional dissemination
of disease within the abdominal cavity. Undoubtedly tumour cells reach the
microvasculature of many organs but extravasation into the organ parenchyma and
growth rarely occurs. The reasons for this phenomenon are unclear.
Altered expression of chemokine receptors in breast tumour cells has been postulated
as a determinant ofmetastatic site (Muller et al. 2001). The lack ofpropensity ofovarian
cancer to spread outside the abdominal cavity suggests some sort ofmechanism whereby
cells can survive only in the milieu of the peritoneum or perhaps a mechanism that
inhibits growth outwith that body cavity. This may be due to due to lack of appropriate
growth factors, pH, cell surface receptors or ligands.
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1.4 HUMAN GENOME PROJECT
The human genome project (HGP) is a publicly financed international research effort
whose goal is to decipher the human genetic code and provide this data freely and
rapidly to the public. The HGP is a collaboration involving 20 groups from the United
States, the United Kingdom, Japan, France, Germany and China. The intent of the
collaborators was to make all the sequence data available without restriction within 24
hours of completion.
The idea of sequencing the human genome was first proposed at scientific meetings
organized by the United States Department of Energy and others from 1984 - 1986. The
United States National Research Council appointed a committee who endorsed the
concept in its 1988 report. Rather than limiting its aim to obtaining just the sequence of
the entire human genome, the committee recommended a broader programme which
included the creation ofgenetic, physical and sequence maps ofthe human genome with
parallel efforts in model organisms such as bacteria, yeast, worms, flies and mice. The
committee also advocated research into the ethical, legal and social issues raised by
human genome research.
By late 1990, the HGP had been launched and involved all the countries previously
mentioned. The Human Genome Organization (HUGO) was also formed to provide a
forum for international coordination ofgenomic research.
Initially, work focussed on construction of genetic and physical maps of the human and
worm genomes. Sequencing of the yeast and worm genomes showed that large-scale
sequencing was feasible and a two-phase paradigm for sequencing was developed. The
first phase would produce a draft genome sequence and the second would be a finishing
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phase in which gaps would be closed and remaining ambiguities resolved through
directed analysis.
Initially pilot projects were launched to demonstrate that cost effective accurate large-
scale sequencing was possible. These projects met their target completion date ofMarch
1999 and from that time on the human genome sequencing project moved into full-scale
production. The completion of a "working draft" of the human genome was announced
in June 2000 and published in the February 15th 2001 issue of Nature (Lander et al.
2001).
To sequence the human genome, a hierarchical shotgun sequencing strategy was
employed. A human genomic DNA library was constructed by fragmenting the genome
with restriction endonucleases. The fragments (typically 100=200kb) making up the
library were then organized into a physical map and non-redundant overlapping BAC
clones selected for sequencing. The BAC clones were further endonuclease digested and
the resulting fragments cloned and sequenced (random shotgun strategy). Finally, the
clone sequences were assembled to reconstruct the sequence of the genome.
1.5 BIOINFORMATICS
With a rapid expansion in the volume and complexity of molecular biological and
genetic data it was a requirement that computerised databases and analysis were
developed to deal with this huge expansion.
In 1988, the National Center for Biotechnologies Information (NCB1) was created. It
was formed as a division of the National Library of Medicine (NLM) at the National
Institutes for Health (NIH). The stated mission of the NCBI was to develop new
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information technologies to aid in the understanding of fundamental molecular and
genetic processes that control health and disease. The NCBI was to be responsible for
creating automated systems for storing and analysing knowledge about molecular
biology, biochemistry and genetics. These systems were to be readily accessible to the
research and medical community. In the early days of the human genome project the
emphasis for the bioinformaticists was on the creation and maintenance of databases.
Now with the release of the first draft of the sequence, the emphasis has shifted to
analysis and interpretation of the data. A major part of this computational biology
involves data mining. In this process, testable hypotheses are generated regarding the
function or structure of a gene or protein of interest by identifying similar sequences in
better characterised organisms.
The Cancer Genome Anatomy Project (CGAP) is an interdisciplinary program
established and administered by the National Cancer Institute (NCI) to generate the
information and technological tools needed to decipher the molecular anatomy of the
cancer cell. The goal of this project is to determine the gene expression profiles of
normal, precancer, and cancer cells, leading eventually to improved detection, diagnosis,
and treatment for the patient.
From CGAP's inception in 1996, NCBI has been a key participant in bioinformatics
planning, data tracking, data archiving, and analytical tool development and
implementation. NCBI is collaborating closely with a component of CGAP called the
Cancer Chromosome Aberration Project (CCAP). Using fluorescent in situ hybridization
(FISH), CCAP is generating clones that are spaced l-2Mb across the human genome.
Once mapped, these sequence-ready DNA BAC clones are then made available to the
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research community. NCBI is involved in identifying candidate BAC clones to be FISH-
mapped, archiving the results, and localizing these clones onto draft sequence contigs.
This data can be viewed through NCBI's Map Viewer and is linked to NCBI's Clone
Registry and UniSTS sites.
CCAP is also characterizing chromosome aberrations in selected tumor types
through the use of spectral karyotyping (SKY) and comparative genomic hybridization
(CGH). SKY facilitates identification of chromosomal aberrations and CGH can be
used to generate a map ofDNA copy number changes in tumour genomes. The
SKY/CGH database has been designed to house this data, and is publicly
accessible. The Mitelman Database ofChromosome Aberrations in Cancer is a summary
of all documented recurrent neoplasia-associated chromosomal aberrations. This work,
which originally appeared in the April 1997 Special Issue of Nature Genetics is
continuously updated and a summary of the latest data can be viewed with NCBTs Map
Viewer.
Molecular biology researchers have an enormous range of bioinformatics programs and
databases available to them over the internet. For the research undertaken in this thesis
several programs have been particularly helpful. BLAST (Basic Local Alignment Search
Tool) (http://www.ncbi.nlm.nih.gov:80/BLAST/) is a set of similarity search programs
designed to explore all of the available sequence databases regardless of whether the
query is protein or DNA (Altschul et al. 1990). ExPASy Translate
(http://www.expasy.ch/tools/dna.html) is a tool that allows the translation of a nucleotide
(DNA/RNA) sequence to a protein sequence. A full discussion of all algorithms and
databases is beyond the scope of this thesis but many of the programs used to facilitate
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the work in this thesis were accessible through the NCBI home page
(http://www.ncbi.nlm.nih.gov:80/).
1.6 MOLECULAR GENETICS OF OVARIAN CANCER
That cancer arises as a result of genetic alterations within cells has been known for a
long time. Tumorigenesis is thought to be a multistep process involving the acquisition
ofmultiple genetic alterations, which allows the cell to escape from the normal growth
constraints/mechanisms in the cell. Alterations of both proto-oncogenes and tumour
suppressor genes are involved in tumorigenesis.
Proto-oncogenes encode genes involved in cell signalling pathways associated with
growth control. They can be converted into activated oncogenes by amplification,
mutation or translocation.
Tumour suppressor genes act as regulators of cell growth and proliferation. They act
recessively at the cellular level; that is to say that the function of both alleles must be
disrupted before tumour suppressor activity is lost. Loss or inactivation of a tumour
suppressor gene may be the result of several mechanisms including point mutations,
deletions, chromosomal loss and epigenetic phenomena such as methylation.
1.6.1 Inherited predisposition to ovarian cancer
Whilst the majority of ovarian cancers are sporadic approximately 5-10% of cases are
demonstrated to have an inherited predisposition as judged by autosomal dominant
familial clustering. Three hereditary syndromes have been identified, namely hereditary
site-specific ovarian cancer, hereditary breast and ovarian cancer and the type 2 Lynch
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syndrome. Linkage analyses of the affected families have identified the susceptibility
genes BRCA1 and BRCA2 on chromosome 17q and 13q respectively (Miki et al. 1994)
(Wooster et al. 1995). Germline mutations ofthese genes can be found in the majority of
cases of hereditary site-specific ovarian and hereditary breast and ovarian cancers. Both
BRCA1 and BRCA2 have been demonstrated to be tumour suppressor genes.
Type 2 Lynch syndrome patients have mutations of certain mismatch repair genes and
have a propensity to develop tumours from the colon, endometrium and ovary (Lynch et
al. 1985b) (Lynch et al. 1985a).
1.6.1.1 BRCA1 and ovarian cancer
The BRCA1 gene was identified by positional cloning in 1994 (Miki et al. 1994).
Located on chromosome 17q it encodes a large protein and spans 84kb of genomic
sequence (Welcsh and King 2001). It contains 24 exons, the largest ofwhich, exon 11
codes for more than 60% of the 1863 amino acid protein. The protein contains several
functional domains including an N terminal RING finger domain and two BRCA1
terminal (BRCT) domains at the carboxy terminus.
Many lines ofevidence confirm that BRCA1 is a tumour suppressor gene. Frequent loss
ofheterozygosity on chromosome 17q has been observed in familial and sporadic breast
and ovarian cancers (Nagai et al. 1994) (Cadufif et al. 1999). In accordance with
Knudson's hypothesis, patients with germline mutations ofthe gene develop early onset
disease, as they only require to sustain one hit in order to have inactivated both copies of
the tumour suppressor gene. Early functional studies involving transfer of the long arm
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of chromosome 17 into a breast cancer cell line demonstrated suppression of the
tumorigenic phenotype (Negrini etal. 1994).
Much progress has been made in the functional analysis of BRCA1 and many of the
proteins with which it interacts have been identified. BRCA1 plays an important role in
DNA damage repair and transcriptional regulation.
The first evidence for BRCA1 involvement in DNA damage repair came from findings
that BRCA1 interacts with RAD50 and RAD51 proteins that are implicated in DNA
damage repair pathways (Chen, Lee, and Chew 1999). Subsequently, BRCA1 deficient
embryonic stem cells have been shown to be hypersensitive to oxidative agents such as
irradiation and display defects in double strand break repair (DSBR) (Deng and Scott
2000). Retrovirally expressed, wild type BRCA1 decreased the gamma radiation
sensitivity and increased the efficiency of double strand DNA break repair of the
BRCA1-/- human breast cancer cell line, HCC1937 (Scully et al. 1999). By contrast,
multiple, clinically validated, mis-sense mutant BRCA1 products were non-functional in
these assays and failed to rescue the phenotype. These data suggest that efficient repair
of double strand DNA breaks is a key BRCA1 tumour suppressor function.
Dysfunction of BRCA1 in cells leading to abnormalities in DNA structure would be
expected to provoke cell death at the point ofcell checkpoint control. This can be seen to
occur in BRCA1 homozygous mutant mouse fibroblasts on exposure to ionising
radiation (Shen et al. 1998). If however, loss of function of BRCA1 occurred in a
premalignant cell that had already acquired inactivation of key checkpoints, aberrant
DNA structures resulting from BRCA1 inactivation might be tolerated without cell cycle
arrest.
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BRCA1 has also been shown to function as a transcription factor. Certain fragments of
the protein when fused to a GAL4 DNA-binding domain can transactivate a GAL4
reporter except when they bear clinically relevant mutations (Chapman and Verma
1996). The C terminal region of BRCA1 contains the two BRCT domains that interact
with multiple transcription activators and co-repressors. The second BRCT domain
interacts with p53 and stimulates p53- dependent transcription ofthe p21 promoter (Chai
etal. 1999). Regulation ofp53 is another way in which BRCA1 can be seen to function
in maintaining genomic stability.
The prevalence of BRCA1 mutations in western populations is between 0.03-0,01%
(Easton, Ford, and Peto 1993). The Ashkenazi Jews have a much higher incidence of
disease associated alleles in the order of 1 % (Bahar et al. 2001).
More than sixty different germline mutations of BRCA1 have been identified (Xu and
Solomon 1 996). The mutations span the entire region of the gene and include deletions
and insertions as well as mis sense, nonsense and splicing mutations. The vast majority
ofmutations such as the 185delAG in exon 2 in Ashkenazi Jewish populations result in
the production of nonfunctional truncated forms of the protein product.
For carriers of a germline BRCA1 mutation, the estimated risk ofovarian cancer is 20-
50% by age 70 years (Ford et al. 1998).The mean age of onset is about 5 years younger
in hereditary than in sporadic ovarian carcinoma. Serous adenocarcinoma is the most
common histological type (83% vs 49% matched controls) (Chang et al. 1995). Several
studies have suggested that patients with ovarian cancer who are carriers of BRCA
germline mutations have a better prognosis than those without mutations. A study by Y
Ben David et al (Ben David et al. 2002) of patients with ovarian cancer found a
32
significant difference in survival between BRCA1/BRCA2 carriers and non-carriers.
The reason why carriers had a better survival is not clear.
1.6.1.2 BRCA2 in ovarian cancer
BRCA2 was cloned in 1995 (Wooster et al. 1995). It is located on chromosome 13ql 2-13
and spans 86kb of sequence. It encodes a protein of 341 8 amino acids. BRCA2 has 27
exons and although it is unrelated in sequence to BRCA1 it also includes an unusually
large central exon 11. Encoded within this exon are eight BRC repeats composed of
approximately forty residues each. These repeats are the major sites for direct binding of
BRCA2 to RAD51 which is involved in DNA repair (Wong et al. 1997).
BRCA2 appears to have very similar functions to BRCA1. It plays a role in DNA repair
and has been implicated in the regulation of transcription. Frequent LOH on
chromosome 13q 12-13 in sporadic ovarian cancer has been documented (Gras et al.
2001).
More than one hundred disease causing mutations in BRCA2 have been identified. The
majority ofmutations are deletions and result in truncation of the BRCA2 protein.
In the largest study to date, the estimated cumulative risks of ovarian carcinoma in
families carrying a mutation in BRCA2 were 0.4% by the age of 50 and 27% by the age
of 70 (Ford et al. 1998). There is some data to suggest that an ovarian carcinoma
mutational cluster region in exon 11 of BRCA2 confers higher risk of ovarian cancer
(Gayther et al. 1997) but not all studies support this.
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1.6.2 Oncogenes
Protooncogenes encode components ofthe signal transduction pathways involved in the
regulation of cell growth. There are four main groups of protooncogenes encoding
growth factors, growth factor receptors, signal transducers and nuclear transcription
factors. Protooncogenes can be converted into oncogenes by insertion, amplification,
mutation or translocation. Activation of oncogenes contributes to the uncontrolled
cellular proliferation that is characteristic of malignancies.
Of the growth factor receptors, the epidermal growth factor (EGF)/ ErbB family has
been extensively studied. The EGF/ErbB receptor family has four members: ErbBl
(HER-1, EGFR-1), ErbB2 (HER-2, NEU), ErbB3 (HER-3) and ErbB4 (HER-4). These
receptors are comprised of an extracellular ligand binding domain, a hydrophobic
transmembrane region and an intracellular portion encoding a tyrosine kinase domain.
Ligand binding induces a conformational change in the receptor that stimulates receptor
dimerisation that can be either homo or heterodimeric. Following dimerisation,
activation of the tyrosine kinase domain of the receptor leads to phosphorylation and
activation of regulators of downstream pathways.
Members of both the EGF family of peptides and the EGF family of receptors show
altered expression in ovarian tumours. Overexpression ofEGF-Rl in ovarian cancer has
been well documented and antisense suppression ofEGF-R expression has been shown
to alter cellular proliferation, cell adhesion and tumorigenicity in ovarian cancer cells
(Alper et al. 2000). Overexpression of HER-2 occurs in approximately 30% of ovarian
cancers and is associated with poor survival (Berchuck et al. 1990).
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Different EGF - like peptides are overexpressed in many human carcinomas compared
with their untransformed counterparts. These tumour-derived growth factors can act as
both paracrine and autocrine factors to stimulate cell proliferation and survival in cells
that express the receptors for these peptides. Antisense oligonucleotides to EGF related
peptides inhibit the proliferation ofovarian carcinoma cells (Casamassimi et al. 2000).
Discovery of an activated form of Ras in a human bladder cancer cell line was the first
identification of a human oncogene. There are 3 human ras genes, Flarvey, Kirsten and
N-ras. The ras proteins bind guanine nucleotides and activate signalling cascades. They
are located on the inner leaflet of the plasma membrane and in their basal state they are
bound to GDP. Activated ras binds GTP and activates downstream signalling proteins
until GTP hydrolysis mediated by the intrinsic activity of ras returns the system to its
basal state. Ras mutations have been identified in many tumour types. Point mutations
that activate ras have been found to cluster in the regions encoding codons 12 and 13
and 59-61. These mutations act by interfering with the GTP hydrolysis leading to
constitutive activation of ras.
K-ras activation was found to occur frequently in mucinous adenocarcinomas but rarely
in other common epithelial tumours of the human ovary (Enomoto et al. 1991). A later
study, of benign, borderline and malignant mucinous tumours identified a frequency of
codon 12/13 mutations of68%. This study identified these mutations in all three groups
of tumours (55,73, 85% respectively) suggesting that k ras mutational activation is an
early event in mucinous ovarian tumorigenesis (Cuatrecasas et al. 1997) .A study of K-
ras mutations in non mucinous ovarian epithelial tumours found an overall prevalence of
mutations of 30.5%(Cuatrecasas et al. 1998). This is much lower than the prevalence of
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mutations in mucinous tumours and suggests that K-ras mutations are not initial events
in the pathogenesis of non-mucinous ovarian tumours.
The myc gene product is a nuclear protein. Myc is expressed at very low levels in
quiescent cells but its expression is rapidly induced in response to mitogenic signals.
The level of myc expression reflects the proliferation status of the cell. Regulation of
expression of nuclear proto-oncogenes is intrinsic to their function and activation of
nuclear oncogenes often occurs by deregulation of expression rather than mutation.
Deregulated expression can occur as a result of translocation or amplification of the myc
gene. Many studies have identified amplification and overexpression of c-myc in
ovarian carcinomas (Diebold et al. 1996) (van Dam et al. 1994) (Berns et al. 1992)
(Tashiro et al. 1992) (Baker etal. 1990) (Rohler et al. 1989). Rates ofamplification and
overexpression ranged from 17-48% amongst these studies. There was no apparent
association with survival. One study identified a significant association of
overexpression of c-myc in stage III ovarian cancers compared to other stages.
The serine/threonine protein kinase, protein kinase B or Akt (PKB/Akt) has been shown
to play an important role in oncogenesis. In humans, there are three closely related Akt
family members designated Aktl, Akt2, Akt3 located at chromosomes 14q32, 19q 13
and 1 q44 respectively. One ofthe first reports ofAkt gene involvement in human cancer
was demonstration of amplification and overexpression ofAkt2 in ovarian tumours and
cell lines (Cheng et al. 1992). The Akt kinases are downstream targets of growth factor
receptor tyrosine kinases that signal via phosphatidylinositol 3-kinase (PI3K). PI3K
generates phosphatidylinositol-345 triphosphate (PIP3) which is essential for the
translocation of Akt to the plasma membrane where it is phosphorylated and activated
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by phosphoinositide-dependent kinase-1 (PIDK1). The tumour suppressor PTEN inhibits
Akt activation by dephosphorylating PIP3 (Tamura et al. 1999). Constitutive activation
of Akt in cancers has been shown to result from amplification of Akt or as a result of
mutations in components of the signalling pathway that activates Akt. Akt appears to
both negatively regulate factors that promote the expression of death genes and
positively regulate factors that induce survival genes (Nicholson and Anderson 2002).
1.6.3 Cytogenetics
Whilst linkage analysis has been used to identify genes involved in cases of inherited
cancer, different approaches are used to investigate the somatic genetic alterations
occurring in sporadic cancers which account for approximately 90-95% of ovarian
cancer cases. Cytogenetic studies can identify frequent non-random structural genetic
alterations ofchromosomes within tumour cells suggesting specific chromosome regions
on which to focus to identify genes involved in the cancer process.
Many studies performing cytogenetic analyses of ovarian cancers have been published
(Brock et al. 1996; Kiechle-Schwarz etal. 1995;Nachevaetal. 1998;Pejovic 1995; Rao
et al. 2002). These studies have indicated the presence ofmultiple complex chromosome
abnormalities in ovarian cancer. The largest study to date is a cytogenetic analysis of
244 primary ovarian cancer specimens (Taetle et al. 1999). This study identifies non-
random patterns of chromosome breakpoints at the level of chromosome regions.
Simultaneous occurrence of multiple abnormalities was common but nearly every
tumour with chromosome breaks had breakpoints in one of thirteen non-randomly
involved regions from chromosomes 1, 6, 7, 11, 12, 13 and 19.
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Comparative genomic hybridisation and fluorescence in-situ hybridisation are
alternative methods used to identify structural genetic abnormalities.
1.6.4 Loss of heterozygosity in ovarian cancer
The finding of a region of frequent loss of heterozygosity (LOH) in tumour DNA
suggests the possibility that a tumour suppressor gene may reside at that locus. To date,
many studies of LOH in epithelial ovarian cancer have been performed and several
hotspots of LOH have been identified. There are however, many obstacles to be
overcome in the interpretation ofLOH data. Despite the large number ofstudies of LOH
it is difficult to perform a meaningful meta-analysis of the results. Studies vary as to
their inclusion of benign, borderline and malignant tumours. Variation between studies
with respect to clinicopathological variables such as histology and stage further
complicates attempts at data comparison. Many studies contain only a small number of
tumours and study findings often fail to reach statistical significance. Another factor that
affects LOH findings and hinders comparison of data is the choice and number of
microsatellite markers examined. Some studies report presence or absence of LOH
based on analysis of only a small number of markers, sometimes only one or two
markers per chromosome arm. Furthermore, rates ofLOH may be influenced by the use
ofmicrodissected or undissected tumour tissue. Studies using undissected tissue may fail
to detect LOH that is masked by a high percentage of normal stromal tissue in the
sample. Finally, definition ofwhat constitutes LOH is an arbitrary one. Commonly LOH
is assigned where the difference in the ratio of normal to tumour alleles varies by greater
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than thirty percent (r < 0.7). Some authors however have used a more stringent cut off,
only assigning LOH where r < 0.5.
To date greater than 1 00 studies of LOH in ovarian cancer have been published. LOH on
almost every chromosome has been identified. The most commonly reported LOH
findings in ovarian cancer are LOH at 17p and 17q, the sites of the p53 and BRCA1
tumour suppressor genes respectively.
1.6.5 p53 - THE PARADIGM OF A TUMOUR SUPPRESSOR GENE
1.6.5.1 p53 The paradigm of a tumour suppressor gene
The p53 tumour suppressor protein is a multifunctional protein. It is a transcription
factor whose 2 main functions are the induction of cell cycle arrest and apoptosis.
The p53 protein has been labelled the "guardian of the genome". p53 responds to
signals produced by a wide range of cellular stresses such as heat, hypoxia, hyperoxia,
cytokines, growth factors, metabolic changes, cell to cell contact and activated
oncogenes. P53 responds to these insults by activating a set of genes whose products
facilitate adaptive and protective activities that include cell cycle arrest and apoptosis.
Cellular stresses such as DNA damage cause p53 accumulation. The factors that
determine whether cell cycle arrest or apoptosis ensues after p53 activation are not
understood. The outcome is likely to be cell type specific and contextual. Cell cycle
arrest at the G1 and G2 checkpoints prior to DNA replication and mitosis allows time for
DNA repair thus preventing the propagation of mutations and aneuploidy. On the other
hand, apoptosis is a fail-safe mechanism to rid the organism of cells with severely
damaged DNA. Transcriptional activation of the p21 WAF/CIP1 cyclin-dependent
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kinase inhibitor plays a key role in the induction of cell cycle arrest but there does not
seem to be a similar single critical apoptotic target.
The p53 gene is located on the short arm of chromosome 17 in a region, which is
subject to loss of heterozygosity in many different cancers. The p53 gene spans a
genomic distance ofmore than 20kb and has 11 exons. The 393 amino acid protein has
several functional domains and five regions that are highly evolutionarily conserved.
(>90% homology between man and rodents in those conserved regions). Starting at the
N terminal of the protein, the functional domains include a transcriptional activation
domain, an SH3 binding domain, a sequence specific DNA binding domain, a
tetramerization domain and a C-terminal basic domain.
In the context of specific binding to a DNA sequence, a region at the acidic N terminal
of the protein forms a transcriptional activation domain which allows the p53 protein to
recruit the basal transcriptional machinery required for mRNA synthesis. This region
forms interactions with other proteins such as mdm2 and is therefore critically involved
in regulating the stability and activity of p53. Interaction with mdm2 targets p53 for
ubiquitin mediated degradation. Mdm2 binding also blocks the ability of p53 to interact
with the transcriptional apparatus. The core of the p53 protein is the sequence specific
DNA binding domain. The binding to DNA is optimal when the protein is in a
tetrameric state which results from an interaction of four separate p53 molecules via the
tetramerization domain adjacent to the C terminal region. The C terminal region is
composed of predominantly basic residues and is involved in nuclear localisation and
DNA damage recognition. The DNA binding domain is separated from the
transcriptional activation domain by the SH3 binding domain. The SH3 binding domain
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contains a series of repeated proline residues typical of a polypeptide that interacts with
signal transduction molecules that contain an SH3 binding domain.
1.6.5.2 P53 in cancer
P53 participates in a cell cycle checkpoint signal transduction pathway that causes either
a G1 arrest or apoptotic death after DNA damage or alternatively non genotoxic stress.
Loss of p53 function would result in inappropriate progression through the cell cycle
after DNA damage allowing survival of a cell that would otherwise have been destined
to die. It is apparent therefore how loss of normal p53 function contributes to malignant
transformation by causing increased genetic instability and a reduction in apoptosis.
P53 is the most commonly mutated gene in human cancers with at least 50% of all
tumours having abnormal p53 genes. Some tumours develop other mechanisms of
inactivating p53 such as overexpression ofthe p53 binding protein mdm2 or by infection
with human papilloma virus (HPV). Expression of the HPV E6 protein binds p53 and
enhances its degradation.
As well as being frequently mutated in sporadic cancer, germline mutations in p53 result
in Li- Fraumeni syndrome, a hereditary cancer susceptibility syndrome predisposing
individuals to sarcomas, lymphomas, breast, brain and other tumours. In accordance
with these findings, mice deficient for p53 are highly tumour susceptible (Donehower et
al. 1996).
In a study of p53 mutations in a range of human cancers, 98% of 280 base substitution
mutations identified were found to occur in a 600bp region spanning exons 5-9. This
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sequence contains a large number ofevolutionarily conserved amino acids (Hollstein et
al. 1991).
The location and type ofmutations in a specific sequence define a mutational spectrum.
By defining a p53 mutational spectrum for all cancer types, mutational hot spots can be
identified. When mutations are examined for individual cancer types, clear differences in
mutational spectra emerge. These spectra vary with respect to the position of the
hotspots and with respect to the frequency of transitions (in which a purine is substituted
for a purine or a pyrimidine for a pyrimidine) and transversions (in which a purine is
substituted for a pyrimidine or vice versa.)
Different carcinogenic agents have been shown to produce different types ofmutation
and therefore analyses of mutational spectra allow us to generate hypotheses concerning
the aetiology and molecular pathogenesis of cancer. G:C to T:A transversions in p53
have been shown to result from polycyclic aromatic hydrocarbon exposure and are
commonly seen in lung cancers. G:C to A:T transitions are the most common p53
mutations seen in colon cancer. This mutation is the result of endogenous mutational
mechanisms caused by deamination of 5methyl cytosine residues found at CpG
dinucleotides. The most striking p53 mutational spectrum is found in hepatocellular
carcinoma arising in people living in geographic areas where aflatoxinB and hepB virus
are major risk factors for liver cancer. In these patients the majority of hepatocellular
carcinomas carry a G:C to T:A transversion at the 3rd base position of codon 249. This
transversion is not found in hepatocellular cancer arising in people living outwith
regions of aflatoxinB exposure. This finding implicates aflatoxinB as the aetiological
factor for this mutation. Another example of the mutational specificity of exposures
42
includes skin carcinoma and UV light yielding distinctive CC to TT transitions (Brash et
al. 1991).
1.6.5.3 P53 and ovarian cancer
Alterations of the p53 gene appear to play an important role in the development of
human ovarian cancers. Frequent LOH on 17p in ovarian cancer has been demonstrated
and frequent mutations of p53 in ovarian cancer have been documented (Okamoto et al.
1991). As in other cancer types, the majority ofmutations are found between exons 5-9.
There is no consensus between the many studies regarding the nature of the mutations in
p53 in ovarian cancer. Detection of varying proportions of transitions, transversions,
insertions and deletions from one series to another may be due to environmental or
endogenous influences or it may be due to the methods employed for detection of p53
mutations. Some studies have analysed only exons 5-9 for mutations whilst others rely
on immunohistochemistry to screen tumours prior to mutation analysis. Normally, p53 is
not immunodetectable. Mis-sense mutations of the p53 gene result in proteins that have
a longer half-life than the wild type protein and are resistant to degradation. Some
investigators have therefore used identification of p53 expression by
immunohistochemistry as an indicator of the presence of mutated p53. This however
means that tumours with p53 mutations that create an unstable protein product will not
be detected.
The prognostic significance and nature of p53 dysfunction in ovarian carcinoma is
uncertain. The relation between p53 expression, p53 mutations and overall survival has
been investigated in many studies but small study size and technical difficulties have
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made it difficult to draw conclusions about the prognostic implications ofp53 mutations.
A study by Fallows found that p53 mutation does not affect prognosis in ovarian
epithelial malignancies (Fallows et al. 2001). In the largest study of its kind to date, of
171 epithelial ovarian cancers, 48.5% and 57.3% of the samples showed p53
overexpression and p53 mutation respectively (Shahin et al. 2000). Although neither p53
overexpression nor the mere presence of a p53 mutation impacted on overall survival,
the combination did reveal adverse prognosis in both univariate and multivariate models.
Studies have been performed to investigate the use of identifying p53 mutations as a
predictor ofchemoresistance. P53 has been shown to have a critical role in the induction
ofapoptosis following DNA damage caused by cytotoxic drugs. Loss of function ofp53
may therefore be a determinant of chemoresistance in tumours. Sato et al showed that
p53 dependent apoptosis in tumours was strongly related to chemosensitivity in
epithelial ovarian cancer (Sato et al. 1999).
1.6.6 NOEY2
NOEY2 (ARH1) is a member of the Ras superfamily of small G proteins that was
mapped to chromosome 1 p31 (Yu et al. 1999). NOEY2 is expressed in normal breast
and ovarian epithelial cells but not in breast or ovarian cancers. NOEY2 is expressed
monoallelically and is imprinted maternally. In one study, LOH ofthe gene was detected
in 41% of breast and ovarian cancers and in most of the cancer samples with LOH, the
non-imprinted functional allele was deleted (Yu et al. 1999). Re-expression ofNOEY2
through transfection suppresses clonogenic growth of breast and ovarian cancer cells.
Overexpression ofNOEY2 inhibits lactation and growth in transgenic mice (Xu et al.
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2000). NOEY2 thus appears to be a putative imprinted tumour suppressor gene whose
function is abrogated in breast and ovarian cancers. Unpublished data suggests that
expression of NOEY2 may truncate signalling through ras/mitogen - activated protein
kinase induced by growth factors (Yu et al. 1999). In a small study, genetic analysis of
NOEY2 by SSCP in eighteen cancer cell lines and four normal controls revealed one
germline mutation in the promoter region but no coding sequence mutations.
1.6.7 LOH on llq in ovarian cancer
LOH on the proximal portion of 1 1 q has been described but at lower frequencies than
LOH on distal 1 lq and therefore will not be considered further. LOH of the 1 lq23-qter
in epithelial ovarian cancer was first identified by Foulkes et al in 1993 (Foulkes et al.
1993). LOH was more common in advanced grade tumours but due to small study size
this finding did not reach statistical significance. A study by Gabra et al identified allele
imbalance at D11S912 to be associated with adverse survival and noted a trend towards
significance for the association of LOH at D11S912 and Figo stage III/V disease (Gabra
et al. 1995). A further study by Davis et al in 1996 identified two regions of LOH, the
first region proximal to 11 q24 and a second region lying between D11S912 and
D11S439 (Davis et al. 1996).
The authors suggested that LOH of this second region was an early event in ovarian
tumourigenesis because LOH was observed frequently in grade one and stage one
tumours (as well as being a common event in higher grade and stage tumours).
Concurrently, an independent study of LOH on chromosome 1 lq in epithelial ovarian
cancer by Gabra et al refined the authors' previously defined region of LOH to an
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overlapping 8.5 Mb region on 11 q24 (Gabra et al. 1996). Loss of this region was
associated with adverse survival. In 1998, Winqvist et al found that LOH at D1 1S912
was correlated with a higher tumour stage, serous histology and finding of residual
tumour but not directly with survival times (Launonen et al. 1998). The lack of
association with survival is contrary to findings ofGabra et al (Gabra et al. 1995) (Gabra
et al. 1996).
1.6.8 Candidate tumour suppressor genes from chromosome llq
Genes from llq that have been investigated as candidate tumour suppressor genes
include the ATM gene and PPP2RIB genes. Both these genes reside in a region of
frequent loss of heterozygosity but neither have been found to be somatically altered in
ovarian cancer suggesting that they are not the tumour suppressor genes from this region
(Koike et al. 1999) (Campbell and Manolitsas 1999) (Wu et al. 1999). Located in the
1 lq24-5 region is Barx2, a homeodomain containing transcription factor that regulates
the transcription of specific cell adhesion molecules in the mouse. Barx2 is expressed in
the normal ovarian surface epithelium and has been shown to have functional tumour
suppressor properties in ovarian cancer cells (Sellar et al. 2001). Using a combination of
DHPLC and fluorescent SSCP, no mutations were detected in DNA from a panel of 71
cell lines (16 ovarian and 55 non-ovarian cell lines) and 12 ovarian tumours.
(Unpublished data). Analysis of the methylation status ofthe Barx2 CpG island revealed
that Barx2 is not methylated in cancer cell lines or ovarian tumours. (Unpublished data).
These data suggest that Barx2 is not the 11 q24-5 tumour suppressor gene.
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1.7 METHYLATION AND CANCER
Methylation of the CpG islands associated with genes has been identified as a
mechanism of inactivation of tumour suppressor genes in cancer. Methylation is an
epigenetic process that produces a heritable change in DNA that does not alter the
nucleotide sequence. Methylation ofCpG islands is associated with the transcriptional
silencing of the affected genes.
CpG islands are found at the 5' ends ofmost genes. They are short stretches of DNA
with a high CG content and a high frequency ofCpG dinucleotides relative to the rest of
the genome. 95% of CpG islands are less than 1 800bp long. (Lander et al. 2001) The
most recent prediction of the number ofCpG islands in the genome is 28890 (Lander et
al. 2001) .CpG islands often include the promoter region of the associated gene as well
as part or all of the first exon of the gene (Cross and Bird 1995). In contrast to the DNA
outside of these CpG islands, the CpG dinucleotide in the island is unmethylated. Under
normal circumstances there are only two exceptions to this lack of methylation.
Imprinted genes, and genes on the inactivated X chromosome in females are methylated
at their CpG islands. This suggests that lack of methylation is a prerequisite for
transcriptional activation.
The mechanisms by which promoter hypermethylation repress transcription are not
clear. The presence of a methylated cytosine may directly inhibit transcription factor
binding but this would only affect factors with a CpG in their binding site. Methylation
has been shown to alter chromatin structure and thereby affect access of transcription
factors to their binding sites. Several proteins have been identified that bind
preferentially to methylated cytosines in DNA. Methyl CpG-binding protein 2 (MECP2)
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was the first member of this family ofmethyl CpG binding domain (MBD) proteins to
be identified (Lewis et al. 1992). These proteins form complexes with proteins that
include histone deacetylases and other transcriptional repressors. Recruitment of a
histone deacetylase to the DNA leads to chromatin remodelling which alters
transcriptional activation potential.
In transcriptionally active chromatin, acetylation of the positively charged lysine
residues in the histones of the nucleosome promotes a relaxed open chromatin structure.
This permits transcription by allowing transcription factors and RNA polymerase access
to regulatoiy regions of the DNA. Deacetylation causes the chromatin to adopt a more
closed compact formation that excludes access to transcription factors. The identification
of MBD proteins provided a mechanism whereby methylation could influence
transcription by recruiting proteins that alter acetylation status. Acetylation status
undoubtedly influences the transcriptional status of genes but a study by Cameron et al
showed that treatment with an inhibitor of deacetylase alone was not sufficient to
reactivate expression of a gene silenced by methylation (Cameron et al. 1999). Only
with the combination of TSA and azacytidine was the gene able to be reexpressed
suggesting that in this context, methylation was the dominant silencing mechanism.
The importance ofCpG island hypermethylation can be appreciated by considering the
frequency of this process in cancer, the nature of the genes involved and the similar
selective advantage conveyed by methylation as by mutations in coding regions. Several
tumour suppressor genes that cause familial cancers through germline mutations are
inactivated in association with promoter hypermethylation in sporadic cancers. These
include VHL (Herman et al. 1994) p 16 (Merlo et al. 1995), E- cadherin (Yoshiura et al.
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1995) hMLHl (Herman et al. 1998) and BRCA1 (Esteller et al. 2000). Until it was
discovered that BRCA1 was frequently methylated in sporadic breast and ovarian
cancers it was intriguing that mutations in the BRCA1 gene in the sporadic forms of
these diseases were rare. The existence of promoter methylation of BRCA1 provided an
alternative method of inactivation of this gene in the non-familial cases. A study by
Esteller at al ofDNA methylation in hereditary human cancers found similar patterns to
those in sporadic tumorigenesis (Esteller et al. 2001). Analysis of the methylation of the
CpG islands of 10 genes in inherited and non inherited breast and colorectal cancers
showed that singly retained alleles of germline mutated genes were never
hypermethylated in inherited tumours. However, in tumours where both alleles were
retained, methylation of the wild type copy was a frequent second hit.
The mechanisms that lead to aberrant methylation of CpG islands have yet to be
elucidated. In normal tissues, the DNA methyl transferases are a family ofenzymes that
catalyse the conversion of cytosine to 5' methyl cytosine. DNAmethyltransferase 1
(DNMT1) is the enzyme responsible for the maintenance of methylation and is
constitutively active in proliferating cells. DNMT3A and DNMT3B are de novo
methyltransferases that catalyse the transfer of a methyl group to previously
unmethylated DNA. All 3 enzymes have been found to be overexpressed in tumour
versus normal tissues with DNMT3B showing the highest overexpression (Robertson et
al. 1999).
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1.8 CELL ADHESION MOLECULES AND THE EXTRACELLULAR MATRIX
Cell adhesion is a fundamental property of multicellular organisms. Adhesion however
does more than merely hold cells together. Cell to cell and cell to ECM adhesion have
been shown in some systems to be required to block programmed cell death. This
suggests that the physical processes of cell adhesion are linked to cellular signal
transduction processes that control cellular differentiation, division and death. Adhesion
therefore can determine the phenotype and fate of the cell. There are four main groups of
cell adhesion molecules. Cadherins are the major cell to cell adhesion molecules with
integrins, selectins and immunoglobulin cell adhesion molecules forming cell to cell and
cell to ECM interactions. The majority of cell adhesion molecules are transmembrane
glycoproteins. The extracellular component ofthe molecule interacts with cell adhesion
molecules on neighbouring cells or with proteins of the ECM. At the intracellular
surface of the cell membrane, cell adhesion receptors associate with cytoplasmic plaque
or peripheral membrane proteins. These proteins link the adhesion system to the
cytoskeleton and transduce signals initiated at the cell surface by the adhesion receptors.
Many cells express a variety of cell adhesion molecules and individual cell adhesion
molecules will not act in isolation. It is likely that a combination ofmany cell adhesion
interactions determines the phenotype of a cell.
1.8.1 Cadherins
1.8.1.1 Cadherins in normal tissues
The cadherins are adhesion molecules that mediate homophilic calcium-dependent cell
to cell adhesion. There are at least six subfamilies of the cadherin superfamily. In
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general, cadherins comprise a large extracellular domain, a single transmembrane region
and a cytoplasmic tail. E-Cadherin is studied as the prototype molecule for the cadherin
superfamily. The extracellular portion of this molecule is made up of 5 subdomains,
commonly designated EC 1-5. Each subdomain comprises approximately ten amino acid
residues (Takeichi 1995). Cadherin cell adhesion is dependent on calcium ions that bind
to the extracellular portion of the molecule stabilising the cadherin structure. Cadherin
mediated intercellular adhesion occurs in a zipper like fashion by interaction of the
cadherin subdomains on one cell with cadherin subdomains on a neighbouring cell. For
cadherins to be fully functional as cell adhesion molecules they require structural
linkage to the cytoskeleton of the cell. This is achieved by binding of the cytoplasmic
domain of the cadherin to catenin proteins. The catenin proteins bind to actin filaments
thus acting as intermediate linker proteins.
Cadherins have been shown to be key regulatory molecules during development. The
expression patterns of cadherins correlate with distinct morphogenetic events such as
blastomere compaction, epithelial-mesenchymal conversion and folding of epithelia.
Both over-expression and loss of function studies have been shown to lead to
perturbations in morphogenesis. E-cadherin deficient mouse embryos cannot develop
normally into blastocysts (Riethmacher, Brinkmann, and Birchmeier 1995) (Larue et al.
1994)) and mice without functional N-cadherin have abnormal heart and neural tube
development. Studies in developing embryos have shown that expression ofcadherins is
dynamic. Altering the subclass ofcadherin expressed or terminating the expression ofan
individual cadherin in a tissue is associated with its separation from the parent tissue e.g.
Formation of the neural tube or formation of the mesoderm.
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Through their interactions with the catenins, cadherins are postulated to influence
intracellular signalling (Behrens 1999). It is impossible however to separate their role as
mediators of cell adhesion from their function as mediators ofcell signalling. As well as
providing a link between cadherins and the cytoskeleton, beta catenin is part ofthe WNT
signalling pathway. Beta catenin is normally found in complex with cadherins or as non-
sequestered free beta catenin. This free cytoplasmic pool is usually rapidly
phosphorylated and subsequently degraded. Accumulation of free cytoplasmic beta
catenin results in its translocation to the nucleus. In the nucleus beta catenin binds to
members ofthe T cell family oftranscription factors and activates transcription of target
genes that have oncogenic effects. Binding of beta catenin at the cell membrane by
cadherins will reduce the pool of free cytoplasmic beta catenin thus decreasing its
translocation to the nucleus with a consequent decrease in beta catenin signalling.
Cadherins exist alone in the cell membrane or as part of a junctional accumulation of
cadherins such as in the zonula adherens of epithelial tissues. Biochemical and
immunohistochemical studies have shown that the zonula adherens contains many
proteins in addition to the cadherin-catenin complexes. The presence of other proteins
suggests a mechanism whereby cadherin based adhesion may influence cellular
signalling other than via the catenins. Signalling molecules such as members of the src
family of non receptor tyrosine kinases are concentrated in adherens junctions and are
good candidates to mediate adhesion dependent signalling events, although as yet, there
is little evidence for this.
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1.8.1.2 Cadherins and cancer
The majority of human cancers arise from epithelial tissues. E-cadherin is expressed in
almost all epithelial tissues, where it is the most abundant adhesion molecule in adherens
junctions (Gumbiner 1996). Expression of E-cadherin has been demonstrated to be
reduced or absent in many different types of carcinomas including those of the female
genital tract (Inoue et al. 1992). It has long been known that cell to cell adhesion is
dramatically altered during the development of malignancy. Loss of E-cadherin cell to
cell adhesion is concomitant with progression towards malignancy but it was a matter of
debate as to whether loss of E-cadherin is a cause or effect of tumour progression. Its
role as a tumour suppressor gene has now been firmly established. The role of E-
cadherin as an invasion suppressor has been well documented in vitro (Behrens 1999)
and direct evidence for a role of E-cadherin in the progression from benign adenoma to
malignant carcinoma has been observed (Perl et al. 1998). It has been shown to be
frequently mutated in cancers of the stomach and breast but is only rarely mutated in
carcinomas of the ovary or endometrium (Risinger et al. 1994) (Berx et al. 1998). The
location of E cadherin on chromosome 16q22 is subject to LOH in many cancers.
Methylation of the CpG island of E Cadherin has been demonstrated to be a common
method of allelic inactivation in many tumours including breast (Cheng et al. 2001)
gastric (Machado et al. 2001), eosophageal (Si et al. 2001). prostate (Kallakury et al.
2001), renal cell (Nojima et al. 2001), oral squamous cell (Nakayama et al. 2001),
hepatocellular (Matsumura, Makino, and Mitamura 2001) and thyroid carcinomas (Graff
et al. 1998). Transient loss of expression of E-cadherin secondary to epigenetic
silencing by methylation rather than disruption of a functional protein resulting from a
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coding region mutation may be advantageous to the malignant cell. Transient loss of
expression of E-cadherin may allow invasion but subsequent demethylation and
reexpression may facilitate cell survival within metastatic deposits. Graff et al
demonstrated that methylation patterns of the E-cadherin CpG island in breast cancer
cells were unstable and reflected the dynamic, heterogeneous loss of E-cadherin
expression during metastatic progression (Graff et al. 2000).
1.8.1.3 Cadherins and ovarian cancer
Despite its wide acceptance as a tumour suppressor gene, it has been proposed that E-
cadherin expression in the ovarian surface epithelium is necessary during the early
stages of its neoplastic transformation. Normal human ovarian surface epithelium has
very little if any expression of E-cadherin (Sundfeldt et al. 1997) In contrast, benign,
borderline and malignant epithelial ovarian tumours have substantial expression of E-
cadherin. Although arising from a simple mesothelium, epithelial ovarian tumours
exhibit varying degrees ofMullerian differentiation and exhibit properties of oviductal,
endometrial and cervical epithelia. It is believed that this more complex differentiated
phenotype is mediated by the expression of E-cadherin (Auersperg et al. 1999). The
requirement for E-cadherin expression in the development of ovarian neoplasia was
investigated by transfecting immortalised normal human surface ovarian epithelial cells
with E-cadherin (Ong et al. 2000). This resulted in the production of an ovarian
adenocarcinoma cell line suggesting that E-cadherin was instrumental in promoting the
transition to the malignant phenotype. Little is known about the role of other cadherin
family members in the normal ovarian surface epithelium and in ovarian tumours. The
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H-cadherin gene (CDH13) is located in a region of frequent deletion on chromosome
16q in ovarian cancer (Kawakami et al. 1999). The authors of this study detected a low
expression of H-cadherin in the tumours with LOH of a polymorphic satellite marker
within the H-cadherin gene. Methylation specific PCR identified methylation of H-
cadherin alleles and they suggested that a combination of hyper-methylation and
deletion cause the inactivation of H-cadherin in ovarian tumours. An
immunohistochemical study of the expression ofE and N-cadherins in ovarian tumours,
detected N-cadherin expression in most benign and borderline tumours but expression
was absent or heterogeneous in most carcinomas (Darai et al. 1997). E-cadherin was
homogeneously expressed in benign tumours but was absent or heterogeneously
expressed in most borderline and malignant tumours. A separate immunohistochemical
study found that serous and endometrioid tumours express both E and N-cadherin. In
contrast, mucinous tumours strongly expressed E-cadherin but not N-cadherin (Peralta
Soler et al. 1997). K-cadherin (CDH6) and a potential regulator of its expression, Barx2,
are expressed in the normal ovarian surface epithelium (Sellar et al. 2001). Sellar et al
report significantly lower expression of both Barx2 and K-cadherin in a clinical sample
of endometrioid and clear cell ovarian tumours as compared with serous or mixed
mesodermal tumours. Barx2 has been postulated to be a tumour suppressor gene and it
may exert its tumour suppressor functions in part, by modulation of K-cadherin
expression.
1.8.2 Integrins
1.8.2.1 Integrins in normal tissues
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Unlike other cell adhesion molecules the integrin family of cell adhesion molecules are
heterodimers. Each heterodimer is composed of one alpha and one beta subunit. Both
alpha and beta subunits are transmembrane proteins. So far at least 18 genes for alpha
subunits and 8 genes for beta subunits have been identified (Hynes 1999). Theoretically
a large number of alpha/beta combinations are possible but only just greater than 20
different combinations have been described. Integrins are transmembrane proteins that
have a large extracellular domain, a membrane spanning region and a proportionally
smaller cytoplasmic domain. Most integrins are predominantly receptors for ECM
proteins (collagen, laminin and fibronectin) but a few have a role in cell to cell adhesion.
This type of interaction is seen on leucocytes where they bind to receptors of the
immunoglobulin superfamily (Walsh et al. 1996) or in one case, a cadherin, (Higgins et
al. 1998). Integrins are expressed on a wide variety of cells and most cells express
several integrins. The specificity of ligand binding by individual integrins is produced by
the association of the extracellular, N terminal domains of the alpha and beta subunits to
form a globular ligand-binding head on each integrin. This globular head binds the
extracellular matrix ligand or the counter receptor. For integrins, the specificity in cell
adhesion is only partially understood. Some integrins recognise the peptide sequence;
arg-gly-asp (RGD) but for others this is not the preferred sequence. It is unclear how
different RGD specific integrins discriminate between different RGD containing
proteins. It is likely that the RGD site represents only part of or one of the integrin
binding sites.
Integrins are the main cell adhesion molecules for the extracellular matrix proteins.
They provide a link between the extracellular matrix and the actin containing filaments
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of the cytoskeleton. They interact with talin and alpha actinin which in turn link with
vinculin, tensin and other proteins linking to the actin cytoskeleton. Over the last few
years however, it has become clear that integrins have many more roles than simply that
of maintaining tissue architecture. Through their binding of the extracellular matrix,
integrins play an important role in regulating many fundamental cellular processes.
These include cell survival and proliferation, cellular differentiation and cell migration.
Integrins have been demonstrated to play important roles in signal transduction and cell
signalling. They participate in bi-directional signalling referred to as inside-out and
outside-in signalling, (Hynes 1992). Integrins also modulate signals initiated through
other receptor types, particularly receptor tyrosine kinases that are activated by
polypeptide growth factors. Sundberg et al described an integrin-mediated activation of
PDGF beta that is independent of ligand (Sundberg and Rubin 1996). Integrin signalling
and signal modulation involves binding of the integrin to its ligand, lateral clustering of
integrins in the plane of the membrane and the formation of integrin-cytoskeletal
complexes. This brings many different molecules into close proximity.
By selectively expressing different integrins, individual cells can vary their adhesive
properties. Further variation in cell adhesiveness is achieved by the ability of cells to
modulate the binding properties of integrins. This modulation of binding affinity of
integrins arises in response to cytoplasmic signals and is known as inside out signalling.
Intracellular signals are proposed to induce conformational changes in the cytoplasmic
domain of the integrin. These changes are propagated to the extracellular ligand binding
head of the integrin and binding affinity is thereby altered (O 'Toole 1994).
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It has long been known that most types of normal cells require attachment to a substrate
to be able to grow and that this dependence on anchorage is reduced in malignantly
transformed cells (Folkman and Moscona 1978). Anoikis (Frisch and Francis 1994) is
the programmed cell death caused by loss of anchorage of certain cell types to the
extracellular matrix. As the main receptors for ECM proteins the integrins were
implicated in the inhibition ofanoikis and have subsequently been shown to be involved.
Apoptosis of a differentiated epithelial cell that has been detached from its underlying
matrix prevents the cell from establishing itself in a new and inappropriate location. This
acts as an inbuilt safeguard to the host to prevent aberrant ectopic cell growth.
In neoplastic cells, alterations in integrins could lead to anoikis resistance thus
facilitating anchorage independent growth or growth at an inappropriate site. Loss of
cell-ECM interactions results in the induction ofapoptosis in epithelial and endothelial
cells (Meredith, Fazeli, and Schwartz 1993) (Frisch and Francis 1994). Loss ofadhesion
between fibroblast and ECM results in arrest of the fibroblasts in the G1 phase of the
cell cycle (Guadagno et al. 1993). Many studies have shown that integrin engagement is
necessary for cell cycle progression. Elevation of cyclin kinases has been shown to
occur in response to integrin binding with concomitant reduction of cell cycle inhibitors
(Fang et al. 1996) (Zhu et al. 1996). Thus it can be seen that outside-in signalling of
integrins is a determinant ofcell growth and survival.
Integrin binding has been shown to contribute to many intracellular signalling events
that are implicated in the regulation of cellular growth, differentiation and survival.
Integrin initiated signals stimulate the tyrosine phosphorylation of a number of cellular
proteins. The best characterised of these is the phosphorylation and activation of focal
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adhesion kinase (FAK). Activated FAK interacts with several proteins that lead to
intracellular signalling. Activated FAK also binds to the structural proteins paxillin and
tensin, which regulate the organisation of the actin cytoskeleton. Integrin binding leads
to the activation of the mitogen activated protein kinase (MAPK) pathway. The pathway
for this activation is not yet fully understood but it may involve activation ofFAK.
1.8.2.2 Integrins and cancer
The role of integrins in cancer cells is intriguing. There are potentially many ways in
which these molecules may contribute to the suppression or promotion of the malignant
phenotype. This is evident from the knowledge of their role in normal cells of cell
survival and proliferation, differentiation and cell signalling. Integrin expression in
normal tissues varies with tissue type. Because of the number of different integrins and
their varying ligand binding specificity and affinities, it is difficult to generalise about
the function of integrins in cancer cells. The role of integrins in cancer cells will also
vary depending on the stage of the cancer. At different stages of progression the loss or
gain of integrin expression may be advantageous to the tumour. Tumour progression and
metastasis is a complex process, which requires cells to have different phenotypes at
different times in the process. To be able to detach and migrate from the site of the
primary tumour, cells must possess reduced adhesive interactions with surrounding cells
and the extracellular matrix. When they reach their new location they must then be able
to reattach and invade the surrounding tissue. One can envisage how loss and gain of
integrin function at varying stages of tumour progression would provide these
phenotypes. Many studies have shown a general down regulation of integrins in tumour
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as compared to normal tissue including tumours of the endometrium, lung, colon,
prostate and breast (Lessey et al. 1995), (Damjanovich et al. 1992) (Buck et al. 1990),
(Hashida et al. 2001), (Perlino et al. 2000), (Alford and Taylor-Papadimitriou 1996).
Other studies document differences in integrin expression between primary tumours and
their metastases. Correlation of integrin expression with clinicopathological features of
the tumour in question has been examined and certainly in melanoma, integrin
expression may be of prognostic value (Vihinen et al. 2000). In metastatic melanomas,
tumours that were betal positive rather than to betal negative had significantly longer
disease free survival and the independent nature of betal integrin expression as a
significant prognostic factor for survival after therapy was confirmed using multivariate
analysis.
Increased expression of integrins in tumours of the oesophagus (Tanaka et al. 2000),
liver (Ozaki et al. 1998) breast (Shaw 1999) have been described as well as significantly
elevated levels of integrins in the peritoneal metastases from gastric cancer (Matsuoka et
al. 2000).
1.8.2.3 Integrins and ovarian cancer
With respect to ovarian carcinoma in particular, the betal integrin subunit was expressed
in 4 out of 4 cell lines and all of the nine primary ovarian tumours sampled and was
associated with various different alpha subunits (Cannistra et al. 1995). In contrast to
studies ofmalignant melanoma where alphavbeta3 is upregulated in association with the
acquisition ofthe invasive phenotype, downregulation ofbeta3in ovarian cancer appears
to be associated with the acquisition of invasive properties (Carreiras et al. 1996).
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Alphavbeta3 is present in well-differentiated and non-invasive borderline tumours but is
absent in invasive carcinomas.
1.8.3 Selectins
The selectin family of cell adhesion receptors is composed of 3 members; L, E and P
selectin. They are composed of an amino-terminal domain that is homologous to
calcium- dependent animal lectins, followed by an epidermal growth factor (EGF) type
domain, two to nine complement regulatory protein repeats, a transmembrane segment
and a short cytoplasmic tail. Selectins mediate heterotypic cell to cell interactions
through calcium-dependent recognition of sialyated glycans. Selectins are only
expressed in endothelial and blood cells. They promote leucocyte adherence to
endothelial cells and platelets during inflammatory processes.
1.8.4 Immunoglobulin superfamily of cell adhesion molecules
1.8.4.1 Immunoglobulin superfamily of cell adhesion molecules in normal tissues
Cell adhesion molecules of the immunoglobulin superfamily of proteins mediate
calcium -independent cell to cell adhesion. They are characterised by the presence of
one or more immunoglobuiin-like domains containing approximately 100 amino acid
residues per domain. The immunoglobulin-like domains are homologous to those found
in antibody molecules. These domains are identified at the primary sequence level by the
presence of two cysteine residues separated by 55 to 75 amino acids (which form a
disulphide bond in the folded structure) and a so called "invariant " tryptophan residue
located 10-15 residues C terminal to the first conserved cysteine. In addition,
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immunoglobulin cell adhesion molecules contain varying numbers offibronectin type 111
domains. Subfamilies ofthe immunoglobulin cell adhesion molecules are grouped based
on the respective number of each type of domain, the mode of attachment to the cell
membrane and the presence of a catalytic cytoplasmic domain.
Neural cell adhesion molecule (N-CAM) is the most prevalent immunoglobulin cell
adhesion molecule in vertebrates and like cadherins, it binds cells together by a
homophilic interaction. Some immunoglobulin cell adhesion molecules such as the
intercellular cell adhesion molecule subfamily (ICAMs) use a heterophilic mechanism of
adhesion.
N-CAM is widely expressed in the nervous system and is also expressed in other
tissues. There are many isoforms ofN-CAM produced by alternative splicing ofan RNA
transcript from a single gene. N-CAM contains five immunoglobulin domains and two
fibronectin type III domains. Most N-CAMs are single pass transmembrane proteins but
one isoform does not cross the lipid bilayer and is attached to the plasma membrane by a
glycosylphosphatidylinositol (GPI) anchor. The three most common isoforms are the
GPI-linked 120kDa isoform (NCAM120) and the MOkDa and 180kDa transmembrane
forms (NCAM140 and NCAM180). Further variation in N-CAM arises as a result of
post translational modification by the addition ofnegatively charged sialic acid residues.
These modifications alter the adhesive properties ofN-CAM. In the nervous system, N-
CAM plays a role in neurite outgrowth and guidance. It is the prototype for the large
family of neural cell adhesion molecules of the immunoglobulin superfamily. As such,
the induction ofneurite outgrowth has been intensively studied in an attempt to elucidate
the signalling mechanisms induced following binding of this cell adhesion molecule.
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The original assay devised by Doherty and Walsh (Doherty et al. 1989) was to grow
PC 12 cells or primary neurons on supporting cell monolayers or fibroblasts that had
been transfected with various isoforms of adhesion molecules. Untransfected cells were
used to control for levels of neurite outgrowth not dependent on the transfected cell
adhesion molecules. Cell adhesion molecules including N-CAM, LI and N-cadherin
promoted neurite outgrowth by two to threefold over that seen on untransfected
monolayers. For N-CAM, both transmembrane and GPI- linked forms in the transfected
supporting cell layer supported neurite extension suggesting that an extracellular portion
of N-CAM was important for signal transduction. To determine intracellular signals
important for cell adhesion molecule enhanced neurite outgrowth, the extent of neurite
outgrowth was measured in the presence of agents that enhance or block the activity of
particular second messenger systems. These experiments showed that cell adhesion
molecule dependent neurite outgrowth was dependent on G protein stimulated activation
of calcium channels (Doherty et al. 1991). Specific tyrosine kinases have been
implicated in the effects of cell adhesion molecules on neurite outgrowth. Inhibiting
receptor tyrosine kinases with an analogue, erbstatin, blocked the ability ofN-CAM and
LI to stimulate neurite outgrowth (Williams, Walsh, and Doherty 1994) suggesting that
a tyrosine kinase is an upstream regulator of the G proteins and calcium channels that
were proposed to mediate neurite outgrowth. This led to a hypothesis involving the
fibroblast growth factor receptor (FGF-R). This hypothesis proposed that the effects of
cell adhesion molecules on neurite outgrowth could be attributable to their ability to
stimulate the FGF-R (Williams et al. 1994) (Williams et al. 1995). The authors identified
a region in the FGF-R that contained sequences similar to short peptide regions within
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the extracellular regions of the N-CAM, LI and N- cadherin proteins. This observation
led to the suggestion that this "cell adhesion molecule homology domain" in the FGF-R
was involved in interactions with the cell adhesion molecule proteins. Evidence for a
direct interaction between N-CAM and the FGF-R has now been obtained (Cavallaro et
al. 2001). In this paper the author showed that N-CAM modulates pancreatic tumour cell
adhesion to matrix by inducing FGF-R signalling.
1.8.4.2 Immunoglobulin superfamily of cell adhesion molecules and cancer
In many human cancers, including Wilm's tumour, colon carcinoma, Ewing's sarcoma,
neuroblastoma, small cell lung carcinoma and multiple myeloma, NCAM expression
changes from NCAM 120 in the normal tissue to NCAM 140 and NCAM 180 in tumours.
In addition, in human pancreatic and colorectal carcinomas reduced levels of NCAM
expression correlate with increased tumour malignancy (Fogar et al. 1997) More
recently, loss of NCAM expression has been correlated with progression to tumour
metastasis (Perl etal. 1999).
The DCC family of immunoglobulin cell adhesion molecules is a subfamily containing
four immunoglobulin domains and six fibronectin type III repeats. The most prominent
member is Deleted in Colon cancer (DCC) which was originally identified as a putative
tumour suppressor gene from the 18q region of frequent LOH (Fearon et al. 1990). DCC
is a receptor for the laminin-related netrinl extracellular matrix protein. In normal
tissues, abundant expression of DCC is found in the central and peripheral nervous
system as well as most epithelial tissues (Hedrick et al. 1994) (Reale et al. 1994)
Expression of DCC is reduced or absent in a variety of human malignancies. The
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function of DCC in normal and cancer tissues is however still relatively poorly
understood. Mice lacking DCC show defects in axonal projections but growth,
differentiation, morphogenesis and also tumorigenesis in mouse intestine are unaffected
(Fazeli et al. 1997). DCC is expressed in normal human ovarian surface epithelium. In
the largest study to date of DCC in ovarian carcinoma, significantly decreased levels of
overall DCC values in carcinomas compared with benign and low malignant potential
lesions were revealed by both immunohistochemical and RT-PCR-Southern blot
hybridisation assays. In carcinomas, reduction or loss of DCC expression was
significantly related to the serous phenotype, high histological grade, and a more
advanced stage. There was no association with survival (Saegusa, Machida, and
Okayasu 2000). In ovarian carcinomas therefore, it appears that altered expression of the
cell adhesion molecule DCC is closely linked with tumour differentiation and
progression.
1.8.4.3 IgLON family of cell adhesion molecules
The IgLONS are also members of the immunoglobulin super family of proteins. They
are characterised by the presence of three immunoglobulin-like domains and are
extracellular molecules that are linked to the plasma membrane by a glycosyl
phosphatidyl inositol (GPI) anchor. There are four family members; opioid binding cell
adhesion molecule (OBCAM) (Schofield et al. 1989), neurotrimin (CEPU) (NTM)
(Struyk et al. 1995) limbic system-associated protein (LAMP) (Pimenta, Fischer, and
Levitt 1996) and kilon (neurotractin) (Funatsu et al. 1999).
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All four of the IgLONs are expressed widely in the central nervous system during
development and adulthood. Almost all of the work done on these molecules has
investigated their role in neurodevelopmental biology. As these proteins are cell surface
molecules, extensive research has been done investigating the nature of interactions that
these proteins make. LAMP, CEPU and OBCAM have been shown to interact
homophilically and heterophilically with each other (Lodge et al. 2000). LAMP and
CEPU also interact with neurotractin but Neurotractin does not appear to bind
homophilically (Marg et al. 1999). NTM-Fc binds to neurons that have had GPI linked
proteins removed by phospholipase C treatment (Gil et al. 1998). This suggests that the
IgLONs form heterophilic interactions with molecules other than IgLONS.
In addition to these trans interactions, IgLONs also form cis interactions. Homodimers
and trimers ofNTM have been identified in the plane of the cell membrane (Gil et al.
1998).
1.9 GPI-ANCHORED MOLECULES
Diverse arrays ofproteins are attached to the cell surface by GPI anchors. These include
proteins_that regulate the activation of the complement cascade (eg DAF1), control T-
cell activation and affect neural cell adhesion (an isoform ofNCAM). Despite the varied
functions of these proteins they are all attached to the cell membrane by a common
glycolipid anchor. The anchor is composed of phosphatidyl inositol (spans the external
leaflet of the membrane), glucosamine, three mannoses and a phosphorylethanolamine
(Yeh, Kamitani, and Chang 1994). Proteins destined to be GPI linked have both N and C
terminal signal peptides to which the preformed GPI anchor is attached within the
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endoplasmic reticulum. Our understanding of how GPI anchored molecules transduce
signals is far from complete but there are a few lines of evidence to suggest how
signalling may be accomplished.
GPI anchored proteins have been shown to be part of functional rafts within the cell
membrane. Rafts are formed by the association ofcholesterol and sphingolipids and can
be isolated as detergent insoluble complexes following treatment with the detergent
Triton -x (Brown and Rose 1992). Clustering of GPI anchored proteins in rafts may
allow cis interactions with signal transducing transmembrane proteins. Signal
transduction molecules such as the src family of non receptor tyrosine kinases and
heterotrimeric G proteins have been detected in the detergent insoluble complexes after
Triton-x treatment and have been shown to co-immunoprecipitate with GPI anchored
proteins in haemopoetic cells.
1.10 OBJECTIVES OF RESEARCH
The starting point for the work in this thesis was the finding of several independent
studies showing a high frequency of LOH in the 1 lq24-5 region in epithelial ovarian
cancer. (Foulkes et al. 1993) (Gabra et al. 1995) (Gabra et al. 1996) (Davis et al. 1996).
These studies suggested that this region houses a tumour suppressor gene involved in
this disease. The initial period of work was to entail an LOH analysis of all sixteen
polymorphic microsatellite markers from the region in a panel of DNAs derived from
112 patients with epithelial ovarian cancer. The intention was then to identify candidate
tumour suppressor genes near markers with interesting LOH findings. Having identified
candidate genes the plan was to look for evidence of inactivation of these genes in
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ovarian cancer cell lines and primary ovarian tumours. Transfection of candidate genes
were then to be performed to allow functional studies to be undertaken.
The most striking finding of the LOH analysis was a high frequency of LOH at the
marker D1 1S4085 and this marker was found to lie within an intron of a gene called
OBCAM. OBCAM therefore became a candidate for the tumour suppressor gene in this
region and much of the work in this thesis relates to the investigation of the potential
role ofOBCAM as a tumour suppressor gene in ovarian cancer. Expression studies of
OBCAM in normal tissues, tumours and cell lines were undertaken. Having identified
LOH as a "first hit "of this gene in ovarian cancer, search for a "second hit" in the form
ofCpG island methylation and mutation screening was performed. Transfection studies
allowed development ofcell lines that were used in in vitro and in vivo assays.
Additionally, analysis of several other potential tumour suppressor genes from the
region was undertaken and this data is also reported.
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2. METHODS AND MATERIALS
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2.1 Mapping and bioinformatics
At the start of the project in August 1999, 16 polymorphic microsatellite markers from
the 1 lq24-25 region were identified from a radiation hybrid map ofchromosome 11 .The
majority of the microsatellite sequences and the corresponding primer pairs were
available from the GenBank sequence database. Two sequences (1884 and 1895) were
determined by sequencing. Initially, physical mapping using YACs from the 1 1 q24
region was undertaken to allow markers and known genes to be ordered with respect to
each other. This produced a crude map of the region.
To refine this map and confirm the order of the microsatellite markers and identify
genes within this region a BAC contig tiling path was created. To do this, each
microsatellite sequence was put into BLAST (Basic Local Alignment Search Tool)
(http://www.ncbi.nlm.nih.gov) and searched against the HTGS database. BLAST is a
program that aligns the sequence of interest with a specified database. BACS on
chromosome 11 that contained the microsatellite sequence were then selected. These
BACS were then subjected to NIX analysis. NIX (Nucleotide identify X)
(http://www.hgmp.mrc.ac.uk/NIX/) is a tool to aid the identification of interesting
regions in genomic or transcribed nucleic acid sequences. Although many individual
computer prediction programs have been developed to do such analysis, these programs
all have strengths and weaknesses. NIX integrates many of these programs and displays
the results side by side. Such direct comparison allows us to identify when several
programs have a consensus feature that strengthens the likelihood ofthe prediction being
correct.
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Initially the NIX program was used on a very simple level to pick out the microsatellite
marker and position of related genes. At this stage the human genome project was in its
early stages for this region. At the end of 1999 several BACS for most microsatellite
markers had been identified. The BACS were all at differing levels of sequence
completion, often being composed of more than 20 separate contigs. The presence of
unordered contigs within the BACS meant that there was always uncertainty with the




A panel of 112 matched normal/tumour DNA samples from patients with epithelial
ovarian cancer was assembled. 49 of the DNA pairs were made from paraffin embedded
normal and tumour tissue blocks obtained from the Department ofPathology, Edinburgh
University. A further 38 pairs were made from fresh tissue collected from the
Department ofGynaecology, Edinburgh Royal Infirmary. The remaining 25 pairs were a
gift from Ian Brown (University of Aberdeen). All clinical material was obtained




Fluorescently labelled oligonucleotide primers for sixteen polymorphic microsatellite
markers from the llq24-25 region were obtained from the ICRF oligonucleotide
laboratory at Clare Hall.
Table 2.1 Chromosome llq24-5 microsatellite markers used in LOH analysis
Microsatellite Sequence 5'-3' ~ size Dye
D11 SI 894 FOR AGATCCCTACAGAACTCTCTCTACA 116 FAM
REV TAGAGTAAGTGTCATGGGGTGTC
D11S912 FOR TGCTTTGGGTATGCATATGT 110 FAM
REV AGCTTTTTGTCTAGCCATGA
D11S4150 FOR TCTCCCTGTTGTGGGG 250 FAM
REV TTACTACCCAGAGATTCATTTGT
GATA69G01 FOR AATTAGAGATGTAGGTGTGAACTCA 84 FAM
REV TATATCTACATTGCAGCTAGGTAGG
D11S4I26 FOR TTGCAGTGAGACAAAGCAAG 100 FAM
REV GTCAGAAGCCTGTGCCG
D11S4131 FOR TCAAGAGCAGTGGTCTAGNTCAAGA 100 FAM
REV ATCACTAGCCAAAGCAGCAG
GATA72A0I FOR TAGGAATATCCAGGCATTGC 150 TET
REV CAGAGGACTTGGAAGCACTT
D11 SI 884 FOR GGTCAGACCCAAGACTTCA 155 FAM
REV TGGCTCACCAAGGATTTA
D11S910 FOR AGCTTTGCAGACAAGGCAAG 156 TET
REV2 TCTAAGGCATGACATTTCAC
D11S1320 FOR AACATTACTAAAAGGTTAAATGAGC 230 TET
REV ATTAAGGCACCAAATGGG
D11S874 FOR AATCATTTTCAAGCATAGGC 160 FAM
REV GGTTTAAAAAGTCAGCCCTC
D11S4085 FOR GCTACAATATCAATAGAAGG 200 FAM
REV GGCCACAGGACTTTCAGAG
D11S969 FOR TTGATTTGGAAGATTTTCAC 145 FAM
REV GGGGCAGAATGGGTAT
D11S1309 FOR CCCTTCGTCACAGAAACA 240 FAM
REV ACTCTAGCCCACAAATTAAGACT
D11S4198 FOR ACTTGGACCGAATGCTGT 120 TET
REV GCTAATCCAGAAGACTTGCC
D11S1895 FOR2 CAGGGCATTCAATCCTTA 136 TET
REV2 TGCTACTTTGAGGATGTC
72
2.2.3 Treatment of oligonucleotides
The primers were supplied fully deprotected and dried down. Ethanol precipitation was
used to remove the side products ofthe synthesis. Each oligonucleotide was dissolved in
200pl containing 20pl 3M sodium acetate (pH5.6), 20pl lOOmM magnesium chloride
and 160pl DEPC water. 600pl of 100% ethanol was added and mixed by briefly
vortexing. The samples were left at -70C for at least 30 minutes. Samples were then
centrifuged at 13000rpm for 20 minutes at 4°C and the supernatant discarded. The pellet
was washed with 250pl 70% ethanol in DEPC water and spun at 13000rpm for 5
minutes at 4C. The supernatant was removed and the pellet dried at room temperature.
The dry pellet was resuspended in 200pl of DEPC water. 5pl of primer solution was
added to 995pil DEPC water. The OD260 of the 1:200 dilution was measured on a
spectrophotometer and the concentration of primer solution determined using the
following formula;
Stock concentration = OD26Q x dilution f200) x 1000 = pmol/pl = pM
Extinction coefficient
2.2.4 Optimisation of PCR conditions
The reaction volume for each PCR was 25pl. Each PCR contained 2.5ju.1 lOx buffer,
0.5pl lOmM dNTP, 0.8pl ICRF Taq polymerase and 0.25pl each of the forward and
reverse primers (50pM stock). The optimal magnesium concentration for each primer
pair differed and is shown below. 1 pi DNA was added to each reaction and the volume
made up to 25pi with water. A touchdown program from 67-55°C was used as follows:
73
1.94°C for 5 mins, 2. 67°C for 30secs -3°C per cycle, 3.72°C for 45secs, 4.Go to 2, 3
times, 5.94°C for 30secs, 6.55°C for 30secs, 7.72°C for 45secs, 8. Go to 6, 29 times,
9.72°C for 5mins, 10.16°C forever, end.
2.2.5 Checking of PCR products by agarose gel electrophoresis
8pl of PCR product was mixed with 2pl of glycerol loading dye and run on a 2%
agarose gel containing ethidium bromide at 120 volts in lx TAE. A lOObp DNA ladder
was also run to confirm the size of the products. The products were visualised under UV
light.
2.2.6 Allelotype analysis
Dilutions of PCR products containing the size standard Tamra 350 and deionised
formamide were prepared and denatured for running on the 310 ABI prism.
Allelotype analysis was performed using the genescan software. Each pair of samples
was assigned to one of the following groups; heterozygous, uninformative
(homozygous) or nondeterminable. For the heterozygotes, the relative ratios of alleles
were determined. LOH was assigned where the tumour allele ratio differed from the
normal allele ratio by greater than 30% (r < 0.7).
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2.3 Gene expression in normal ovary, normal tissues, cell lines and tumour samples
To determine the expression of candidate genes in normal ovary, cell lines and tumour
samples RNA was first extracted from the respective samples. The RNA was DNAsel
treated and first strand cDNA synthesis performed.
2.3.1 RNA extraction from cell lines using Tri Reagent
Cell lines were grown in 175cm until 70% confluent. The media was removed and
17.5ml Tri Reagent (1ml per 10cm culture plate surface area) added to the flask to
detach and lyse the cells. After addition of the Tri Reagent, the cells were repeatedly
pipetted to form a homogenous lysate and the sample split equally into two 15ml
Sarstedt polypropylene tubes. At this stage samples can be frozen at -70°C for up to 1
month.
If the samples had been frozen they were thawed and incubated at room temperature for
5 minutes to ensure dissociation of nucleoprotein complexes. 1.7ml chloroform was
added per tube using an RNase free glass pipette. The sample was covered and shaken
vigorously for 15 seconds. Following a 10 minute incubation at room temperature the
samples were centrifuged at 12000g for 15 minutes at 4°Cin the SorvalRC5B centrifuge
using the SS34 rotor. This separated the mixture into 3 layers. To precipitate the RNA,
the upper aqueous phase was transferred into a fresh Sarstedt tube using a sterile
pastette. 4.25ml isopropanol was added per tube and the samples inverted to mix. After a
further 10 minute incubation at room temperature the samples were spun at 12000g for
10 minutes at 4°C. An RNA pellet was visible at this stage. To wash the RNA, the
supernatant was discarded. 10ml 75% ethanol in DEPC water was added and mixed by
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vortexing. After a 5 minute centrifuge at 12000g at 4°C the supernatant was removed
and discarded. 0.5ml 75% ethanol in DEPC water was used to transfer and combine the
pellets in a sterile microfuge tube. The tubes were washed out with a further 5ml 75%
ethanol in DEPC water. The samples were spun in a microfuge at 13000rpm for 5
minutes at 4°C. To soiubilise the RNA, the ethanol was removed and the sample allowed
to air dry for 15 minutes in a class II hood. lOOpl DEPC water was added and the
sample pipetted to mix. The RNA was then incubated for 15 minutes at 55°C. The
sample was placed on ice and quantitation of RNA performed using a
spectrophotometer. The RNA was stored as 20pg aliquots at -70°C.
2.3.2 Isolation of Total RNA from Normal Ovary
Human normal ovary (100 mg), snap frozen in liquid nitrogen at time of collection, was
pulverised in a Mikro-Dismembrator U (B.Braun Biotech International) for 2 minutes at
2,000rpm. 1ml of Tri Reagent (Sigma) was then added and the protocol for RNA
extraction from cell lines followed with all reagent volumes scaled down accordingly.
RNA from the primary human ovarian tumours had been made previously.
2.3.3 DNasel treatment ofRNA
This procedure is used to remove contaminating DNA from the RNA sample.
5.7pl lOx buffer and lpl Dnasel (10units/pl)(Message Clean Kit) were added to 20pg
of RNA and the volume made up to 57pl with DEPC water. This was mixed well and
incubated for 30 minutes at 37°C. A phenol/chloroform extraction was then undertaken
to ensure removal ofprotein contamination and DNasel from the RNA. 30pl phenol and
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lOpI chloroform were added and vortexed for 30 seconds. Following a 10 minute
incubation on ice the sample was spun at 13000rpm for 5 minutes at 4°C. The upper
phase was removed into a 200pl microfuge tube. An ethanol precipitation was then
performed. 5pl 3M sodium acetate and 200pl 100% ethanol were added and mixed by a
brief vortex. The sample was incubated at -70°C for more than an hour and then spun at
13000rpm for 10 minutes at 4°C. The supernatant was carefully removed and discarded
and the RNA pellet washed with 500pl 70% ethanol in DEPC water. After a briefvortex
the sample was spun at 13000rpm for 5 minutes at 4°C and the supernatant discarded.
The RNA was dissolved in 1 Opl DEPC water and 1 pi used to make a 1:1000 dilution for
quantitation on the spectrophotometer. The DNase treated RNA was stored as 1 pg
aliquots at -70°C.
2.3.4 First strand cDNA synthesis
Using the first strand cDNA synthesis kit (Boehringer Mannheim), RNA is reverse
transcribed into single stranded cDNA. In this method, using the oligo p(dT) primer,
AMV reverse transcriptase synthesises the new cDNA strand at the 3' end of the poly
(A) mRNA. The resulting first strand cDNA can then be used as a template for PCR.
1 pg of RNA was used for each first strand cDNA synthesis of 20pl. A master mix of
reagents was prepared and a varying volume ofwater added to each RNA to give a final
reaction volume of 20pl. To degrade the secondary structure of the RNA, the
RNA/water mixture was denatured at 65°C for 15 minutes and then placed on ice for 5
minutes.
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A master mix of reagents was prepared to include 2pl 10X buffer, 4pl 25mM MgCh,
2pl deoxynucleotide mix, 2pl oligo p(dT) primer and 1 pi RNAse inhibitor per reaction.
The master mix was divided equally into two tubes and 0.8pl AMV reverse transcriptase
added to the first tube. This allowed a first strand cDNA synthesis (+RT) and a control
reaction (-RT) to be produced for each RNA sample. (2x1 pg aliquots RNA required).
Each reaction was incubated at 42°C for 60 minutes for reverse transcription to occur,
followed by a 5 minute incubation at 95°C to denature the AMV reverse transcriptase.
The samples were cooled on ice and aliquots of 2pl first strand cDNA prepared and
frozen at -70°C.
2.3.5 Quantitative determination of gene expression using a Light Cycler
The level ofOBCAM expression was determined by quantitative RT-PCR using a Light
Cycler (Roche) (Euan Stronach) in a series of 18 ovarian primary tumours (DNasel-
treated total RNAs were a gift from Dr. Simon Langdon) and 17 ovarian and 14 non
ovarian cancer cell lines. Quantitation of PCR products was performed via detection of
incorporated SYBR Green I. OBCAM expression was calculated relative to Actin
expression in each sample, and then expressed as a percentage normalised to the
expression level in a sample of normal ovary.
Table 2.2 Primers for the determination ofOBCAM expression by Light Cycler
Primer Sequence 5'-3' Ace. No Nucleotide Size
bp
OBCAM FOR4 TACCATAGATGACCGGGTAA NM 002545.2 221-240 224
OBCAM REV4 CTATTAGGTGAACCCGGGAC NM 002545.2 444-425
Beta Actin FOR CTACGTCGCCCTGGACTTCGAGC NM 001101 724-746 385
Beta Actin REV GATGGAGCCGCCGATCCACACGG NM 001101 1108-1086
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2.3.6 Semi-quantitative determination of gene expression using RT-PCR
Multiple Tissue cDNA (MTC) panels (Human I and Human II; BD Biosciences,
Basingstoke, UK) were tested for OBCAM expression by semi-quantitative RT-PCR
using the Advantage 2 PCR kit (BD Biosciences) with an OBCAM primer pair to
identify the full length OBCAM transcript (Genevieve Rabiasz)
Table 2.3 Primers for the determination of OBCAM expression by semiquantitative
RT-PCR
Primer Sequence 5'-3' Ace. No Nucleotide Size
bp
OPCML FORI AGTTGTGGCTGTCGAGAATG NM 002454.2 34-53 1079
OPCML REV1 TCAGAGGACCTAGGATTTCT NM 002454.2 1110-1091
Semi-quantitative RT-PCR was also used to determine Flil gene expression in a panel of
thirty human ovarian tumours (HOVs) and thirteen ovarian cancer cell lines.
Table 2.4 Primers for the determination of Flil expression by semi-quantitative
RT-PCR
Primer Sequence 5'-3' Ace. No Nucleotide Size
bp
Flil 9BFOR AACGCCAGCTGTATCACCTG NM 002017.2 1058-1077 301
Flil 9CREV GGGACAAAGTTCACCTTCTG NM 002017.2 1377-1358
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2.4 Mutation Detection by Single Strand Conformation Polymorphism
Electrophoresis (SSCPE)
Single Strand Conformation Polymorphism Electrophoresis (SSCPE) is a technique used
to identify abnormalities in nucleotide sequence. A single nucleotide difference between
two short single stranded DNA molecules induces a difference in the conformations
adopted by the two strands. This conformational change is sufficient to produce changes
in the molecules' electrophoretic mobilities on neutral polyacrylamide gels. The
difference in electrophoretic mobility is seen as a band shift on the gel.
SSCPE analysis was performed on the OBCAM, Flil and Barx2 genes. SSCPE of the
OBCAM and Flil genes was performed by Diane Scott, Eric Miller and Charles Massie.
SSCPE of the Barx2 was performed by Claire Taylor at the Cancer Research UK
Mutation Detection Facility in Leeds. DNA samples used in the SSCPE analysis were
extracted from fresh and archival ovarian tumour and matched normal tissues and
ovarian and non ovarian cancer cell lines.
2.4.1 Primers for SSCPE
Bioinformatic comparison ofOBCAM mRNA and Human Genome Project sequences
predicted the human OBCAM gene to comprise 7 exons. PCR primers to amplify the
predicted exons were designed (Grant Sellar). Two overlapping primer sets were
required to span exon 2 due to size limitation ofPCR product useful for SSCPE analysis.
The OBCAM exon specific primers are documented in table 2.5 .
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Table 2.5 Primers for OBCAM SSCPE
Exon Primer Sequence 5'-3' Acc.No Nucleotide Size
bp
1 OBCAM IFOR GACCAGGACTGTGCGGCTGC NM 002545.2 1-20 188
OBCAM I REV CGTCACGTTGTCCATAGCTT NM 002545.2 188-169
2 OBCAM2AFOR CACCACTCCCTGCCTCACTG AC012234.6 75226-75245 175
OBCAM2AREV CATCCACATTTTGGATCATG ACO 12234.6 75400-75381
OBCAM2BFOR ATAGACCCTCGTGTGATCAT AC012234.6 75331-75350 180
OBCAM2BREV TGGCAACCCCAGATCCAGCT AC012234.6 75510-75491
3 OBCAM3FOR CAGGTATTTCTTCTATCCTG AP000843.3 37032-37051 179
OBCAM3REV GTCCTCCAGGTCAGCACCTT AP000843.3 37210-37191
4 OBCAM4FOR TGGTTACACAGTTTCCTGAT AP000843.3 2881-2900 214
OBCAM4REV AGAACCCCCTGGCTGCAGGT AP000843.3 3094-3075
5 OBCAM5FOR GTGCGTGCATGCCTGTGCAT AP000843.3 3466-3485 195
OBCAM5REV CAGAACTGTCCAGGTGTCAT AP000843.3 3660-3641
6 OBCAM6FOR TAGCAATGTCTTCCCTCTTG AP000843.3 4028-4047 198
OBCAM6REV GCATCCAGGCTTCCAGCACT AP000843.3 4225-4206
7 OBCAM7FOR TCCTTGGGTGTATGCTAATG AP000843.3 19945-19964 176
OBCAM7REV GCGTTGCTCAGAGGACCTAG AP000843.3 20120-20101
Primer pairs were designed for each of the 9 exons of Flii, amplifying from flanking
introns across the exons. Four overlapping SSCPE primer pairs forexon 9 were required
to allow complete analysis of this exon. In order to design these primers, the Fli 1 mRNA
sequence (NM_002017.2) was blasted against BAC AP000920 that was known to
contain sequence of the Flil gene. This allowed identification of the intronic sequence
flanking the exons. The primers are shown in table 2.6.
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Table 2.6 Primers for Flil SSCPE
Exon Primer Sequence 5'-3' Acc.No Nucleotides Size
bp
1 F1 11DFOR CTGCGAGGTCAGGCTGTAAC AF275879.1 4311-4330 191
F1 1 IDREV GGGAGAGAGGCCACGTCTTC AF275879.1 4501-4482
2 F1 1 2CFOR2 GTGAAGAGTGACACTGGGCT AP000920 56384-56365 114
F1 1 2CREV2 AGTCATGTCGGCCTTGGGGA AP000920 56253-56272
F1 12DFOR TCCCCAAGGCCGACATGACT AP000920 56243-56224 125
F1 1 2DREV CAATCCTGCACAGGCCTGGT AP000920 56100-56119
3 F1 13AFOR AGTGCTGACCGCCTCTGGGC AP000920 981 1-9830 219
F1 1 3AREV CAGGCAGCCTGGTTCTCGAA AP000920 10029-10010
4 F1 14CFOR CAATGGCTGGAGTGGGCCAT AP000920 14531-14550 194
F1 14CREV CTGGGTACTTGGGCGGCACT AP000920 14725-14706
5 Fl 15AFOR CCTACTCTTGATCTCAGAAG AP000920 23617-23636 176
F1 1 5AREV GTCATGTCTGGTACAGAAGA AP000920 23792-23773
6 Fl 1 6AF0R CTACAGATAATGCTCATGCA AP000920 46716-46735 195
Fl 1 6AREV ATCCTGTCCTCAGAAACATG AP000920 47210-47191
7 Fl 1 7FOR AGCTGGGTCCTACTCACTGC AP000920 63456-63475 175
Fl 1 7REV TCCATCAGTTGACCATGTGA AP000920 63630-63611
8 Fl 1 8FOR2 ACACTGAAGCAAATTTCCTT AP000920 65439-65458 179
Fl 18REV2 CCACTCAGGTGTCTGGACTT AP000920 65617-65598
9 Fl 19AFOR CATTTAGGGAACTGGGTTCT AP000920 66700-66720 179
Fl 19AREV CATTTTGAACTCCCCGTTGG AP000920 66878-66859
Fl 19BFOR AACGCCAGCTGTATCACCTG AP000920 66831-66850 174
Fl 19BREV GCCGTGCACTTTGGTCATAA AP000920 67004-67985
Fl 19CFOR GGCCCTCCGTTATTACTATG AP000920 66956-66975 171
Fl 19CREV GGGACAAAGTTCACCTTCTG AP000920 67126-67107
Fl 19DFOR2 GTACCCTTCTGACATCTCCT AP000920 67085-67104 164
Fl 1 9DREV2 TGGGGTTGGGGTAGATTCCC AP000920 67248-67229
Fl 19EFOR1 GCATCACAATACTGGACCTC AP000920 67200-67219 172
Fl 19EREV1 TGAGTCCAAAGCATCCAGTA AP000920 67371-67352
Primers for SSCPE analysis of the 4 exon Barx2 gene were designed by Hani Gabra and
are shown in table 2.7.
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Table 2.7 Primers for Barx2 SSCPE
Exon Primer Sequence 5'-3' Acc. No Nucleotides Size
bp
1 BARX2F1 IB ATGCACTGCCACGCCGAGCT AF171219 1650-1669 145
BARX2RI1 ACACGGAGTAGAGGGAAAGT AF171219 1770-1789
BARX2F1 ATGATCGACGAGATCCTCTC AF171219 1723-1742 186
BARX2R5 TACACGGACGTGAAAGCTAC AF171219 1869-1888
2 BARX2F6 CAGGTCCTGGCCTGCTTCCC AF171220 76-95 165
BARX2R12 AGGACAGTGCCTGGGCGATT AF171220 228-247
BARX2F13 TCATCTCCCACCTGGTCCCT AF171220 197-216 182
BARX2R13 CTCGGTGAAGATGGTGCGAC AF171220 359-378
BARX2F14 CGAGTCAGAGACGGAACACC AF171220 309-328 202
BARX2R6 CCCACAATGGGAGCAAGTCT AF171220 491-510
3 BARX2F10 TCCTGCTGCCTCCCATTCTG AF171221 284-303 134
BARX2R14 TCTTCCATTTCATCCTGCGA AF171221 396-415
BARX2F15 TCAGTCTCTGGGACTCACTC AF171221 348-367 167
BARX2R15 CAAACTGCCAAATGGTCCGG Unpublished sequence
4 BARX2F8 TGGAGGGAAGGAATTATTTC AF171222 313-332 155
BARX2R16 CTGTTCATCTTCTCTTCAGC AF171222 449-468
BARX2F16 GAACTCCATCCCCACATCAG AF171222 418-437 160
BARX2R17 TGGTGGCTCTGCCATCTCTA AF171222 558-577
BARX2F17 AGGAGGAGCTCTGTGAAGCA AF171222 500-519 153
BARX2R8 AGTCTCCCTCTTCCCTCAAA AF171222 643-662
PCR conditions for all primer pairs were optimised in 25pi reaction volumes. SSCPE
and silver staining of 5-1 Opl denatured PCR product was carried out as described.
2.4.2 Electrophoresis
A non denaturing 10% acrylamide, 3% bis-acrylamide gel was prepared using
lxTBE.Depending on the strength of PCR product, either 5 pi or lOpl was mixed with
2pl or 4pl denaturing dye respectively (95% formamide, 20mM EDTA, 0.25%
bromophenol blue, 0.25% xylene cyanol). This mixture was then denatured at 98°C for 3
minutes and place immediately onto ice. The mix was loaded into the gel with
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duckbilled tips and run at room temperature for 20 minutes at 20mA before transferring
to the cold room (4°C). The gel was run overnight for between 14-16 hours at 10mA per
gel. The running buffer was lxTBE.
2.4.3 Silver staining
Following electrophoresis, the gel was transferred gently into a Pyrex dish for silver
staining. The gel was soaked in 10% ethanol for 5 minutes, 1% nitric acid for 3 minutes
and then briefly rinsed in distilled water. The gel was soaked for 20 minutes in a freshly
prepared solution of lmg/ml silver nitrate in distilled water, ensuring that the silver
nitrate had been completely dissolved before adding to the gel. The developer buffer was
prepared by dissolving 15g ofanhydrous sodium carbonate in 500ml distilled water and
adding 250jul formaldehyde. The gel was rinsed in distilled water to remove the silver
nitrate and 100ml of the developer buffer added until the buffer turned brown and was
discarded. The remaining 400ml developer buffer was added and at this stage the nucleic
acid bands became visible. When the desired intensity had been reached the developer
buffer was discarded. The gel was rinsed twice in water and the reaction was stopped
with 10% glacial acetic acid for 2 minutes. A photograph was taken of the gel after
which it was dried on the gel drier at 85°C for 3 hours to make a permanent record.
2.4.4 Exo/sap purification of PCR products
PCR products that produced band shifts were sequenced to detect any nucleotide
alterations compared with the GenBank reference sequences. Prior to sequencing, the
PCR products were purified using a combination of shrimp alkaline phosphatase and
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exonucleasel. For the exosap purification, 2-3 pi of PCR product (maximum 6.5pl) was
mixed with 0.5 pi Exol (lOU/pl), 1 pi SAP (lu/pl) and water to a final volume of 8 pi.
Products were run on the SAP program as follows; 37°C for 15 minutes, 80°C for 15
minutes and 4°C hold.
2.4.5 Sequencing
4pl of EXO/SAP product was used for each of the forward and reverse sequencing
reactions. To the 4pl of EXO/SAP mixture was added 4pl Big Dye, 1 pi sequencing
primer (3.2pM stock) and water to a final volume of20 pi. The sequencing programme
that follows was run; 96°C hold, 96°C for 30 seconds, 50°C for 15 seconds, 60°C for 4
minutes for 24 cycles then 4°C hold.
2.4.6 Precipitation of sequencing reactions
The sequencing reactions were precipitated using the following method. For each
sequencing reaction a 1.5 ml microfuge tube was prepared containing 2pl 3M sodium
acetate (pH 4.6), 0.5pl pellet paint and 5Opl of 100% ethanol. The contents ofeach tube
were vortexed and left at room temperature for at least 15 minutes to precipitate the
extension products. The tubes were then spun for 20 minutes at 13000 rpm at 4°C. The
supernatant was aspirated and discarded. The pellets were rinsed by the addition of
250pl of 70% ethanol and a brief vortex. The tubes were spun for 5 minutes at
13000rpm at 4°C. The ethanol was removed using a fine tip pastette and the pellets
allowed to dry briefly at room temperature. The precipitated sequences were run on an
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ABI 377 DNA sequencer (Agnes Gallagher, Medical Research Council, Human
Genetics Unit.).
2.5 Investigation of OBCAM homology between species and other human IgLON
family members
Amino acid and nucleotide sequences for human OBCAM (HS), rat (RN), bovine (BT),
chicken (GG), Drosophila (DM) and Caenorhabditis elegans (CE) OBCAM, were
obtained from GenBank (http://www.ncbi.nlm.nih.gov), FlyBase
(http://flybase.bio.indiana.edu/) and Worm Base (http://www.wormbase.org/)
respectively. Sequences for human NTM and LAMP were also obtained from GenBank.
Table 2.8 documents the accession number for each sequence. Investigation ofOBCAM
homology between species and the other human IgLON family members was performed
using the Clustalxl.8 and LALIGN
(http://www.ch.embnet.org/software/LALIGN_form.html) multiple sequence alignment
programs.
Table 2.8 Accession numbers for OBCAM species and other IgLON family
members
Species/IGLON Accession Number
HS OBCAM NM 002545.2
RN OBCAM NM 053848.1
BT OBCAM X12672.1
GG OBCAM AF292934.1





2.6 Methylation Specific PCR
Methylation specific PCR (MSP) is used to detect the presence or absence of
methylation in DNA sequences. The technique consists of chemical modification
followed by amplification of DNA. In bisulphite modification of the DNA, all
unmethylated cytosines are converted to uracils, while 5-methyl cytosines remain
unaltered. Thus, the sequence of the treated DNA will differ depending on whether the
DNA was originally methylated or unmethylated. Primers are designed to specifically
amplify the sequences based upon the chemically induced differences. PCR products can
be further analysed on a gel or by DNA sequencing.
2.6.1 Methylation Specific PCR Assay
Genomic DNAs isolated from the normal/ovarian tumour matched pairs), cancer cell
lines (ovarian, breast, lung, colon and pancreatic cancer), normal ovary, and control
methylated DNA (CpGenome Universal Methylated DNA, Intergen, Purchase, NY,
USA) were incubated with sodium bisulphite to deaminate unmethylated cytosines using
the CpGenome Modification kit (Intergen). All MSP primer sequences were designed by
Dr Hani Gabra with the exception of the Barx2 MSP primers.
For the OBCAM MSP assay, bisulphite-treated DNAs (40ng) from 'fresh'
normal/ovarian tumour matched pairs, cell lines, and normal ovaiy, were PCR amplified
in a 1-step assay with primer pairs to discriminate between the methylated (M) and
unmethylated (U) alleles, respectively, of the human OBCAM CpG island. The 25 pi
PCR reaction consisted of 1 x Buffer II (Applied Biosystems), 2.5 mM MgCU, 200 mM
dNTPs, 200 nM each primer and 1 unit ofAmpliTaq Gold DNA polymerase (Applied
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Biosystems). PCR cycle conditions consisted of a hot start at 95 °C for 12 minutes, then
35 cycles of 95 °C for 30 s, (55 °C OBCAM3B-U) (56 °C U OBCAM1 / U OBCAM3B)
(60 °C M OBCAM3B / M OBCAM 1) for 30 s, 72 °C for 30 s and a final extension at 72
°C for 4 minutes. 10 pi ofMSP product was then visualised on a 2.5 % agarose gel. A
similar one step assay was used for MSP of the FLU and Barx2 genes (Gen Rabiasz).
For OBCAM, a two stage nested MSP assay was used with DNA extracted from
archival specimens. The external primers, (OB2ST) amplify a 243bp PCR product from
bisulphite modified DNA independent of methylation status. Modified DNA was
initially amplified in a 25pl PCR reaction with the external primers. PCR products were
then diluted 1/50 with distilled water and 2pl used in the second-step PCR using the
primer combinations as detailed above for the 1-step assay (Gen Rabiasz). In the tables
of primers used in the MSP assay, M = methylation specific primer, U= unmethylated
specific primer.
Table 2.9 Primers for OBCAM MSP




M OBCAM IFOR AGGCGTTTAGTGGAGGGGTACGGGC NT 030800.5 824881-824905 136bp
M OBCAM 1 REV CATCGCGCTACAATCGACTCCCCG NT 030800.5 825016-824993
U OBCAM IFOR AGGTGTTTAGTGGAGGGGTATGGGT NT 030800.5 824881-824905 136bp
U OBCAM 1 REV CATCACACTACAATCAACTCCCCA NT 030800.5 825016-824993
M OBCAM 3BFOR GCGCGGTGCGGGTTTATTTTC NT 030800.5 825275-825295 135bp
M OBCAM 3REV TCCCGATACCGCCTCGAAACGAACG NT 030800.5 825409-825385
U OBCAM 3BFOR TCCCGATACCGCCTCGAAACGAACG NT 030800.5 825275-825295 13 5bp
U OBCAM 3REV GTGTGGTGTGGGTTTATTTTT NT 030800.5 825409-825385
OBCAM 2ST FOR GTTTTTTTTGTAGGGGAAGT NT 030800.5 825439-825419 244bp
OBCAM 2ST REV CAACAACTCCATCCCTAACC NT 030800.5 825196-825215
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Table 2.10 Primers for Flil MSP




M Flil BFOR CGGTTCGTGGATTTTAAGTTAGGGC AP001535.2 176453-176477 194
M Flil BREV ACACGCTATACGCCAACCG AP001535.2 176664-176646
U Flil BFOR TGGTTTGTGGATTTTAAGTTAGGGT AP001535.2 176453-176477 194
U Flil BREV ACACACTATACACCAACCA AP001535.2 176664-176646
Table 2.11 Primers for Barx2 MSP




M BARX2FOR GGGATAACGTAGTTGTTAATTAGCGC AF 171219.1 194
M BARX2REV CAAAAACCGCCGAACACTAAACGCG AF171219.1
U BARX2FOR TTTGGGATAATGTAGTTGTTAATTAGTGT AF 171219.1 196
U BARX2REV CAACAAAAACCACCAAACACTAAACACA AF 171219.1
2.6.2 Bisulphite Sequencing of the OBCAM CpG Island
MSP bisulphite-treated ovarian tumour and normal ovary DNA 529 bp products
obtained by amplifying between U OBCAM 1 / U OBCAM3B or U OBCAM1 / U
OBCAM3B- were subcloned into the pGEM-T Easy TA cloning vector (Promega,
Southampton, UK). Two to six subclones corresponding to each PCR product were then
sequenced using Big Dye (PE Biosystems) chemistry following standard methods (Gen
Rabiasz).
2.7 OBCAM Transfection into SKOV3
2.7.1 Preparation of plasmid DNA for transfection
The full coding sequence of human OBCAM plus Kozak consensus sequence and
3'UTR overlap encompassing nucleotides 34-1110 (NM_002454.2) was PCR amplified
from normal human ovarian surface epithelium RNA with the primers OPCML F1 and
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OPCML R1 primers previously tabled. The OBCAM PCR product was then subcloned
into the pcDNA3.1 Zeo (zeocin-resistant) mammalian expression vector (In vitrogen) in
both the sense and antisense orientations, and the insert sequence verified (Grant Sellar).
Plasmid DNAs corresponding to OBCAM sense and antisense constructs were prepared
using the QIAGEN plasmid purification kit. Prior to use in transfection experiments, the
plasmid DNA was linearised with the enzyme Pvul. Pvul-linearised sense and antisense
OBCAM constructs (2 pg) were transfected using Lipofectin (In vitrogen) into the
SKOV-3 neomycin-resistant clonal derivative cell line, SKNV3.3. OBCAM sense and
antisense-transfected clonal cell lines were then established.
2,7.2 Lipofection of plasmid DNA into cell lines
Pvul-linearised sense and antisense OBCAM constructs were transfected using
Lipofectin (In vitrogen) into the SKOV-3 neomycin-resistant clonal derivative cell line,
SKNV3.3. This technique utilises Lipofectin (BRL) which is a 1:1 (w/w) liposome
formulation of the cationic lipids DOTMA and DOPE in water. 2x105 cells per 60mm
petri dish were seeded and incubated for 24-48 hours until 30-50% confluent. Lipofectin
and plasmid were allowed to warm up to room temperature for at least 20 minutes prior
to use. A similar length of incubation time for RPMI (serum free and 10%FCS, both
antibiotic free) at 37°C was allowed before use.lOOpl serum free RPMI was aliquoted
into sterile microfuge tubes, two per lipofection. 2pg plasmid DNA was added to the
first tube.lOpl of Lipofectin (check) was put into the second tube. The solutions were
gently mixed in a 5ml tube and incubated at room temperature undisturbed for 15
minutes. Immediately prior to lipofection, the recipient cultures were washed once in
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serum free RPMI. 1.8 ml serum free RPM1 was added to the plasmid / lipid suspension
and the 5ml tube inverted gently several times. The resultant 2ml suspension was added
to the recipient Petri dish and incubated at 37°C for 6 hours. The suspension was then
removed and 4ml of RPMI containing 10%FCS was added and the cells incubated
without selective pressure for at least 48 hours to expand cell numbers. The cells were
subcultured 1:5 into geneticin and zeocin selective media at previously optimised
concentrations. Clones were picked by trypsinisation using fine tipped pastettes at 2-4
weeks. OBCAM sense and antisense transfected clonal cell lines were then established.
2.7.3 Zeocin Kill curves
Zeocin kill curves were performed to establish the optimal concentration needed for
transfection selection. The chosen concentration was the lowest concentration that began
to give massive cell death at about five days and killed all the cells witin two weeks. 1 x
10 SKNV3.3 cells were seeded per well into a 24 well plate. Varying concentrations of
zeocin ranging from 0 - 500pg/ml were placed in each of 3 wells. The plates were refed
and visualised uunder the microscope eveiy three days for two weeks. The optimal
antibiotic concentration of I25pg/ml was clear from inspection and therefore formal cell
counts were not undertaken. Optimal geneticin concentrations had been previously
determined in the lab prior to the creation of the SKNV3.3 cell line.
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2.7.4 DNA miniprep
DNA was prepared from the transfected cell lines for use in PCR to identify successful
integration of the transfected plasmid DNA.
Cells from a confluent 24 well plate were harvested and pelleted in a 1.5 ml
microcentrifuge tube and frozen at -70°C until adequate numbers of samples were
accumulated. To make DNA, the Qiagen QIAamp DNA minikit was used. The cell
pellet was resuspended in PBS to a final volume of 200pl and 20pl of proteinase K
added. 200pl buffer AL was added and mixed by pulse vortexing for 15 seconds.
Following a 10 minute incubation at 56°C the tube was briefly centrifuged. 200pl of
100% ethanol was added and mixed by pulse vortexing for 15 seconds. After a brief
centrifuge, the mixture was carefully applied to a QIAamp spin column in a 2ml
collection tube. This was centrifuged for 1 minute at 8000rpm. The spin column was
transferred to a fresh tube and the tube containing the filtrate discarded. 5 OOpil of buffer
AW1 was added and centrifuged for a further minute at 8000rpm. The filtrate was again
discarded. 500pl buffer AW2 was added and centrifuged at 130000rpm for 3 minutes.
The column was placed in an empty collection tube and centrifuged at 13000rpm for 1
minute. Finally, the column was placed in a collection tube and 50pl ofbuffer AE added
and incubated for 5 minutes at room temperature. To elute the DNA, the tube was spun
at 800rpm for 1 minute. This elution step was repeated to maximise the DNA yield.
2.7.5 Genomic PCR using zeocin primers
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Genomic PCR using zeocin primers was performed on the DNAs made from the
transfected cell lines. 2pl ofDNA was used per 25pl PCR reaction. A Mg concentration
of 1,5mM was used and a TD67-55 program run to amplify the 252bp product.
Table 2.12 Primers for detection of zeocin plasmid incorporation
Primer Sequence 5'-3' Ace. No Nucleotide Size
bp
ZEOFOR CAAGTTGACCAGTGCCGTTC pcDNA3.1 2189-2208 252
ZEO REV GAAGTTCGTGGACACGACCT pcDNA3.1 2422-2441
2.7.6 RNA preparation from the transfected cell lines
RNA from the transfected cell lines was prepared using the Stratagene Absolutely RNA
RT- PCR miniprep kit. When the transfected cells were 70% confluent in a 25cm3 flask
the media was poured off and a mixture of 4.2pl Beta mercaptoethanol and 600pl of
lysis buffer added to cover the bottom of the flask. The cell lysate was mixed and
collected by repeated pipetting and transferred to a 1,5ml microfuge tube. The tube was
vortexed to homogenise the lysate. The lysates were frozen at -70°C until a batch of
lysates were ready to process. The homogenate was transferred to a prefilter spin cup
seated in a 2ml receptacle tube. The tube was spun in a microcentrifuge at maximum
speed for 5 minutes and the filtrate retained. An equal volume of 70% ethanol was added
to the filtrate and the tube vortexed for 5 seconds. This mixture was transferred to a
filter-matrix spin cup seated in a fresh 2ml receptacle tube. This was spun at maximum
speed for 60 seconds. The spin cup was retained and the filtrate discarded. The spin cup
was replaced in the receptacle tube. To DNase treat the sample, the following procedure
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was followed. 600pl of lx low salt wash buffer was added and spun at maximum speed
for 60 seconds. Again the spin cup was retained and the filtrate discarded. The spin cup
was replaced in the receptacle tube and spun at maximum speed for 2 minutes. The
DNase solution was prepared by gently mixing 50pl DNase digestion buffer with 5ml of
reconstituted RNAse- free Dnasel. This solution was added directly onto the fiber
matrix inside the spin cup. The sample was incubated at 37°C for 15 minutes in an air
incubator. 600pl of lx high salt buffer was added to the spin cup and spun at maximum
speed for 2 minutes to dry the filter matrix. The spin cup was transferred to a clean
1.5ml microfuge tube and 60pl elution buffer added directly onto the center of the
matrix of the spin cup. The tube was incubated at room temperature for 2 minutes and
then spun at maximum speed for 1 minute.
The purified RNA in the elution buffer was quantified by measuring the optical density
at 260 and 280nm.
Concentration = OD26Q x dilution factor x 40 = pg/pl RNA
1000
Aliquots ofRNA were stored at - 70C.
2.7.7 Determination of construct expression in OBCAM transfected ce(I lines
Semi-quantitative RT-PCR was used to determine expression of the sense and antisense
constructs in the transfected cell lines. The OPCML F7/BGH primer pair was used to
detect expression of the sense construct and OPCMLR3/BGH used to detect expression
of the antisense construct.
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Table 2.13 Primers for detection of construct expression
Primer Sequence 5'-3' Ace. No Nucleotide Size
bp
OPCML FOR7 CCACTGGTCTGGATGGAATG NM 002545.1 841 -860 -320
BGH REV TAGAAGGCACAGTCGAGG
OPCML R3 CGTCACGTTGTCCATAGCTT NM 002545.1 188-169 -230
BGH REV TAGAAGGCACAGTCGAGG
2.8 OBCAM Functional Analyses
2.8.1 Maintenance of cell lines
Cell lines were maintained in RPMI 1640 with heat inactivated 10% Fetal Calf Serum
(FCS) and penicillin (1 OOunits/ml) streptomycin (lOOpg/ml) and G418 (3ml 20mg/ml
per 100ml media = 600pg/ml) and Zeocin (In vitrogen) (125jul per 100ml media =
125pg/ml) as appropriate.
2.8.2 Growth Assay
Log phase cultures of parent and OBCAM transfected cell lines were harvested and
lxlO4 cells in 1ml media seeded in triplicate into 24 well trays. Every third day, one
plate of cells was harvested and counted. To harvest, the media was removed and the
cells washed twice with PBS. 250pl trypsin was added and the cells incubated at 37°C
until completely detached. To resuspend the cells, 750pl of serum containing media was
added to each well. The cells in each well were syringed 3 times through a 21 gauge
needle to create a single cell suspension. The media was replaced on the remaining
plates every three days. The assay was performed three times.
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2.8.2.1 Use of the Coulter counter
The Coulter counter was drained ofCoulter Klenze and filled with saline. A background
count was taken to ensure that the counter was working adequately. (High background
counts suggest caution). To count, 200pl of trypsinised single cell suspension from each
well was added to 9.8ml saline in a counting pot. The pot was capped and gently
inverted twice to mix. After counting, the counter was flushed, drained and refilled with
Coulter Klenze.
2.8.2.2 Analysis
The actual cell count was determined by multiplication of the count by the dilution
factor, 5000. Linear plots were drawn allowing comparisons between parent/control cell
lines and cell lines transfected with both sense and antisense OBCAM gene constructs.
2.8.3 Aggregation Assay
Log phase SKNV3.3 control and OBCAM transfected cells were trypsinised and
resuspended in media containing 10% FCS. 1 x 106 cells were resuspended in 1ml of
media and passed through a 21 gauge needle to create a single cell suspension. Cell
suspensions were then incubated in 5% CO2 at 37 °C. At defined time points, aliquots
were removed by a wide bore pipette, and single cells were counted with a
haemocytometer.
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2.8.4 Intraperitoneal and Subcutaneous Tumorigenicity Assays
Log phase SKNV3.3 control and OBCAM transfected cells were harvested and 5 x 106
cells injected either intraperitoneal^ (i.p.) or subcutaneously (s.c.) into the flanks of
nude mice, with 3 i.p. and 6 s.c. injections per cell line. Size measurements of
s.c.tumours were taken weekly for 4 weeks. Mice that received cells via i.p. injection
were sacrificed at 9 weeks post injection and tumours removed from the peritoneal
cavity, weighed and photographed.
2.8.4.1 Harvesting cells for xenograft experiments
Each cell line was bulked up in 175cm flasks and cells were harvested in log phase at
70-80% confluence. Cells were washed twice with PBS and 2.5ml trypsin added to each
flask. The flasks were incubated at 37°C until the cells had detached. The cells were
resuspended in RPMI containing 10% FCS and the cells from each cell line
amalgamated. The cells were syringed four times through a 21 gauge needle to create a
single cell suspension and counted using a haemocytometer. The volume of cell
suspension required was calculated and aliquoted into sterile universal containers and
spun for 5 minutes at 2000rpm at room temperature. The supernatant was discarded and
the cells resuspended by flicking. The cells were amalgamated into one universal per
cell line by adding 10ml of serum free RPMI into the first universal and transferring it to
the next until all the cells were in one universal. This process was repeated with another
10ml serum free RPMI. The cells were then spun twice more in serum free media to
remove any remaining traces of fetal calf serum. The resulting cell pellet was
resuspended in serum free media to give 5 x 106 cells per lOOgl injection volume. This
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suspension was put onto ice and taken immediately to the Biomedical Research Facility
for injection into the nude mice by Alison Ritchie and Morwena Muir, Cancer Research
UK, BRF.
2.9 OBCAM Demethylation in SKOV-3 with 5'-Aza 2'-deoxycytidine Exposure
lxlO5 SKNV3.3 cells (a neomycin-resistant, clonal SKOV-3 derivative) were seeded
3 > •into a 25cm tissue culture flask in 10ml media. The media was replaced after 24 hours
and 5'-aza 2'-deoxycytidine (Sigma) added to a final concentration of 20pM. A
duplicate flask of control cells was not exposed to 5 '-aza 2'-deoxycytidine. After 4 days,
cells were harvested, DNasel-treated total RNA prepared and first strand cDNA
synthesised. P-Actin RT-PCR was performed to confirm the integrity of the 1st strand
cDNA from control and 5'-aza 2'-deoxycytidine-treated SKVN3.3 cells.
OBCAM RT-PCR was performed with primers to amplify a 474bp product. Products
from this reaction were size separated on a 2% agarose gel, Southern blotted overnight
onto MSI nylon membrane and then UV crosslinked to the membrane. The blot was
hybridised with a 395 bp OBCAM probe amplified by PCR from RNA from normal
human ovary. The probe was purified through a QIAquick PCR purification column
(Qiagen), and labelled with a32P-dCTP. Following overnight hybridisation, the blot was
washed to remove unbound probe, and the blot exposed to XAR-5 autoradiography film
for 1 hourat-70°C and then developed.
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Table 2.14 Primers for RT-PCR for use in demethylation experiment
Primer Sequence 5'-3' Acc.No Nucleotide Size bp
For TACCATAGATGACCGGGTAA NM 002545.2 221-240 474
Rev TTCCGCACATCGGGCGCAGC NM 002545.2 694-675
Table 2.15 Primers for RT-PCR ofOBCAM probe
Primer Sequence 5'-3' Acc.No Nucleotide Size bp
For ATAGACCCTCGTGTGATCA NM_002545.2 300-319 395
Rev TTCCGCACATCGGGCGCAGC NM 002545.2 694-675
2.10 Reagents and solutions - manufacturers and suppliers
Tissue culture
5aza2deoxycytidine 50mg Sigma Cat No. A3656
Fetal calf serum PAA Laboratories
Geneticin GibcoBRL Life Technologies CatNo. 10131
Hygromycin B lg Roche CatNo. 843555
Lipofectin Gibco BRL Life technologies CatNo 1892-011
Penicillin/streptomycin In vitrogen CatNo. 15140-122
PBS (Phosphate buffered saline) Oxoid lOOtabs BR14a
RPMI 1640 Media with glutamine In vitrogen
Tissue culture plastics Falcon
Trypsin-EDTA lx In vitrogen
Zeocin In vitrogen CatNo R250-05
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ABI310
Genescan 350 TAMRA PE Applied biosystems Cat No. 401736
310 capillaries 47cm x 50pM PE Applied biosystems Cat No. 402839
310 genetic analyser buffer 1 Ox with EDTA PE Applied biosystems
PCR/RTPCR/sequencing
96 well plates, 0.2ml strips, 0.5ml microfuge tubes, 1.5ml eppendorfs AB Gene
lOx buffer Roche
1 Ox reaction bufferll PE Applied biosystems
lOObp DNA ladder GibcoBRL Life Technologies
Absolutely RNA RT-PCR Miniprep kit Stratagene Cat No 400800
Agarose Sigma Cat No. A-9539
AmpliTaq Gold PE Applied biosystems
Big Dye PE Applied Biosystems CatNo.4303152
Chloroform Sigma C-2434
CpGenome DNA Modification kit Intergen
Diethlypyrocarbonate Sigma D-5758
Dynex plate sealers 1541892 Thermo Labsystems
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit PE Applied Biosystems
Dynex plate sealers 1541892 Thermo Labsystems
Ethidium bromide Sigma Cat No. E1510
Filter tips Anachem
Magnesium 25mM PE Applied biosystems
Microseal "A" film GRI MJ Research Cat No. MSA-5001
100
Pellet paint Novagen 70748-3
PicTaq CRUK
QIAquick PCR purification kit QIAGEN Cat No. 28104
Sterile water Sigma Cat No. W4502
TRI Reagent Sigma T-9424
Ultrapure dNTP Pharmacia Biotech Cat No. 27-2035-02
SSCPE
Acrylogel3 BDH Laboratory supplies
lOxTBE buffer
10 % AMPS Ammonium persulfate Sigma A-6738
TEMED (N,N,N',N'-Tetramethylethylenediamine) Sigma T-8133
10% ethanol
1 % nitric acid




0.5M EDTA pH 8.0
186.1 g disodium EDTA (Sigma E-5134)
-add ~ 800ml dH20
-add 20g NaOH pellets and mix until dissolved, using heat ifnecessary,
-adjust pH to 8.0 with NaOH pellets (Fisons)
Make up to 11 with dH20
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lOx TBE buffer
108 g Trizma base (Sigma E-l 503)
55g boric acid (Sigma B-7901)
-add ~ 800ml dH20 and stir until dissolved
-add 40ml 0.5M EDTA pH 8.0
Make up to 11 with dFEO
10% AMPS
O.lg AMPS in 1ml dFEO. Make up fresh for use each day.
SSCPE Loading buffer
19ml formamide
0.8ml 0.5M EDTA pH 8.0
50mg Bromophenol Blue (Sigma B-5525)
50mg Xylene Cyanol FF ( Sigma X-0377)
SSCPE Staining Solutions
10%ethanol 250 ml
1% nitric acid 250 ml
0.1% silver nitrate (0.25g silver nitrate/250 ml dFEO) 250 ml
Developer (15g anhydrous Sodium carbonate, 500ml dFEO, 250 pi formaldehyde)500
ml
Fixer (100 ml methanol, 25 ml acetic acid, 7.5 ml glycerol + dHbO to 250 ml)250 ml
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20x TAE running buffer
145.2g Trizma base (Sigma E-1503)
34.26ml glacial acetic acid
60ml 0.5M EDTA pH8
Make up to 1.51itres with dH20
PBS (Phosphate buffered saline)
10 tabs per litre dH20
Autoclave 115°C for 10 mins
0.1% DEPC H20
100fj.l DEPC per litre dH20
Leave to stand in glassware over night






3.1 LOH on chromosome llq24-5 in epithelial ovarian cancer
Amplification of 16 polymorphic microsatellite markers from a panel of 112
normal/tumour DNA pairs was undertaken and LOH analysis performed using the
Genescan software. Table 3.1 shows the results. A hatched box indicates that the patient
was homozygous at that marker. A black box indicates loss of heterozygosity whilst an
open box indicates retention of heterozygosity in the tumour at that marker. Not all
markers were amplified from every DNA pair. Only a limited quantity of DNA from
Aberdeen was available and therefore only a subset ofmarkers was amplified from those
DNAs.
3.2 Clinicopathological characteristics of study cohort
Table 3.2 shows the clinicopathological characteristics of study cohort.
3.3 Ordering of microsatellite markers on 1 lq24-5
Figure 3.1 shows the predicted order of the microsatellite markers within the 1 lq24-5
region. This figure is not to scale. Throughout this research this map was constantly
updated and rearranged as new data became available through the Human Genome
Sequencing Project. This final marker order was the best prediction available based on
data available at the middle of June 2002. The majority of markers were annotated on
contig NT 009115.8. At this time this contig was 7715220bp long and was still
unfinished, working draft sequence. Several of the markers used in this study were not
yet annotated and the position of these markers was determined by blasting the
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microsatellite sequences against the contig. Using this approach the position of
GATA69G01 was unambiguously determined. Blast search of D11S4131 and
GATA72A01 revealed several hits on the contig. This may be due to sequence
duplication or alternatively be due to error in the working draft sequence. Combining
this data and information obtained from previous physical mapping, these markers were
placed in their most likely location on the map. Two markers, D11S4198 and D11 SI 895
were unable to be placed in this region of chromosome 11. This may be because these
markers are actually out with the region. Alternatively, they may reside in locations that
are not yet sequenced. These two markers will not be discussed further.







Mixed en do /serous 3
Mixed endo/clear 2
Unclassified epithelial 2























































3.4 LOH rates at individual polymorphic markers
Table 3.3 shows the number of pairs analysed for each marker. It also documents the
number of informative cases and the number of those cases that sustained LOH. If the
background (random) rate of LOH is taken as the lowest detected rate of LOH, it can be
seen that several markers from this region display modestly elevated rates of LOH. A
striking feature of this data is the markedly elevated frequency of LOH at the marker
D11S4085. Just over half of the patients who were informative at this marker had LOH
in their tumours.




D11 SI 894 58 44 11 25
D11S912 80 68 24 35
D11S4150 74 66 22 33
GATA69G01 64 24 8 33
D11S4126 63 30 11 37
D11S4131 99 79 25 32
GATA72A01 94 39 12 31
D11 SI 884 54 26 9 35
D11S910 91 56 16 29
D11S1320 91 60 18 30
D11S874 100 53 18 34
D11S4085 97 68 35 51
D11S969 89 60 18 30
D11S1309 53 27 8 30
D11 SI 895 65 36 10 28
D11S4198 61 48 13 21
3.5 Graphical representation of the % LOH at each microsatellite marker
Figure 3.2 is a graphical representation of the % LOH at each microsatellite marker.
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3.6 Relationship between LOH and the clinicopathological features of ovarian
cancer
Investigation of the association of LOH at individual markers with the clinical and
pathological variables of the cohort of patients was undertaken using the STATA
statistics package. Correlation of LOH of any of the markers with FIGO stage, grade,
histological type and debulk status was performed. There were several significant
correlations associated with LOH at individual markers and these are shown in table 3.4.
Table 3.4 also includes correlations that showed a trend towards significance.
LOH at D11S4150 was significantly associated with non clear cell histological type (p
= 0.045). There was a trend towards significance for LOH and non clear cell histology at
the markers D11S4131 (p = 0.051), D11 SI884 (p = 0.063) and D11S1894 (p = 0.085).
The explanation for these correlations is uncertain. In general, tumours of clear cell
histological type are regarded as a poor prognosis group of tumours. LOH at D11 S4131
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was significantly associated with non-serous histological type (p= 0.015). LOH at
D11S4150 was significantly associated with mucinous histology (p = 0.045), with LOH
at D11S912 showing a similar trend (p = 0.083). LOH at D11S969 was significantly
associated with late stage (non stagel) disease (p = 0.0085).
Table 3.4 Statistical association between defined polymorphic loci and
clinicopathological features of ovarian cancer
Prognostic Marker No. Informative Fisher's p-value
parameter assoc'd
LOH
Non clear cell D11S4131 79 0.051
Non clear cell D11S4150 66 0.045
Non clear cell D11 SI 884 26 0.063
Non clear cell D11 SI 894 44 0.085
Non clear cell D11S4126 30 0.014
Nonserous histology D11S4131 79 0.015
Mucinous histology D11S4150 66 0.045
Mucinous histology D11S912 68 0.083
Late stage disease D11S969 60 0.0085
3.7 Relationship between LOH and survival of patients with ovarian cancer
Kaplan-Meier survival analysis using the log rank test for statistical significance showed
significant adverse survival with LOH at the markers D11S4150 (p = 0.0336),
D11S4131 (p = 0.0170) and D11S1309 (p = 0.0231). The survival curves for these
markers are shown below. Table 3.5 details the p value for each marker produced by the
log rank test. This table details the number of informative cases at each marker along
with the number of patients in each of the heterozygous and LOH groups that had died
(Dead/HET and Dead/LOH). Survival data was not available for two patients in the
110
cohort and therefore the number of informative cases at each marker in this analysis
varies by up to two from table 3.3. The Kaplan-Meier survival curves for LOH at
D11S4150, D11S4131 and D11 SI 309 are shown in figures 3.3, 3.4 and 3.5.
Table 3.5 Statistical association between LOH of defined polymorphic loci and
survival of patients with ovarian cancer
Marker No. informative Dead/Het Dead/LOH P value
D11S1894 44 17/33 6/11 0.5325
D11S912 68 19/44 11/24 0.6489
D11S4150 66 16/44 13/22 0.0355
GATA69G01 25 5/16 4/8 0.5411
D11S4126 30 11/19 6/11 07346
D11S4131 77 25/53 17/24 0.0170
GATA72A01 38 14/27 6/11 0.3408
D11 SI 884 26 9/17 7/9 0.2255
D11S910 54 22/39 6/15 0.5050
D11S1320 59 19/41 10/18 0.2907
D11S874 51 18/34 9/17 0.9928
D11S4085 66 18/33 14/33 0.5931
D11S969 59 21/41 11/18 0.0528
D11S1309 27 10/19 6/8 0.0231
D11S1895 36 11/26 6/10 0.0302
D11S4198 48 15/35 7/13 0.2953
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Figure 3.3 Kaplan - Meier survival estimate - D11S4150
(years)
Figure 3.4 Kaplan - Meier survival estimate - D11S4131
(years)
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3.8 Multivariate analysis of prognostic parameters in patients with epithelial
ovarian cancer
Multivariate analysis was carried out on a subgroup of 65 patients with ovarian cancer.
The analysis had to be restricted to this set ofpatients as there was missing data for some
ofthe patients from Aberdeen. The results are shown in table 3.6. As would be expected
stage and debulk status were independent prognostic markers. Of great interest is that
LOH ofD11 S4131 appears to be an independent prognostic indicator.
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Table 3.6 Multivariate analysis - Statistical association between LOH of
polymorphic loci and clinicopathological features of ovarian cancer
Prognostic factor Hazards Ratio 95% CI P value
Stage I + II 1.000
Stage III + IV 4.419 (1.485, 13.146) 0.0076
Other histology 1.000
Serous histology 2.502 (1.165,5.373) 0.0190
D11S4131 HET 1.000
D11S4131 LOH 3.53 (1.486, 8.383) 0.0043
Debulk complete 1.000
Debulk partial/none 3.245 (1.193, 8.827) 0.0210
3.9 LOH at D11S4085
Figure 3.6 shows an example of the data that was analysed using the genescan software.
An ascending group of peaks represents one allele. These patients are heterozygous at
the three markers shown. In these patients' tumours, there is complete loss ofone allele
at D11S4085 with retention of heterozygosity at the flanking markers. LOH at
D11S4085 was frequently complete, indicating a lack of tumour cell heterogeneity
suggesting that this event occurs early in the development of the tumours.
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As illustrated in figure 3.7, the mean level of allele imbalance (r) at D11S4085 was
lower than that of the flanking markers.




3.10 Identification of a consensus region of deletion involving D11S4085
Having identified a high rate ofLOH at the marker D11S4085, a closer inspection of the
LOH data (see table 3.1) revealed a consensus region of loss centred on the marker
D11S4085. The shortest region of overlap was found to lie between the markers
D11S874 and D11S969. This region is approximately 1 Mb in size.
An estimate of the frequency of loss of this region in DNA from this cohort of patients
with epithelial ovarian cancer was made. To determine the LOH rate of this region, as
well as including cases informative at D11S4085, homozygous cases at this marker were
included in the analysis if they had clear loss or retention of heterozygosity of both the
flanking markers as this was felt to be indicative of the likely status at D11S4085. 42/79
informative cases (53%) had LOH of this region.
3.11 Relationship between LOH at Region 4085 and D11S4085 and survival of
patients with ovarian cancer
As can be seen in figure 3.8, there was no association between LOH of this region and
adverse survival. Figure 3.9 shows the Kaplan-Meier curve for the individual marker
D11S4085 revealing that there is no association with adverse survival.
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Figure 3.8 Kaplan - Meier survival estimate - Region 4085
(years)




Table 3.7 documents the proportion ofpatients with loss and retention ofheterozygosity
who had died and the p value as determined by the log rank test.
Table 3.7 Statistical association between LOH at region 4085 and survival of
patients with ovarian cancer
Marker No. informative Dead/Het Dead/LOH P value
Region 4085 78 22/38 20/40 0.9458
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4. RESULTS
OBCAM - A CANDIDATE TUMOUR SUPPRESSOR GENE
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4 OBCAM - A CANDIDATE TUMOUR SUPPRESSOR GENE
4.1 Identification of a gene in Region 4085
Identification of a high frequency of almost complete LOH at D11S4085 suggested that
loss of a gene near this marker was likely to be an early event in the development of
ovarian carcinomas. Using bioinformatics analysis, D11S4085 was found to lie within
the second intron of a gene called Opioid Binding cell Adhesion Molecule (OBCAM)
(see figure 3.1). Further analysis revealed that OBCAM lies telomeric to a gene called
Neurotrimin (NTM). NTM and OBCAM are both members of the IgLON family of cell
adhesion molecules. Their extensive homology and close proximity suggests that these
genes arose as a result of a gene duplication event. Figure 4.1 shows the orientation of
these two genes on chromosome 1 lq24 and indicates the positions of the associated
polymorphic microsatellite markers used in the LOH analysis.
Figure 4.1 Localisation and orientation of OBCAM and NTM on chromosome
1 lq24-5
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D11 SI 320 and D11 S874 lie within the NTM gene. Calculation of the LOH rate ofNTM
is rather more difficult than defining the rate ofOBCAM LOH because the NTM gene
spans two polymorphic markers. The most conservative estimate of LOH at NTM is
determined by identifying all cases that are informative at either or both markers. The
LOH rate is calculated as the number of cases displaying LOH at either or both of these
markers. Using this method, the LOH rate at NTM is 29/77 cases (38%). OBCAM LOH
occurred frequently in the absence ofNTM LOH (12/31 39%) whereas NTM LOH
rarely occurred in the absence ofOBCAM LOH (1/26 4% (p= 0.0001).
This suggests that LOH targets OBCAM rather than NTM in epithelial ovarian cancer
and therefore OBCAM was taken forward for investigation as the candidate tumour
suppressor gene from this region.
4.2 Expression of OBCAM in normal ovary, normal tissues, cell lines and tumour
samples
4.2.1 Expression of OBCAM in normal tissues
The combination of OPCMLF1/OPCMLR1 primers amplifies the full length OBCAM
mRNA transcript (1076bp). Figure 4.2 shows strong OBCAM expression in the normal
ovarian surface epithelium and in the brain. Weaker expression of OBCAM was
detected in heart, placenta, liver, kidney, testis and colon.
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Figure 4.2 Semi-quantitative RT-PCR expression ofOBCAM in normal tissues
4.2.2 Expression ofOBCAM in cell lines and primary ovarian tumours
Quantitative RT-PCR using a Light Cycler was performed on a series of 18 human
primary ovarian tumours (HOVs), and 17 ovarian and 14 non-ovarian (breast, colorectal,
prostate, pancreas, lung and myeloid) cancer cell lines. In this RT-PCR, a 224bp product
was amplified using the OPCMLF4/OPCMLR4 primer pair. Figure 4.3 shows the result
of this assay. OBCAM expression (normalised for Actin expression) was completely
abolished in 16/18 (89%) primary ovarian tumours. No OBCAM expression was
detectable in 15/17 (88%) of ovarian cancer cell lines. In the two expressing ovarian
cancer cell lines, expression was 5% (PEOl 6) and 19% (CaOV3) of normal total ovary.
In non-ovarian cancer cell lines, OBCAM expression was undetectable in 10/14 (71%)
cell lines. Of the four non-ovarian cell lines with detectable OBCAM expression, three
had levels that were not dissimilar to that of the control ovarian sample. The normal
level ofexpression for these tissues (breast, colon and myeloid) however is unknown. In
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essence, OBCAM expression is abrogated in the majority of primary ovarian tumours
and ovarian cancer cell lines.
Figure 4.3 Quantitative RT-PCR expression of OBCAM in human ovarian tumours
and ovarian and non-ovarian cell lines
□ normal ovary
□ ovarian carcinoma
□ ovarian cell lines
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4.3 Identification of the OBCAM CpG island and determination of its methylation
status
4.3.1 Identification of the OBCAM CpG island
Having identified that expression of OBCAM is abrogated in the majority of ovarian
cancer cell lines and ovarian tumours, it was necessary to investigate the nature of this
silencing of expression. A proposed mechanism for this silencing was somatic
methylation of the OBCAM CpG island. Using BLAST homology searches, the 5'
nucleotide sequence of OBCAM mRNA, corresponding to a predicted first exon,
identified a BAC clone (GenBank Accession AC027631) that is contained within the
chromosome 11 q25 Human Genome Contig Sequence NT_030800. Analysis of the
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available sequence of this BAC clone with the GRAIL program CpG algorithm
predicted a CpG island spanning lkb approximately 500bp upstream of the translation
start site ofOBCAM.
Methylation Specific PCR (MSP) primers were designed to distinguish methylated (M)
from unmethylated (U) alleles of the OBCAM CpG island sequence following sodium
bisulphite modification of genomic DNA. An MSP assay that amplified a 134bp
fragment was used to determine the methylation status of the OBCAM CpG island.
4.3.2 The OBCAM CpG island is unmethylated in normal human ovary
MSP of bisulphite-treated genomic DNAs extracted from normal ovaries from 5 women
who underwent oophorectomy for non-malignant conditions showed that the OBCAM
CpG island is normally unmethylated. Bisulphite sequencing across the 529bp OBCAM
MS-PCR product from two of these normal ovaries showed sequence that was
unmethylated at almost every one of the 58 CpGs within this region.
4.3.3 OBCAM is frequently somatically methylated in primary ovarian tumours
MSP was performed to detect methylated and unmethylated alleles ofOBCAM in 69
matched normal/ovarian tumour DNA pairs. A representative set of MSP assays on 9
normal/tumour pairs including control universally methylated DNA and normal ovary
DNAs is shown in Fig 4.4. The OBCAM CpG island is somatically methylated in 83%
(57/69 cases) of ovarian primary tumours. In a subset of26 samples for which both one
stage MSP and LOH data was available, the MSP rate was 90% (9/10) where there was
124
LOH of OBCAM. The MSP rate was 69% (11/16) in those cases where there was no
LOH ofOBCAM.
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4.3.4 The OBCAM CpG Island is Methylated in Ovarian Cancer Cell Lines
The OBCAM CpG island was found by MSP to be methylated in 82% (14/17) ovarian
and in 82% (14/17) non-ovarian (breast, lung, colon and prostate) cell lines. The level of
OBCAM expression in this cell line panel had previously been determined by
quantitative RT-PCR (Fig 4.3) and therefore correlation between OBCAM methylation
and expression was possible. Comparison ofthe MSP data with the quantitative RT-PCR
expression profile revealed a significant correlation between OBCAM CpG island
methylation and absence of detectable expression (P=0.02). Furthermore, five normal
ovaries showed no evidence ofCpG island methylation and expressed OBCAM.
4.3.5 Bisulphite sequencing of the OBCAM CpG island
From representative samples, an overlapping 529bp MSP product was amplified that
contains 58 CpGs. This larger product was then sequenced to ascertain the extent of
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methylation within the CpG island itself as opposed to just that of the primer binding
sites. Bisulphite sequencing across the 529bp OBCAM MS-PCR product from two
normal ovaries showed sequence that was unmethylated at almost every one of the 58
CpGs within this region. Bisulphite sequencing of the 529bp MSP product amplified
from a sample of primary ovarian tumor DNAs demonstrated that the OBCAM CpG
island was extensively methylated across 58 consecutive CpGs. This data is shown in
figure 4.5. ■ denotes methylated C and □ denotes unmethylated C of a CpG
dinucleotide. The shaded boxes represent CpGs for which the methylation status was
undeterminable.
Figure 4.5 Bisulphite sequencing data from the OBCAM CpG island
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4.3.6 Demethylation and Re-expression ofOBCAM in SKNV3.3
In order to confirm that methylation was the mechanism underlying the repression of
OBCAM expression, SKNV3.3 cells were exposed to the demethylating agent 5 '-aza-2'-
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deoxycytidine. The cell line SKNV3.3 is a neomycin resistant clonal derivative of the
SKOV3 ovarian cancer cell line. SKNV3.3 does not express OBCAM as determined by
quantitative RT-PCR. MSP and bisulphite sequencing have shown the OBCAM CpG
island to be methylated at almost every CpG across the 529bp amplified fragment (see
fig 3.14). Re-expression of OBCAM is clearly evident in the treated SKNV3.3 cells. In
contrast, no OBCAM expression is detectable in control SKNV3.3 cells (Fig. 4.6). Actin
RT-PCR confirmed the integrity of the isolated RNA and 1st strand cDNA. As SKVN3.3
cells do not express OBCAM, this cell line was selected for subsequent functional
studies following transfection with OBCAM.
Figure 4.6 Re-expression of OBCAM following deoxyazacytidine exposure
OBCAM
ACTIN
4.4 Mutation screening of the OBCAM gene using SSCPE
4.4.1 Mis-sense mutations identified in the OBCAM gene
SSCPE was employed as a method for the identification of somatic mutations within the
coding region of the OBCAM gene. SSCPE analysis for each OBCAM exon was
performed on DNAs from 212 EOCs and 116 cancer cell lines. In keeping with the high
rate of LOH and CpG island methylation observed for OBCAM, we found a low
SKNV3.3
-AZA +AZA PCR Mix
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frequency of somatic mutation. Surprisingly, no polymorphisms or somatic silent
mutations were identified in this series. Analysis of the 212 tumour samples by SSCPE
identified a single somatic mis-sense OBCAM mutation associated with a primary
epithelial ovarian cancer. Two mis-sense mutations were identified from the panel of
cell lines. The three mutations are documented in table 4.1.








Change Amino Acid Functional
Domain
PEOl Ovaiy 2 334 C —> G Pro —> Ser
Codon 95
1st Ig domain
5637 Bladder 4 621 G —> T Asp -> Tyr
Codon 191
2ndIg domain
KG1 AML 6 967 A —> G Asn —> Ser
Codon 306
Glycosylation
site 3' to 3rd Ig
domain
4.4.2 OBCAM Somatic Mutation in a Primary Ovarian Tumour
In the primary ovarian tumour, PEOl, a heterozygous peak corresponding to the
presence of both a C and a G nucleotide at position 334 in codon 95 (NM 002545.2)
indicates a transversion in the primary tumour (Fig4.7). This position is homozygous for
C in the patient's normal DNA (marked by *). The mutation lies within the first Ig
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domain of OBCAM. The original paper describing the cloning of OBCAM (Shark and
Lee 1995) indicated that OBCAM consists of three "C2" like Ig domains. Analysis by
Paul Bates, Cancer Research UK, Biomolecular Modelling Lab, indicates that the three
domains are better classified as belonging to the "I" set of Ig domains. The "I" domain
set is common for Ig domains within cell surface adhesion and receptor molecules
(Harpaz and Chothia 1994). Based on this description ofeach domain P95 is predicted to
lie within a beta turn between the D and E beta strands of the first Ig domain. The three-
dimensional molecular model for this domain (Fig4.8) suggests that the P95R mutation
would cause the hydrophilic arginine residue to point across the BED face of the domain
(beta sheet consisting of beta strands B, E and D), and therefore, may interfere with any
protein-protein interactions utilising this face









Figure 4.8 Biomolecular ribbon model of the first Ig domain of human OBCAM
4.4.3 SSCP identifies two mis-sense mutations in cancer cell lines
Two mis-sense mutations were identified in the panel of cancer cell lines. It is not
known whether these represent somatic changes and modelling analysis has therefore
not been undertaken. The first mutation in K5637, a cell line derived from a transitional
cell carcinoma, shows a heterozygous peak corresponding to the presence ofboth G and
a T nucleotide in exon 4 at nucleotide 621 in codon 191 (NM 002545.2). This codon is
part of the second immunoglobulin domain ofOBCAM and the mutation results in the
substitution of a hydrophilic, charged aspartate residue with a hydrophilic, neutral
tyrosine residue. The second mutation in KG1, a cell line derived from an acute myeloid
leukaemia, also shows a heterozygous peak corresponding to the presence of both an A
and a G nucleotide in exon 6 at nucleotide 967 in codon 306 (NM 002545.2). The
affected amino acid is a predicted glycosylation site that lies carboxy terminal to the
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third immunoglobulin domain ofOBCAM. This mutation results in the substitution of a
hydrophilic, neutral asparagine residue with a serine residue, another hydrophilic neutral
residue.
Figure 4.9 5637 cell line DNA sequence reveals a mis-sense mutation in the
OBCAM gene
Figure 4.10 KG1 cell line DNA sequence reveals a mis-sense mutation in the
OBCAM gene
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4.5 Homology ofOBCAM between species
The Clustalxl.8 multiple sequence alignment program was used to investigate the
homology ofOBCAM between species. OBCAM has been cloned in Rattus norvegicus
(RN), Bos taurus (BT) and Gallus gallus (GG). Homologues have also been identified in
Drosophila melanogaster (DM) and Caenorhabditis elegans (CE).
Inspection of the multiple sequence amino acid and nucleotide alignments ofOBCAM
in these different species immediately reveals the high homology ofOBCAM between
species (figs 4.11 and 4.12). This homology exists at both the amino acid and the
nucleotide level.
The protein in mammals and GG is 345/344 amino acids long. OBCAM in DM is 315
amino acids long whilst a larger protein of496 residues is seen in CE. The phylogenetic
tree shown in figure 4.13 was drawn using the NJ tree program from within the
Clustalxl.8 program. The length of branches is directly proportional to the divergence
between species. The closest homologue to human OBCAM (HS) is that of RN. The
LAL1GN program was used to quantify the extent of homology in OBCAM between
species. The results obtained using this program are shown in table 4.2. Analysis of
homology was performed at both the amino acid and nucleotide sequence level. The
amino acid or nucleotide overlap over which the homology was identified is included in
the table. It can be seen that OBCAM in HS, RN and BT is highly conserved at the
amino acid level. There is only marginally less conservation at the nucleotide level
between these species. There is significantly less homology between HS and DM and
CE.
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Table 4.2 Amino acid and nucleotide homology ofOBCAM between species
HS OBCAM amino acid
sequence





RN 98.3 345 92.6 1038
BT 97.7 345 90.6 1038
GG 84.9 345 79.4 1038
DM 30.4 296 51.5 747
CE 25.9 317 51.8 583
In attempt to determine the significance ofthe presence ofthe three mis-sense mutations
detected in the ovarian tumour and two cell lines, homology between these nucleotides
and their associated amino acid codons was examined. Table 4.3 shows the presence or
absence of homology at each position between species. Y = nucleotide or amino acid
conserved at that position. N = nucleotide or amino acid not conserved at that position.
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/ = gap in sequence. 1 = mutation at codon 95, 2 = mutation at codon 191,3 = mutation
at codon 306. All three mutations are found at sites that are conserved between HS, RN
and BT. The second and third mutations are also conserved in GG. This data suggests
that these are functionally important nucleotides.
Table 4.3 Amino acid and nucleotide conservation of positions of identified
mutations in the OBCAM gene
OBCAM HS HS
Aminoacid Nucleotide sequence
1 2 3 1 2 3
RN Y Y Y Y Y Y
BT Y Y Y Y Y Y
GG N Y Y N Y Y
DM N N N Y Y Y
CE / N N Y Y N
4.6 Homology ofOBCAM with other human IgLON family members
Inspection of the Clustalx amino acid and nucleotide alignments reveals high homology
between OBCAM and the other two human IgLON family members, NTM and LAMP
(figs 4.14 and 4.15, 0= OBCAM, N=NTM, L=LAMP).
On inspection of the nucleotide sequence alignment, a striking feature is the 100%
homology of the first 170 nucleotides of OBCAM and NTM. This high conservation
between family members indicates that this region is functionally important.
The LALIGN program was used to quantify the extent of homology of OBCAM with
the other two human IgLON family members. Table 4.4 documents the % homologies
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identified using this program and the amino acid/nucleotide overlap over which the
homology was identified.
Table 4.4 Amino acid and nucleotide homology between OBCAM and other human
IgLONs





NTM 76.5 345 76.4 1046
LAMP 56.2 322 65.3 1012
Table 4.5 shows the extent of conservation of the nucleotide sequence and amino acid
residue at the position of the three mutations. Interestingly the position of the third
mutation is conserved between IgLONs at the amino acid and nucleotide level. The
codon determined by the third mutation is therefore conserved not only between species
but also between IgLON family members. This suggests that disruption at this position
is likely to be deleterious to protein function.
Table 4.5 Amino acid and nucleotide conservation of positions of identified
mutations in OBCAM between IgLONs
HS OBCAM OBCAM
Aminoacid Nucleotide sequence
1 2 3 1 2 3
NTM N N Y N Y Y
LAMP N N Y Y Y Y
4.7 Functional analysis of OBCAM in SKOV3 ovarian cancer cells
4.7.1 OBCAM Transfection into SKOV3
The full coding sequence of human OBCAM was PCR amplified from normal human
ovarian surface epithelium RNA and cloned into pcDNA3.1 Zeo (zeocin-resistant)
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mammalian expression vector in both the sense and antisense orientations. The OBCAM
constructs were transfected into the neomycin-resistant SKOV3 clonal derivative cell
line, SKNV3.3 that has no endogenous expression ofOBCAM.
4.7.2 Genomic PCR confirms integration of plasmid DNA in transfected cell fines
Using zeocin primers, amplification of a 252bp fragment from DNA made from the
transfected cell lines confirmed the presence of integrated plasmid DNA in the majority
of the transfectants.
Figure 4.16 Genomic PCR confirms integration of plasmid DNA in the transfected
cell fines
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4.7.3 RT-PCR determines expression from the transfected constructs
Semi-quantitative RT-PCR was used to determine expression of the sense and antisense
constructs in the transfected cell lines. The F7/BGH primer pair was used to detect
expression of the sense construct and R3/BGH primer pair used to detect expression of
the antisense construct. Several examples of each type of transfected cell line were
picked and used in functional assays. Figure 4.17 shows the expression of sense and
antisense constructs in the transfected cell lines selected for use in the functional assays.
Actin RT-PCR confirmed the integrity of the cDNA at the time of synthesis.
Figure 4.17 Semi-quantitative RT-PCR expression of OBCAM sense and antisense





4.8.1 In vitro growth assay
The effect ofOBCAM expression was determined in growth assays, comparing parent,
OBCAM sense (2 independent clones) and anti-sense transfected clonal SKOV3 cells.
Transfection of OBCAM sense expression construct into SKNV3.3 cells resulted in
suppressed growth in vitro as compared with SKNV3.3 control and OBCAM anti-sense
transfected cells. The assay was repeated three times. The data shown in figure 4.18 is
from one experiment.
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4.8.2 In vitro aggregation assay
As a measure of the tendency of cells to aggregate, and therefore of cell adhesion
function, the number of single cells remaining in suspensions of parent, OBCAM sense
(2 clones) and antisense-transfected clonal SKOV3 cells were counted over a time
course. Transfection ofOBCAM sense expression construct into SKNV3.3 cells resulted
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in enhanced rate ofaggregation ofcells compared to the parent cells. Transfection of the
OBCAM antisense expression construct into SKNV3.3 cells resulted in decreased
aggregation of the cells compared to the parent. As there is no endogenous expression of
OBCAM in the parent cell line, it may be postulated that the antisense construct is
targeting a similar but as yet unidentified member of the IgLON family. The assay was
repeated three times and the graph in figure 4.19 shows the mean of the 3 repeats.
Figure 4.19 In vitro cell aggregation assay with parent, OBCAM sense and
antisense transfected cell lines
4.8.3 In vivo subcutaneous tumour growth assays
Tumour growth was measured over a 28 day period following sub-cutaneous injection of
parent, OBCAM sense and antisense-transfected clonal SKOV3 cells into nude mice.
Bilateral subcutaneous injections were made into three mice per cell line giving a total
of six potential tumours per cell line. The experiment was repeated three times. Figure
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4.20 shows representative data from one experiment. Sub-cutaneous tumour growth in
nude mice is markedly suppressed by OBCAM expression in SKNV3.3, compared with
parent and OBCAM antisense-transfected controls.
Figure 4.20 In vivo subcutaneous tumour growth assay with parent, OBCAM sense
and antisense transfected cell lines
CO
4.8.4 In vivo intra-peritoneal tumour growth assays
To create an intra-peritoneal model of tumour growth, parent, OBCAM sense and
antisense-transfected clonal SKOV3 cells were injected intraperitoneally into nude mice.
Three mice per cell line were injected. Tumours were visualised at 65 days, in two
independent experiments. OBCAM transfection markedly suppressed tumour growth
and intra-peritoneal attachment in nude mice, compared with parent and OBCAM
antisense-transfected cells. The data shown in figures 4.21 and 4.22 is data from one
experiment. The mean tumour weight per mouse was 2634mg for parent and antisense,
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and 283mg for the independent sense controls (p=0.0001) and is shown in figure 4.21.
Figure 4.22 shows the tumours removed from the 4 groups of mice at the time of their
cull.
Figure 4.21 In vivo intraperitoneal tumour growth assay - Mean tumour volume
per mouse in controls versus sense transfected cell line injected mice
Figure 4.22 In vivo intraperitoneal tumour growth assay with parent, OBCAM













INVESTIGATION OF OTHER CANDIDATE TUMOUR SUPPRESSOR GENES
FROM THE Ilq24-q25 REGION
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Although it was clear from early on that the investigation of OBCAM as a candidate
tumour suppressor gene associated with the LOH of D11S4085 was going to be
fascinating and certainly important, it was felt that the other significant findings of the
LOH study should not be overlooked or forgotten. Preliminary investigation of several
of these findings was undertaken. Investigation of a gene close to the marker D11S4150
was initiated and analysis of methylation and mutation of the Barx2 gene, another
candidate tumour suppressor gene in the region was performed. Bio informatics analysis
was performed in attempt to identify genes close to the marker D11S4131 but due to the
unfinished state of sequencing in this region, no candidate genes could be identified.
Adverse survival was also associated with LOH at D11S1309. Although established to
be the most telomeric marker used in this study the incomplete state of the sequence in
this region did not allow identification of genes near this marker.
It must be stressed that the following results are preliminary and sometimes incomplete
data but they are included to show the breadth of investigation undertaken in trying to
identify candidate tumour suppressor genes from the 11 q24-5 region.
5.1 Investigation of Flil as a candidate tumour suppressor gene from the llq24-5
region
In several previous studies, LOH at D11S912 has been found to be associated with
adverse survival. No such association was found in this analysis (p = 0.6489). Adverse
survival was however associated with LOH at D11S4150 (p = 0.0355). When this
association of adverse survival with LOH at D11S4150 was first identified, a search for
candidate genes near this locus was instituted. At this time, the best prediction of
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microsatellite order placed D11S4150 and D11S912 next to each other. D11S912 was
found to lie within an intron of the Flil gene and this gene appeared to lie immediately
centromeric of D11S4150. As a result of these findings, it was decided to investigate
Flil as a candidate tumour suppressor gene.
5.1.1 Expression of Flil in normal ovarian surface epithelium and ovarian cancer
cell lines
Expression analysis ofFlil by semi-quantitative RT-PCR was performed on a panel of
thirteen ovarian cancer cell lines and a sample of normal human ovarian surface
epithelium. Flil was found to be strongly expressed in normal ovarian surface
epithelium. Expression of Flil equivalent to that in normal ovarian surface epithelium
was found in 7/13 (54%) of the cell lines with 6/13 (46%) cell lines displaying markedly
reduced or absent expression ofFlil. This data is shown in figure 5.1.
5.1.2 Expression ofFlil in human ovarian tumours
RT-PCR using the same primer combination as used to determine expression in normal
ovary and the cell lines was used to investigate the expression ofFlil in a panel ofthirty
human ovarian tumours. Figure 5.2 shows that strong expression of Flil was found in
every tumour sample. Having found that FLU is expressed in only approximately 50%
ofovarian cancer cell lines this was an unexpected result. These ovarian tumour samples
were non-microdissected and would be expected to contain some normal, non-malignant
tissue such as blood vessels and stromal tissue. It is known that Flil is expressed in
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haematopoeitic tissues and it is therefore likely that the observed Flil expression is a
reflection of contaminating normal tissue in the ovarian tumour samples.
Figure 5.1 Semi-quantitative RT-PCR expression of Flil in ovarian cancer cell lines
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5.1.3 Identification of the Flil CpG island and determination of its methylation
status
A 780bp putative CpG island for Flil was identified on BAC AP001535.2 (nucleotides
176084-176863). This was identified by performing NIX analysis on this BAC that was
known to contain FLI1 gene sequence. The GRAIL CpG island prediction algorithm
within the NIX analysis produced a good quality CpG island prediction. This CpG island
was approximately 1.8kb upstream of the gene.
Methylation Specific PCR (MSP) primers were designed to distinguish methylated (M)
from unmethylated (U) alleles of the Flil CpG island sequence following sodium
bisulphite modification of genomic DNA. An MSP assay that amplified a 211 bp
fragment was used to determine the methylation status of the Fli-1 CpG island.
5.1.3.1 The Flil CpG Island is Unmethylated in Normal Human Ovary
MSP of bisulphite-treated genomic DNAs extracted from normal ovaries from 2 women
who underwent oophorectomy for non-malignant conditions showed that the Flil CpG
island is normally unmethylated. Bisulphite sequencing across the 21 lbp Flil MS-PCR
product from these normal ovaries showed sequence that was unmethylated at all but
one ofthe 13 CpGs within this region.
5.1.3.2 Flil methylation in primary ovarian tumours
MSP was performed to detect methylated and unmethylated alleles ofFlil in 31 ovarian
matched normal/tumour DNA pairs. The Flil CpG island is somatically methylated in
61% (19/3 leases) of ovarian primary tumours. Strong methylation was seen in 8/31
cases and weak methylation in 11/31 cases.
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5.1.3.3 Flil CpG Island methylation in ovarian cancer cell lines
The Flil CpG island was found by MSP to be methylated in 67% (12/18) ovarian cancer
cell lines.
5.1.3.4 Demethylation and re-expression of Flil in OAW28
In order to confirm that methylation was the mechanism underlying the repression of
Flil expression, OAW28 ovarian cancer cells were exposed to the demethylating agent
5'-aza-2'-deoxycytidine. This cell line does not express Flil as determined by semi¬
quantitative RT-PCR.
Re-expression of Flil is clearly evident in the treated cells. In contrast, no Flil
expression is detectable in control cells (Fig5.4). Actin RT-PCR confirmed the integrity
of the isolated RNA and 1st strand cDNA.
Figure 5.4 Re-expression of Flil following deoxyazacytidine exposure
Flil 10F/9CR 1 1 Actin




lOObpladder OAW28CON+ OAW28CON- OAW28AZA+ OAW28AZA lOObpladder OAW28CON+ OAW28CON- OAW28AZA+ OAW28AZA
147
5.1.4 Mutation screening of the Flil gene using SSCPE
SSCPE was employed as a method for the identification of somatic mutations within the
coding region of the Flil gene. Primer pairs were designed for each of the 9 exons of
Fli 1, amplifying from flanking introns across the exons. Four overlapping SSCPE primer
pairs for exon 9 were required to allow complete analysis of this exon. SSCPE analysis
of 24 normal/tumour DNA pairs was completed for exons 2, 3, 4, 5, 6, 7 and 3 out of 4
of the pairs for exon 9. These 24 pairs were selected because they showed LOFl at either
or both of D11S4150 and D11S912. It was hoped that by analysing a panel of pairs that
had already sustained one "hit" ofthe gene that this may enhance the chance of finding a
mutation. Exons 5 and 6 were analysed in 16 ovarian cancer cell lines. At this time point
the study was stopped as newly released data from the HGP suggested that D11 S4150
was not so intimately associated with the Flil gene as had been previously thought. Of
the analysis undertaken only one silent mutation was identified in a single ovarian
tumour. Table 5.1 documents this mutation. The alteration was substitution ofa guanine
nucleotide for an adenine in the third base of codon 210.This did not alter the glutamine
aminoacid residue at this position.
Table 5.1 Silent mutation identified in the Flil gene
BT pair Mutation Nucleotide
NM 002017.2
Codon Aminoacid
(97,98) A -> G 802 210 Glutamine
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5.2 Investigation of BARX2 as a candidate tumour suppressor gene from the
llq24-5 region
Prior to the LOH study in this thesis being performed, a gene called Barx2 had been
identified as a candidate tumour suppressor gene from this region. Work in our lab had
suggested that Barx2 had tumour suppressor characteristics. In order to identify a second
hit for this gene, methylation and mutation studies were undertaken.
5.2.1The Barx2 CpG island is not methylated in ovarian tumours or ovarian cancer
cell lines
Sequence of the Barx2 CpG island was published by Hjalt and Murray and primers were
designed to a region of this island. Methylation specific polymerase chain reaction was
used to amplify a 194bp fragment from bisulphite treated DNA extracted from 25 cancer
cellines and 12 normal/ovarian tumour pairs from patients with epithelial ovarian cancer.
Not one of the sixteen ovarian cancer cell lines showed evidence ofmethylation of the
Barx2 CpG island. Of the nine non-ovarian cancer cell lines, K562 and Hela were both
methylated. There was no evidence of somatic methylation of the Barx2 CpG island;
none of the 12 matched normal/ tumour pairs showed evidence ofmethylation.
5.2.2 Two Barx2 mis sense mutations are identified in a panel of cancer cell lines
Two Barx2 mis-sense mutations were identified in the panel of 71 cancer cell lines
comprising 16 ovarian cancer cell lines and 56 non ovarian cancer cell lines. It is not
known whether these represent somatic changes. The first mutation identified shows a
heterozygous peak corresponding to the presence of both T and a C nucleotide at
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position 142 (AF171220) in three ovarian cancer cell lines (SKOV3, PE014 and
PE023) and one cell line derived from a malignant melanoma (DX3). This alteration
results in the substitution of a hydrophilic neutral serine residue for a hydrophobic
proline residue at codon 39, contained within exon 2 of Barx2. The second mutation,
identified in the chronic myelogenous leukaemia cell line K562, also shows a
heterozygous peak, corresponding to the presence of both guanine and cytosine
nucleotides at position 21 7 (AF171220). This results in the substitution ofa hydrophobic
alanine residue for a hydrophobic proline residue at codon 63, also in the second exon of
BARX2.
No mutations were identified in the panel of 70 normal/ovarian paired DNAs.
Three single nucleotide polymorphisms (SNPs) in Barx2 have been described. Two of
these SNPs were identified in this analysis. Two normal/ovarian tumour pairs were
homozygous for the C->T SNP in exon 4 at nucleotide 400. Three pairs were
heterozygous at this position with one of these pairs showing reduction to homozgosity
in the tumour suggesting that the tumour had been subject to LOH of one allele. The
same pattern was observed for these five pairs with the C->T SNP in intron 3 ofBarx2 at
nucleotide 360. Table 5.2 shows the Barx2 mutations identified.
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Table 5.2 Mis-sense mutations identified in the Barx2 gene
Exon Mutation Nucleotide
AF171220
Codon Aminoacid Cell lines









The starting point for the work in this thesis was the finding of several independent
studies showing a high frequency of LOH in the 1 lq24-5 region in epithelial ovarian
cancer. (Foulkes et al. 1993) (Gabra et al. 1995) (Gabra et al. 1996) (Davis et al. 1996).
This suggested that this region houses a tumour suppressor gene involved in this disease.
For those women unfortunate enough to be diagnosed with epithelial ovarian cancer, the
overall five year survival rate is poor. Our understanding of the aetiology and
pathogenesis of ovarian cancer is limited and with the exception ofplatinum and taxane
compounds, there have been few new developments in the therapeutic management of
ovarian cancer over the last forty years. The quest therefore, for greater knowledge and
understanding of this disease, which may lead to earlier diagnosis and more effective
treatment is ongoing. Identification ofgenes involved in the genesis ofepithelial ovarian
cancer is the first step towards this goal. Working in the setting of the multidisciplinary
gynaeoncology clinic, the availability of clinical resources allied with comprehensive
clinicopathological and follow-up data for these specimens has provided an invaluable
opportunity to investigate the genetic basis of ovarian cancer. Understanding the role of
tumour suppressor genes in cancer is crucial and characterisation of these genes is a vital
key to novel concepts in malignant disease.
6.2 Tumour suppressor genes
The definition of a tumour suppressor gene is a hotly debated topic. The earliest
description of tumour suppressor genes came from Theodor Boveri in 1902 when he
postulated the existence of negative regulators of tumour development. Some seventy
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years later, Alfred Knudson proposed that development of the childhood tumour
retinoblastoma required two rate limiting genetic hits, subsequently shown to represent
mutations ofboth alleles of a tumour suppressor gene (Knudson 1971). The requirement
for two genetic hits established that these genes act recessively at the cellular level. The
link between germline mutation and increased cancer risk provides incontrovertible
evidence ofa gene's role in tumourigenesis. Positional cloning methods based on human
cancer predisposition syndromes have identified several tumour suppressor genes
including RB (Friend et al. 1987), WT1 (Call et al. 1990) (Gessler et al. 1990), APC
(Hampton et al. 1991), NF1 (Cawthon et al. 1990) (White and O'Connell 1991), NF2
(Rouleau et al. 1993) and VHL (Latif et al. 1993). In sporadic cancers, LOH analysis has
been used as a method to identify regions of the genome that may harbour tumour
suppressor genes.
The identification of the presence of truncating or inactivating mutations in a candidate
tumour suppressor gene has until now been regarded as necessary to designate a gene as
a tumour suppressor gene. Haber and Harlow (Haber and Harlow 1997) define tumour
suppressor genes as " genes that sustain loss offunction mutations in the development of
cancer". They believe that demonstration of LOH in the region of a candidate tumour
suppressor gene with concomitant reduction of expression of that gene in the same
tumour type is not adequate proof of it being a tumour suppressor gene. Down-
regulation of gene expression may simply be a reflection of the malignant phenotype
rather than a causal factor in cancer development. The demonstration of gene
inactivating mutations in DNA from tumours suggests that these events provide a
growth advantage to the cell and are thereby selected for. More recently however, the
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importance of epigenetic regulation as a method of tumour suppressor gene inactivation
has been highlighted. Baylin and Herman (Baylin and Herman 2000) believe that
methylation acts as an alternative to mutations to disrupt tumour suppressor gene
function. Studies demonstrating the ability of treatment with a demethylating agent to
promote transcriptional reactivation of silenced genes provide evidence that CpG island
methylation is an active process that provides a growth advantage to the cell that is
selected for.
The functions of the known tumour suppressor genes are diverse, ranging from DNA-
binding transcription factors (p53) to cell cycle kinase inhibitors (p 16) to genes involved
in DNA repair (MSH2, MLH1, BRCA1 And BRCA2). Considered as a group, tumour
suppressor genes are integral components of complex cellular pathways regulating cell
proliferation, differentiation, apoptosis and response to genetic damage. Functional
experiments using transgenic and knockout mice have been used to demonstrate tumour
suppressor gene function in vivo (Hooper 1998). In vitro gene transfection studies of
candidate tumour suppressor genes have been criticised for producing non-physiological
levels of gene expression and possibly artefactual phenotypes. Furthermore, transfection
studies are also subject to clonal variation.
6.3 LOH analysis
Although LOH studies have been widely used to define regions of chromosomal loss in
sporadic cancers, the identification of the associated tumour suppressor genes has
proven to be challenging. This approach often highlights many potential candidate genes
in a region ofLOH, which then require to be individually assessed. Alternatively, lack of
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genomic information in the region of loss requires a comprehensive gene identification
screen to be initiated. Recent refinement ofthe human genome sequence has provided an
opportunity to re-evaluate the power of the LOH approach for identification of tumour
suppressor genes. Previous studies have indicated that a tumour suppressor could reside
at 1 lq24-25 in sporadic ovarian cancer, but candidates until now have remained elusive.
During this period of research, data generated by the human genome project has been
used to order markers and genes across the 11 q24-25 region.
My analysis of LOH in epithelial ovarian cancer on chromosome 1 lq24-25 is the largest
study to date of LOH in this region combining the highest number of cases with the
greatest number of microsatellite markers. This has allowed a greatly refined map of
LOH on 1 lq24-25 in epithelial ovarian cancer to be produced.
A 1Mb minimal region of loss centred on D11S4085 has been defined. Additionally,
correlation of LOH at individual markers with survival times and the clinicopathological
variables of the disease has identified several markers for which LOH is associated with
adverse survival. Subsequent multivariate analysis has identified LOH of the marker
D11S4131 as an independent adverse prognostic variable. These data suggest the 1 lq24-
25 region houses several potential tumour suppressor genes. Previous LOH studies have
produced conflicting results concerning the association of LOH and survival in this
region. These conflicting results may be explained by the most recent findings
suggesting the presence of several potential tumour suppressor genes in the 1 lq24-25
region. This highlights the difficulty in attempting to assimilate data from independent
LOH studies that have used different and varying numbers ofmicrosatellite markers.
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6.4 Candidate tumour suppressor genes from the llq24-5 region
6.4.1 OBCAM
6.4.1.1 OBCAM - an extracellular protein
The marker with the highest frequency of LOH, D11S4085 lies within the second intron
of the gene encoding OBCAM. OBCAM is a 345 amino acid protein that is located
entirely extracellularly and is attached to the outer leaflet of the apical bilayer membrane
by a GPI anchor. As a member of the immunoglobulin superfamily it is easy to
understand how it acts as a cell adhesion molecule. Due to its lack of a transmembrane
or cytoplasmic region, it is harder to envisage how this protein can mediate intracellular
signalling and act as a tumour suppressor gene. OBCAM mediated signalling may arise
as a consequence of heterophilic interactions with proteins on the same cell or on a
different cell. Homophilic interaction of OBCAM may induce growth regulatory
signalling indirectly by bringing ligand and receptors into close enough proximity to
allow their interaction. However, this mechanism whereby OBCAM could influence
signalling would be just as likely to oppose activating ligands and receptors.
Heterophilic interaction ofOBCAM with a transmembrane protein in the same cell may
modulate cell signalling. This may be a positive or negative regulation. Binding of
OBCAM to a growth factor receptor may act as a competitive antagonist by inhibiting
access of the ligand to its receptor. Alternatively, binding ofOBCAM to a growth factor
receptor may enhance its activation leading to enhanced growth regulation. GPI-
anchorage to the cell membrane facilitates diffusion of these proteins in the plane of the
cell membrane. GPI-anchored proteins tend to localise in the cholesterol rich areas ofthe
cell membrane known as lipid raffs (Friedrichson and Kurzchalia 1998) where they can
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interact with other similarly localised proteins. Consequently, a potential function of
rafts is to provide a local concentration of receptors to facilitate rapid signal transduction
as well as limiting potential cross talk between signalling pathways. The GPI-anchored
neuronal cell adhesion molecule contactin/Fl 1 has been shown to localise with the src
family protein tyrosine kinase, Fyn in detergent-resistant immune complexes (Zisch et
al. 1995). This tyrosine kinase is associated with the inner leaflet of the plasma
membrane. The authors propose that signalling events underlying dynamic interactions
via GPI-linked contactin/Fl 1 in the nervous system rely, at least partially on the action
of the nonreceptor tyrosine kinase Fyn. GP55, a member of the IgLON family in the
chicken, can inhibit neurite extension on substrata. This process can be inhibited by
pertussis toxin, indicating that IgLON molecules may function via a G-protein coupled
pathway (Clarke and Moss 1997).
6.4.1.2 Mechanisms ofOBCAM inactivation in ovarian cancer
The frequency ofOBCAM somatic mutation is extremely low with only three mis-sense
mutations in a total of 328 primary tumour samples and cell lines being identified. No
truncating mutations in primary epithelial ovarian cancers were identified but a potential
loss of function somatic mutation has been investigated. In contrast to its low somatic
mutation rate, the frequency ofOBCAM somatic methylation is extremely high (83%).
Ifone accepts the broader definition of a tumour suppressor gene that acknowledges the
contribution of methylation to gene inactivation then OBCAM clearly undergoes
inactivation in keeping with Knudson's two hit mechanism for loss of tumour suppressor
gene function. OBCAM is subject to frequent LOH and somatic methylation in the vast
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majority of ovarian tumours. The observed somatic methylation ofOBCAM appears to
be specifically selected for with 90% of those cases with LOH displaying somatic
methylation whilst only 69% of cases without LOH are methylated. Barx2, a gene
located centromeric of OBCAM in the 11 q24 region is not methylated in ovarian
tumours. This suggests that methylation in ovarian tumours specifically targets OBCAM
rather than merely being the result of a chromosome wide or global phenomenon
resulting from the malignant phenotype. Furthermore, the ability of treatment with
deoxyazacytidine to re-express OBCAM in a non-expressing ovarian cancer cell line
that has extensive methylation of its CpG island suggests that methylation is the gene
inactivating mechanism and not just a bystander effect.
Although only one somatic mis-sense mutation (P95R) in a primary tumor sample was
detected in a series comprising 212 ovarian tumours, impaired protein function may well
result from the non-conservative change altering a proline to an arginine residue. A
collaboration with Paul Bates (CRUK, Biomolecular Modelling Laboratory) has
provided some insight into the potential significance of the identified somatic mis-sense
mutation. The three-dimensional model of the first Ig domain that was generated, whilst
not sufficiently accurate to determine if this domain actually is involved in homophilic
adhesion (i.e. by constructing protein-protein docked models), does not preclude this
possibility. The BED face of the domain has been implicated in protein-protein
interactions between molecules on the same cell, such as for ICAM-1 (Casasnovas,
Bickford, and Springer 1998). The opposite face of the domain, the CFG face, often
mediates homo- and heterophilic protein interactions between cells (Chothia and Jones
1997) and has been proposed to have evolved as a sticky patch to recognise a variety of
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protein-protein interactions (Springer 1990). A model for a related GP1 linked molecule
to OBCAM, carcinoembryonic antigen (Bates, Luo, and Sternberg 1992) suggests that
by utilising the BED face for interactions on the same cell and the GCF face of the first
N-terminal domains for homophilic adhesion, a distributed network of interactions can
exist between cells. A similar network has been shown within the crystal structure ofN-
cadherin (Shapiro et al. 1995). Therefore, it is possible the P95R mutation, lying
between the D and E strands, could potentially disrupt a similar interaction between
OBCAM molecules on the same cell and, therefore, indirectly affect potential
interactions between cells. A less likely but possible explanation is that P95 is located
within the fold of the D and E strands, that a change to a hydrophilic arginine residue
could disrupt this fold, and therefore OBCAM protein-protein interactions.
6.4.1.3 Evolutionary conservation of OBCAM
The first member of the IgLON family of proteins to be identified was LAMP. LAMP
was initially identified in the rat limbic system (Levitt 1984). Since their identification in
the nervous system, the work on this family of proteins has concentrated almost
exclusively on their role in the developing nervous system. Although three human
IgLON molecules have been cloned, their role in Homo sapiens is implicated solely
from studies of homologues in chickens and rats. Even in chickens and rats, little infact
is known about the expression and function of IgLONs outside the nervous system. In
the published literature, there is only one study documenting investigation of IgLON
expression out with the nervous system. Hachisuka et al (Hachisuka et al. 1996)
developed monoclonal antibodies to a synthetic OBCAM peptide and documented high
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levels of OBCAM expression in bovine, rat, mouse, guinea pig and rabbit brains. In
other tissues, the protein was found in the spleen at very low levels but not at all in the
liver or kidney of the rat.
The interest in the IgLONs in the nervous system has focussed on their role in the
development of the nervous system. The finding of highly specific and temporal
expression ofOBCAM, NTM and LAMP in the developing nervous system is evidence
supportive of a role in controlling neurite outgrowth and axonal guidance. Indeed,
LAMP and NTM have been shown to have bifunctional effects on neurite outgrowth that
are neuron type-specific and strongly suggest that homophilic interactions promote
outgrowth, whereas heterophilic interactions between NTM and LAMP inhibit neurite
outgrowth (Gil et al. 1998). The ability ofOBCAM to modify neurite outgrowth has not
yet been studied. A recent publication by McNamee et al (McNamee et al. 2002)
suggests that IgLONs may not have a primary role in axon guidance but may be more
important for cell to cell adhesion and recognition. These authors speculate that
clustering of IgLONs on the cell surface may be more important for the stability of
interactions and the initiation of the appropriate signal transduction cascade.
The high degree of conservation ofOBCAM between species is strong evidence for a
protein with a fundamentally important function. The homology is greatest amongst
mammalian species with RN being the closest homologue to HS OBCAM. As well as
looking at the overall homology between species and the other human IgLONs it is
interesting to look for conserved regions of the protein. The 100% homology between
the first 60 amino acids ofNTM and OBCAM (also 100% conserved at nucleotide level)
suggests a strong evolutionary constraint inhibiting divergence. It is interesting to note
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that at both the amino acid and the nucleotide level, the position of the three mis-sense
mutations are conserved between mammalian species. In fact, the position of the third
mis-sense mutation is conserved not only between species but between IgLON family
members. This provides evidence that the presence of any of these three mutations
would be deleterious to OBCAM protein function. The high conservation of this protein
suggests that OBCAM plays a fundamental physiological role.
6.4.1.4 OBCAM and the ovary
In functional analyses, OBCAM expression in a clonal derivative ofSKOV3 suppressed
growth and enhanced cell-cell aggregation in vitro; and also suppressed sub-cutaneous
tumour growth and intra-peritoneal tumour growth in vivo. These features suggested
both tumour suppressor and cell-cell adhesion functions for OBCAM. The finding that a
GPI-anchored molecule has the characteristics of a candidate tumour suppressor gene is
unusual. The only other GPI-anchored molecule for which tumor suppressor activity has
been proposed is hyaluronidase 2 (HYAL2) (Rai et al. 2001). HYAL2 was proposed as a
candidate lung tumor suppressor gene based upon its localisation to 3p21.3 (Rai et al
2001), a region of chromosomal deletion in lung and breast cancers (Wei et al. 1996)
(Lerman and Minna 2000). No functional evidence has been presented to support a
tumour suppressor function for HYAL2. Indeed, it is now been demonstrated to function
as the receptor for the jaagsiekte sheep retrovirus, the envelope protein of which
mediates oncogenic transformation (Rai et al. 2001).
It has been proposed that "incessant ovulation" contributes a major factor underlying
ovarian epithelial oncogenesis (Fathalla 1971a). Ovulation has been considered to be a
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cyclical inflammatory reaction (Espey 1980) (Ness and Cottreau 1999), with the
involvement of multiple proinflammatory cytokines, including interleukin 1-beta (IL-
1(3), its associated type I and type II receptors and receptor antagonist (Kol, Kehat, and
Adashi 2002). IL-1(3 appears to promote various facets of the ovulatory process by
stimulating the expression of numerous downstream effector genes in a tightly
controlled hierarchical manner (Ando et al. 1998). In a chondrosarcoma model of
arthritis, OBCAM expression in chondrocytes was downregulated 4-fold in response to
IL-1 P exposure (Vincenti and Brinckerhoff2001). As the ovarian surface epithelium is a
site of localised and tightly regulated IL-1 p production during the "tear and repair" cycle
ofovulation, it is possible that OBCAM expression may be subject to modulation during
this process. This leads to the proposal that continual cyclical down-regulation of
OBCAM is a contributing factor to the early steps of ovarian carcinogenesis. A
speculative but attractive model inferred from the functional data would be that loss of
OBCAM would reduce intercellular adhesion and accelerate cell growth simultaneously,
thereby promoting the early steps of ovarian carcinogenesis.
6.4.2 Flil
In several studies, LOH at D11S912 has been found to be associated with adverse
survival. This finding was not corroborated by the present analysis. D11S912 lies within
the Flil gene. Flil is a member of the Ets family of transcription factors that are
characterised by the presence of a highly conserved DNA binding domain called the Ets
domain. Most Ets proteins have been shown to be transcriptional activators but there is
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also evidence that some ofthese genes act as transcriptional repressors (Mavrothalassitis
and Ghysdael 2000).
Flil was first identified as a common site of retroviral integration in friend virus-
induced erythroleukaemias (Ben-David et al. 1991). In cancer, Flil is widely regarded as
an oncogene and therefore the suggestion that Flil may have tumour suppressor function
albeit contextually in the setting of ovarian cancer would radically challenge current
thinking about the function of this gene. There is a spectrum of cancer including soft
tissue sarcomas and leukaemias in which balanced reciprocal translocations result in the
production ofoncogenic fusion proteins that contain the Ets DNA binding domain. Loss
of function of Ets family members may also contribute to the pathogenesis of human
cancers. In TEL/AML leukaemias there is often deletion of the residual TEL allele
resulting in there being no functional TEL in the cell suggesting that TEL may have
tumour suppressor function.
Flil is subject to a translocation in human Ewing's tumour. More than 85% ofEwing's
family tumours carry a specific chromosomal translocation that fuses the amino terminus
of the EWS gene to the carboxy terminus of the Flil gene. The product of this
translocation is a potent transforming oncogene. The mechanisms by which the
EWS/Flil protein exerts its oncogenic actions are currently being investigated by the
scientific community. Repression of the gene encoding TGFbetaRII appears to be a
major target of the EWS/Flil oncoprotein (Hahm et al. 1999). In normal cells, Flil
promotes transcription of TGFbetaRII (Truong and Ben-David 2000). In this manner,
Flil may exert tumour suppressor properties. Loss of Flil function with subsequent
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down regulation of the TGFbetaRII expression would be expected to be associated with
a loss of growth inhibition normally imposed by TGFbeta signalling.
Analysis in the lab has shown the normal ovarian surface epithelium to be a site of
strong Flil expression. In a panel of ovarian cancer cell lines, Flil was expressed at
levels equivalent to that of normal HOSE in 7/13 ovarian cancer cell lines but its
expression was markedly reduced or absent in the remaining lines. The gene was
somatically methylated in 19/31 human ovarian tumours and methylated in 12/18
ovarian cancer cell lines. Treatment of an ovarian cancer cell line that has no expression
of Flilwith deoxyazacytidine resulted in re-expression of Flil suggesting that
methylation is the method of gene silencing in this cell line. An analysis of the Flil gene
by SSCP did not detect any mis-sense or inactivating mutations of the gene. This
analysis was not fully completed for exons 1, 8 and 9 and the number of samples was
small. Despite this however, having detected a lower second hit rate of methylation
(61% Flil v 83% OBCAM) than in the OBCAM gene it seems reasonable to surmise
that if Flil was a bona fide tumour suppressor gene we would probably have found an
inactivating mutation in the samples tested.
6.4.3 P53AIP1 and D11S4150
To date, there are no published data regarding LOH at D11S4150 in epithelial ovarian
cancer. In this analysis, LOH at D11S4150 was found to be associated with adverse
survival. 76bp centromeric of D11S4150 lies KCNJ5, a gene encoding a potassium
channel protein, which is an unlikely candidate tumour suppressor gene. 134bp
telomeric of D11S4150 lies p53- regulated apoptosis-inducing proteinl (p53AIPl). As
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its name suggests, p53AIPl is a downstream target of p53. p53AIPl was identified by
direct cloning ofp53 binding sequences from human genomic DNA (Oda et al. 2000). It
has been suggested that p53A!Pl is likely to play an important role in mediating p53
dependent apoptosis with phosporyiation of Serine-46 of p53 appearing to regulate the
transcriptional activation of p53AIPl. In colony forming assays, the same authors show
that p53AIPl functions as a growth suppressor. p53AIPl is thus a good candidate
tumour suppressor gene. p53 mutation in ovarian cancer is not a predictor ofoutcome. It
may be that knowledge of the status of both p53 and p53AIPl in tumours may give a
clearer indication of the functional status of the p53 pathway and thereby be of use as a
prognostic indicator.
6.5 Summary and future directions
The LOH study presented in this thesis has produced several significant findings that
have led to the identification of at least one very exciting candidate tumour suppressor
gene from the 11 q24-5 region in epithelial ovarian cancer. Information made freely
available through the Human Genome Project has transformed the power of LOH
analyses and has contributed enonnously to the success of this project.
The data presented provides strong evidence that inactivation of the extracellular cell
adhesion molecule OBCAM is an early event in ovarian carcinogenesis, and that it is an
excellent candidate for the 1 lq25 epithelial ovarian cancer tumour suppressor gene.
The finding of adverse survival of patients with LOH at D11S4150 and D11S4131
suggests the presence of genes important in ovarian cancer near these loci. p53AIPl is
an excellent candidate tumour suppressor gene at the D11S4150 locus and investigation
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ofthis gene in ovarian cancer must be pursued. As yet there are no annotated genes close
to the D11S4131 locus whose loss is an independent adverse prognostic variable in
epithelial ovarian cancer. At the present time therefore, expression analysis of ESTs in
the vicinity of D11S4131 may be a reasonable first step approach to cloning this
important gene.
An important area for future studies investigating the OBCAM gene will be to study the
signal transduction biology of OBCAM. The nature of OBCAM's signalling pathway
and its transcriptional effects have yet to be elucidated. In order to characterise the
signalling pathway(s) through which expression ofOBCAM-induced genes is mediated,
Western blotting studies using protein isolates from OBCAM transfected and control
cells can be performed with a range of antibodies against major signalling pathway
components. Creation ofa Tet-On doxycycline inducible transfection system would be a
valuable resource for analysing the effects of regulated OBCAM expression and would
provide the ideal resource to investigate the transcriptional consequences of OBCAM
expression in a genome-wide profiling study. In view of the lack of somatic mutation of
OBCAM in ovarian tumours, creation of a mouse knockout ofOBCAM will hopefully
confirm its tumour suppressor function. Inactivation ofOBCAM appears to occur early
in ovarian carcinogenesis. Unlike in other cancers such as cervical and colorectal
tumours, it is uncertain whether or not there is an ovarian cancer precursor lesion. It will
be intriguing to investigate whether OBCAM inactivation also occurs in borderline and
or benign ovarian tumours. The potential for identification ofmethylated OBCAM in the
blood of patients with ovarian cancer may provide the basis for a diagnostic test for
ovarian cancer. Furthermore, following identification of a phenotype associated with
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OBCAM expression it should be possible to identify OBCAM mimetic molecules for
use in therapy of patients with ovarian cancer. This is the first description of the
involvement of IgLON family members in cancer and as such opens up a whole new
area of research.
The quest to understand the molecular biology of epithelial ovarian cancer with the
ultimate aim of translating this knowledge into methods for achieving earlier detection
and better treatment for patients with ovarian cancer is an evolving area of research.
Data from the Human Genome Project and rapidly developing powerful new
technologies are providing new levels of investigation. Hopefully in the not too distant
future we will see that research such as that in this thesis will have lead to developments
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Figure 4.11 Clustalx analysis of amino acid homology of OBCAM between species
RN_ MGVCGYLFLPWKCLVWSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTIDDRVT-RVAWL—NRSTILYAGNDKWSIDPRVIILVNTPTQYSIMIQNVDVYDKGPYTCSVQTDNHPKTSRVHLIVQVPPQIMN— 140
HS_ MGVCGYLFLPWKCIVWSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTIDDRVT-RVAWL—NKSTXLYAGNDKWSIDPRVIILVNTFTQYSIMIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQIMN 140
BT_ MGVCGSLFQPWKCLVWSLRLLFLVPTGVPVRSGDATFPKAMDNVTVRQGESATLRCTIDDRVT-RVAWL—NRSTILYAGNDKWS TDPRVIILVNTF TQYSIMIQNVDVYDEGPYTCSVQTDNHPKTSRVHLIVQVPPQrMN 140
GG_ MGVGGCLPLPWRCLWLCLKLLFLVFAGVPVRSGDATFPKAMDNVTVRQGESATLRCTVDDRVR--RVAWL NRSTILYAGNDKWSIDNRWILSNTKTQYSIKIHNVDVYDEGPYTCSVeTDNHPKTSRVKLIVQVPPQIVN 140
DM_ MMKAINAKPLGLVPP SSFAADPKFSGPINNSTVPVGRDALLTCWHDLVSFKVAWLRVDTQTILSIQNHVrTKNHRISISHTEHRIWQLKIRDVQESDRGWYMCQINTD-PMKSQMGYLDVVVPPDrVDYQ 130
CE_ MMKLVLLILGLLIAS TSAQIRTKGGTLIAKEGESLTLRCEVEDPSV-AIIWR KNTEWAVDDEILDTYGGYEISMEG-STSVLTIKRVEP INSANYSCALAEP-EVSVTFVIKVQVKPLWISPD 122
ruler 1 10 .20 30 40 50 . ..!.... 60 70 ........ 80 90 . 100 ...... .110 120 130 140
RN_ ISSDITVNEISSVTLLCLA-IGRPEPTVTWRHLSVK EGQGFVSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTG-VSVGQKGILSCEASAVPMAEFQWFKEDTRLATG LDGVRIB 273
HS_ ISSDITVNEGSSVTLLCLA— IGRPEFTVTWRHLSVK EGQGFVSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRKVKITVNYPPYISKAKNTG-VSVGQKGILSCEASAVPMAEFQWFKEETRLATG—LDGMRIE 273
BT_ ISSDVTVNEGSSVTLLCLA-IGRPEPTVTWRHLSVK —EGQGFVSEDEYLEISDIKRDQSGEYECSALNDVAAPDVRXVKITVNYFPYISKAKNTG-VSVGQKSILSCEASAVPMAEFQWFKEDTRLATG—LDGMRIE 273
GG_ ISSDITVNEGSSVTLMCLA-FGRPEFTVTWRHLSGK GQGFVSEDEYLEITGITREQSGEYECSAVNDVAVPDVRKVKVTVNYPPYISNAKNTG-ASVGQKGILQCEASAVPVAEFQWFKEDTRLANG LEGVRIE 272
DM_ TSQDWRSTGQNVTLTCSA-TGVPMPTITWRREEATPILISDDGDREVFSVEGQNLTLWQVQRSHMGAYLClASNGVPPTVSFRVMLVVNFAPTIWTRYDTIYVGLGQKLTLECITESQPASVNFWLRDSQLLeGGS-YESVSVD 273
CE_ TGVYHARVGEKNLVrTCHVKEGNPKPGWWTKQAAKLP EDIKREBGGARIVITEVKK.KHAGKYNCLAEN-IAGSDRATrDIHVAEKPWVKNEDTFIPVRKNQNASFWCTYDGTPVPQVEWLFNGYKINFNDEKFKKTS;E 260
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Figure 4.12 Clustalx analysis of nucleotide homology of OBCAM between species
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Figure 4.15 Clustalx analysis of nucleotide homology of OBCAM and the other human IgLONS
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